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Chapter I 1
General introduction and outline
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1 Background
1.1 Alzheimer's Disease
The most important risk factor for dementia is ageing. Since the population of people 
older than 65 years enlarges, the prevalence of dementia also increases considerably. In 
2000, 11 European population based studies were pooled to obtain the prevalence of 
dementia in Europe, revealing an age-standardized prevalence of dementia of 6.4 % .1 
Further, the prevalence nearly doubled with every five years of increase in age, leading 
to a prevalence of 28.5 %  at age 90 years and older.1 Worldwide, 24.3 million people were 
estimated to suffer from dementia in 2001 and this number was predicted to double 
every 20 years, leading to an expected number of 81.1 million patients suffering from 
dementia in 2040.2 In 2009, the total number of people with dementia in the European 
Union is estimated 7.3 million.3 Alzheimer's disease (AD) is the most important form of 
dementia, accounting for 50 - 60 %  of all cases.2 AD results in progressive mental 
deterioration with memory disturbance and disorientation. As the disease advances, 
symptoms include confusion, irritability and aggression, mood swings, language 
breakdown, and long term memory loss. At the end stage, body functions such as 
walking, eating, and toileting are lost, ultimately leading to death. However, the end 
stage of AD is reached only in a minority and most AD patients die before because of 
co-morbidity and inter-current diseases (e.g. pneumonia).4
Worldwide, dementia, and especially AD, is among the top five of most costly diseases 
and places a great burden on individual caregivers, which includes both psychological 
and physical aspects. This is the direct reason why the European Union decided on a 
political level to start a joint program on researching AD. This thesis aims already to 
contribute to the body of knowledge that was started a century ago by Alois Alzheimer. 
This is highly needed to improve understanding and ultimately care for the patients and 
caregivers suffering from this devastating disease.
Alois Alzheimer was a German neuropathologist and psychiatrist, who is credited for 
identifying the first case of AD in 1907. After the death of this patient in 1906, Alzheimer 
identified in the brain the amyloid plaques and neurofibrillary tangles, which we today 
know as the hallmarks of the disease. Amlyoid plaques are microscopic foci of extracellular 
amyloid deposition, containing deposits of the amyloid p-protein (Ap42 and Ap40).5 
The currently leading hypothesis for the cause of AD, the amyloid cascade hypothesis, is 
based on these Ap depositions. It states that an imbalance between the production and 
clearance of Ap in the brain is the initiating event of the disease, ultimately leading to 
neuronal degeneration and dementia.6 Whereas plaques are extracellular deposits in the
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brain, neurofibrillary tangles are intracellular aggregates, composed of a hyperphospho- 
rylated form of the tau protein.6 The formation of tangles is incorporated in the amyloid 
cascade hypothesis as a downstream phenomenon and, according to this hypothesis, 
could contribute to neuronal dysfunction and cognitive symptoms.7 Even before the loss 
of function, the loss of neurons and synapses, probably already causes the first symptoms 
and signs.8
In the early eighties, the proteins Ap and tau were disentangled from the plaques and 
tangles. Since then research into the pathology of AD has primarily focused on these two 
proteins. Besides the plaques and tangles however, Alois Alzheimer also described the 
presence of arteriosclerotic plaques in the brain. Vascular lesions since then have played 
a different role in the scientific thinking on AD. The last decade, research again has 
focused on the cerebrovascular factors in AD and mounting evidence indicates that 
cerebrovascular factors play an important role in the pathogenesis of AD.9 The Rotterdam 
Study was one of the first large studies that called attention to this issue. This study 
showed that both dementia of the vascular type and AD were associated with the 
presence of atherosclerosis.10 Now, a growing body of epidemiological and pathological 
studies highlight the important contribution of vascular risk factors in AD, with 
hypertension and diabetes mellitus as the primary examples.11 The mechanisms by 
which these vascular factors increase the risk of AD are not yet fully elucidated. Most of 
the vascular risk factors have been associated with subcortical lesions seen on brain 
magnetic resonance imaging, like white matter hyperintensities, lacunar infarctions, and 
cerebral microhemorrhages.11
Besides the epidemiological evidence that states the importance of vascular factors in 
the pathogenesis of AD, evidence from studies of neuropathology also indicates that 
cerebrovascular disease plays an additive or synergistic role in AD.12 The structure of the 
cerebral vessels in patients with AD is profoundly altered: large cerebral vessels display 
arteriosclerotic plaques, whereas pial and intracerebral arteries develop amyloid lesions 
and have a thinner smooth muscle layer, characteristic of cerebral amyloid angiopathy.13 
Amyloid lesions are also present at the level of the capillaries. At this level, the endothelium 
is degenerated and the basement membrane is thickened.13 In addition to this altered 
structure of the cerebral microvessels, function of these vessels is also impaired.13- 14 
Moreover, in mouse models of AD, using mice that overexpress the amyloid precursor 
protein, the regulation of cerebral perfusion is impaired.15' 16 These observations have 
partially been confirmed in human AD patients. In AD, the CO2-induced cerebral 
vasodilatation (cerebrovascular reactivity) is impaired, the coupling between local 
cerebral blood flow and neuronal activity is disturbed, and cerebral hemodynamics are 
altered.17-19 Whether or not the regulation of cerebral perfusion during blood pressure
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(BP) changes in AD is disturbed, remains unknown.
Taken together, especially in old age, it becomes clear that AD is both a neurodegenera­
tive and a cerebrovascular disease. The recognition of vascular risk factors may help to 
identify those people who are most at risk and who are most likely to benefit from 
preventive interventions.20 If by such vascular prevention projects the onset of AD could 
be delayed by 5 years, the expected prevalence on a US base would decrease by more 
than 1 million cases after 10 years and more than 4 million cases after 50 years.21
1.2 Cholinesterase inhibitors
Acetylcholine is an important neurotransmitter in the brain. In the mid-1970's, the 
emerging role of acetylcholine in memory and learning was discovered. Meanwhile, a 
loss of cholinergic innervation was observed in the brain of AD patients.22 These two 
observations gave rise to the former cholinergic hypothesis in AD. This hypothesis, which 
is not the leading hypothesis anymore, but still serves an important therapeutic route, 
suggests that a dysfunction of acetylcholine containing neurons in the brain contributes 
substantially to the cognitive decline in AD.23 A degeneration of the cholinergic neurons 
in the basal forebrain nuclei causes disturbances in presynaptic cholinergic terminals in 
the hippocampus and neocortex, leading to memory disturbances and other cognitive 
symptoms.6 The treatment of AD with cholinesterase inhibitors (ChEI's) is based on this 
cholinergic hypothesis. These drugs reduce the synaptic breakdown of acetylcholine 
and thus partially correct the cholinergic deficit.
At present, ChEI's have widespread use as a treatment for AD, even though the average 
benefits of this treatment are very modest. Treatment effects of rivastigmine, donepezil, 
and galantamine, the most commonly prescribed ChEI's, are global and consist of modest 
improvements in cognition, attention, and executive functions in patients with mild to 
moderate AD.24 Not only are the effects moderate, but the response to treatment also 
varies markedly among patients and the treatment effects are not specific for AD.25-27 
The cholinergic hypothesis fails to account for these drawbacks of treatment with ChEI's. 
Partially, the heterogeneous response may be explained by underlying neuropatho- 
logical diversity in patients labeled with AD.6 However, the described disadvantages may 
be even better explained by the premise that ChEI's primarily or at least for a substantial 
part, act by augmenting cerebral perfusion: the cholinergic-vascular hypothesis.28 
According to this hypothesis, ChEI's have potential effects on both cerebral and systemic 
circulation. In chapter 2.A. of this thesis, I will provide a detailed overview of these effects, 
which may interfere with the outcome of treatment on cognitive and functional status 
and could promote the heterogeneous treatment response.
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2 Methods on measuring cerebral perfusion
To maintain a stable cerebral blood flow (CBF) during changes in blood pressure (BP), the 
cerebral circulation has an autoregulatory system based on myogenic, metabolic, and 
neurogenic mechanisms that adapt cerebrovascular resistance in response to alterations 
in BP.29 The term cerebral autoregulation (CA) was induced by Lassen, who reviewed over 
more than 200 clinical studies assessing CBF.30 His review included the now classic studies 
regarding static CA, which describe the response of CBF, averaged over a longer period 
of time (within hours or days), to long term changes in BP. In contrast to these classis 
studies, dynamic studies of CA quantify the fast modifications in CBF in relation to rapid 
BP changes (within seconds). Technological developments in the eighties, such as the 
transcranial Doppler (TCD) by Aaslid, the Finapres by the Institute of Applied Science 
(TNO), and a single stand-alone near-infrared spectroscope (NIRS), have offered the 
possibility to investigate these dynamic properties of CBF in relation to BP. The term 
dynamic CA was introduced by Aaslid in 1989.31 He was the first to study the response of 
CBF to rapid changes in BP, using continuous measurements of CBF and BP.31 The dynamic 
approach is the most promising approach for the clinical evaluation of CA, since the 
measurements are less time consuming and obtrusive, entirely non invasive, and can be 
performed at bedside. This thesis will therefore focus on the dynamic aspects of CA. 
Two preceding dissertations from our group, 'Hypotensive syndromes and cerebral 
oxygenation' (Mehagnoul-Schipper) and 'Cerebral hemodynamics in aging: the interplay 
between blood pressure, cerebral perfusion, and dementia'(Claassen) also addressed the 
dynamic properties of regulation of CBF by using either near-infrared spectroscopy 
(Mehagnoul-Schipper) or transcranial Doppler (Claassen). In this thesis both transcranial 
Doppler and near-infrared spectroscopy together with finapres are used to assess 
dynamic CA.
2.1 Measurements of cerebral perfusion
The classical studies described by Lassen used the inert gas method, developed by Kety 
and Schmidt, and the indicator-dilution method, developed by Gibbs, Maxwell, and 
Gibs.30 These methods measure global CBF and are rather invasive and time consuming. 
In contrast, TCD is non-invasive, easy to use, and offers a very high temporal resolution 
(< 0.1 s) to measure changes in CBF in one of the supplying arteries of the brain.32 
In chapter 2.B. I will provide a detailed overview of the pros and cons of TCD.
A disadvantages of measuring CBF with TCD is that it does not provide information on 
cerebral tissue perfusion. Therefore, in this thesis, NIRS measurements are added to those 
of TCD. NIRS is a noninvasive technique for continuous measurements of tissue
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oxygenation and hemodynamics, which was introduced in human studies by Jobsis in 
1 977.33 The basic principle of the NIRS method is that near-infrared light penetrates the 
skull and brain, and is absorbed by the chromophores oxygenated and deoxygenated 
hemoglobin (O2Hb and HHb, respectively), which have different absorption spectra in 
the near-infrared region. Assuming constant scattering, changes in concentration of the 
chromophores can be deduced, using the Lambert-Beer law. This law is a mathematical 
means of expressing how light is absorbed by matter. It states that the amount of light 
emerging from tissue is diminished by three physical phenomena: concentration, optical 
path length, and extinction coefficient.
The use of the Lambert-Beer law however, assumes constant scattering of the tissue, 
whereas brain tissue is a scattering medium. This will lead to a lengthened pathway and 
loss of the photons. Therefore, in this thesis a modified Lambert-Beer law will be used.34 
The modifications include a multiplication factor for the increase in optical path length 
and a correction for the photon loss. Further, in the present thesis, a continuous-wave 
NIRS device, which produces 3 light bundles with wavelengths of 775 nm, 845 nm, and 
904 nm, is used. This device measures cerebral cortical changes in the concentration 
O2Hb and HHb, and can be reliably used in old subjects.35, 36
2.2 Assessment of Cerebral Autoregulation
Beside continuous measurements of cerebral perfusion, continuous measurements of 
BP and end-tidal CO2 are essential in the assessment of CA. Those measurements are vital 
since CA describes the relation between BP and CBF, and since CO2 is a very potent 
cerebral vasodilator and constrictor.37, 38 Changes in respiratory pattern during tests of 
autoregulation may greatly confound measurements of CBF. BP can be measured 
non-invasively and beat-to-beat with a servo controlled finger photoplethysmography 
as in the Finapres device,39 whereas information on end-tidal CO2 can easily be obtained 
with a capnograph. Further, a fast change in BP and CBF and a (mathematical) method to 
quantify the relation between BP and CBF are essential. In chapter 2.B. I will provide a 
thorough overview of the different methods that have been applied to induce BP 
changes, and to quantify dynamic CA. In this thesis, measurements during sitting rest, 
single sit-stand maneuvers, and repeated sit-stand maneuvers are used. Dynamic CA is 
then quantified by transfer function analysis of the baseline measurements and repeated 
sit-stand maneuvers. Transfer function analysis makes it possible to quantify the relation 
between the input, BP, and output, CBF, of the autoregulatory system. In chapter 2.B.
I will present a detailed explanation of transfer function analysis. For the single sit-stand 
maneuvers, the calculation of absolute and percentage changes in cerebral perfusion 
during the maneuvers will be used.
15
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3 Aim and outline
To summarize, cerebrovascular factors play an important role in the pathogenesis of AD 
and ChEI's have a possible effect on (the regulation of) cerebral perfusion. At present, 
whether or not dynamic CA is impaired in AD patients and is affected by ChEI's, remains 
unknown. The main aim of thesis is to answer the question whether the regulation of 
cerebral perfusion in patients with AD is changed compared to healthy old people and 
whether treatment with ChEI's in AD patients will influence this regulation.
In chapter 2, this thesis provides a clinical and methodological background of the present 
study. In chapter 2.A., a brief overview of the potential effects of ChEI's on the cerebral 
and systemic circulation is presented. In chapter 2.B. the different methods to assess 
dynamic CA are reviewed and an overview of the studies that measured dynamic CA in 
old people is provided.
Chapter 3 deals with the development of a new method to measure dynamic CA and 
with the assessment of cerebrovascular reactivity in the old. In this age-group, it is 
essential that methods to assess dynamic CA are minimally obtrusive. A variety of 
methods to induce BP changes, ranging from repeated leg cuff deflation to repeated 
squatting, have been used to characterize dynamic CA. All of these methods however, 
are deemed unsuitable for clinical application in older subjects as they are too obtrusive. 
Therefore, we introduce a repeated sit-stand maneuver to generate rapid BP and CBF 
changes in chapter 3.A. We compare this method to a more established method, the 
analysis of spontaneous fluctuations in BP and CBF, and we assess the feasibility and 
reproducibility of the repeated sit-stand maneuvers.
In chapter 3.B. we investigate a commonly used method to measure cerebrovascular 
reactivity, the breath hold method. The breath hold method is easy to use, since it only 
requires measurements of CBF and an instruction to subjects to hold their breath. The 
reliability and reproducibility of this method has only been tested in young and middle-aged 
subjects, yet it is often applied in older patients. Additionally, the influence of CO2 on CBF is 
confounded importantly by the effects of BP. Therefore, in this chapter we test the reliability 
and reproducibility of the breath hold method in the assessment of cerebrovascular reactivity 
in the old, and we also take into account the changes in BP during this assessment.
In chapter 4, we apply the assessment of dynamic CA described in chapter 3.A., in patients 
with AD. This chapter starts with the assessment of dynamic CA in patients with AD before 
the treatment with ChEI's compared with healthy old subjects (chapter 4.A.). Here we also 
add the application of NIRS in the evaluation of dynamic CA to provide information on the 
cerebral tissue oxygenation. In chapter 4.B. and 4.C. this thesis will address the influence of 
ChEI's on the systemic and cerebral circulation, respectively, in AD patients.
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Chapter I 2.A.
Short Review: Acetylcholinesterase-Inhibitors 
in Alzheimer's Disease Have Opposing Effects on 
Blood Pressure and Cerebral Perfusion
Jurgen A.H.R. Claassen 
Arenda H.E.A. van Beek 
Marcel G.M. Olde Rikkert
Journal of Nutrition, Health & Aging. 2009 Mar;13(3):231-3
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Introduction
Acetylcholinesterase-inhibitors (ChEI's) have widespread use as a treatment for 
Alzheimer's disease (AD). Most research has focused on the effects of ChEI's on cognition 
or functional abilities in patients with AD in trials with short follow-up periods.1 
The results of these trials indicate that the average benefits of ChEI treatment for AD 
patients are very modest. Furthermore, there is considerable heterogeneity in the 
response to treatment. This heterogeneous response may in part be explained by 
underlying neuropathological diversity in patients labeled with the clinical diagnosis of 
AD.2 However, there is also evidence which suggests a more complex mode of action of 
ChEI's than is commonly assumed. Here, we will provide a brief overview of the potential 
effects of ChEI's on the cerebral and systemic circulation. These complex interactions 
may interfere with the outcome of treatment on cognitive and functional status and 
could promote heterogeneous treatment response.
The direct effects of ChEI's on the cerebral circulation
Mounting evidence indicates that ChEI's exert direct effects on brain perfusion.3 Based on 
neuropharmacological evidence, a beneficial effect of ChEI's on cerebral blood flow (CBF) 
is expected and an augmentation of cerebral blood flow has indeed been reported in 
several studies.3 Enhancement of cerebral vasodilatation by ChEI's may protect against 
ischemia, and possibly will improve cognitive functioning, especially on attention- 
related tasks. The increase in CBF could also explain the immediate cognitive benefit 
observed after a single dose of ChEI in AD and controls.4 On the other hand however, 
recent data suggest an opposing mechanism through which ChEI's may actually impair 
rather than augment cerebral vasodilatation.5 This impairment of vasodilatation will affect 
the coupling between flow and activation, more correctly named neurovascular coupling, 
which refers to the relationship between local neural activity and subsequent changes in 
CBF. Any positive cognitive effect that is brought about by ChEI-induced cortical activation 
may thus be counteracted or abolished by an impairment in local blood flow response. 
Below, we will provide a brief overview of the most recent literature describing the 
effects of ChEI's on CBF.
Intrinsic and extrinsic cerebrovascular innervation
In a simplified scheme, brain vascular innervation can be divided into "intrinsic" and 
"extrinsic" vascular innervation. The intrinsic innervation consists of perivascular nerves
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that originate from centers within the brain, whereas the extrinsic innervation stems 
from "outside" the brain, i.e. from the autonomic nervous system. The intrinsic innervation 
is found in penetrating cortical arteries and arterioles further downstream. On the other 
hand, the larger arteries (e.g. the basal arteries of the Circle of Willis) receive extrinsic 
innervation from "extra cerebral" autonomic ganglia.
Evidence that ChEI's enhance vasodilatation
Cholinergic neurons not only project from the basal forebrain (the nucleus basalis of 
Meynert) to neurons in the hippocampus and cortex, but they also have projections to 
the cortical microvascular bed. There they have both direct vascular innervations, and 
indirect innervations through nitrergic interneurons.3' 6 7 This system is therefore part of 
the "intrinsic" cerebrovascular innervation. Regarding direct vascular innervations, 
perivascularly released acetylcholine exerts vasodilatation through muscarinic 
acetylcholine receptors found on endothelium, smooth muscle cells, and perivascular 
astrocytic end-feet.7 The last mentioned astrocytes are also in close contact with both 
neurons and supplying vasculature, and therefore have an important role in neurovascular 
coupling.7, 8 In the indirect vascular innervations, stimulation of the nitrergic interneurons 
induces vasodilatation through release of nitric oxide.3
Activation of cholinergic basal forebrain neurons has repeatedly been shown in animals 
and humans to induce immediate widespread cortical vasodilatation, most notably in 
the frontal lobe.3 A similar effect has been observed with cholinergic stimulation by 
administering ChEI's. This vasodilatation is a direct vascular effect, and not a consequence 
of enhanced metabolic demand following cortical activation by ChEI's.3 Recently, 
evidence has been added that the acute vasodilatation in brain parenchymal arterioles, 
induced by administration of the ChEI donepezil, is mediated by activation of neuronal 
nitric oxide synthase.9
In summary, the net effect on vasodilatation following cholinergic activation will depend 
on the integrity of all components of the neurovascular unit, including astrocytes, as well 
as on intact nitric oxide pathways. AD pathology affects both neurons and blood vessels 
and therefore may alter neurovascular coupling and reduce the vasodilatory response to 
cholinergic enhancement by ChEI's.10, 11
Evidence that ChEI's impair vasodilatation
In addition to their effects on the intrinsic cerebrovascular innervation, there is evidence 
that ChEI's affect the extrinsic, autonomic, innervation. Although the role of the autonomic 
nervous system in control of cerebral circulation awaits further elucidation12 it may be 
important for the adaptation of CBF to changes in blood pressure, e.g. in hypertension.
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The nicotinic acetylcholine-receptor, located on sympathetic vascular nerves, is an 
important mediator of vasodilatation.13 Part of this autonomic synaptic neurotransmission 
is cholinergic, and may be affected by ChEI's. Indeed, animal studies have demonstrated 
that treatment with ChEI's impairs this nicotinic receptor mediated cerebral vasodilatation 
in basal arteries.5 Of interest, this effect could be reduced by concomitant administration of 
statins.5 Although galantamine differs from other ChEI's in its action on the nicotinic 
receptor, it impaired vasodilatation in a similar fashion as other ChEI's.5
ChEI's and cerebral perfusion: clinical perspective
In summary, ChEI's may on the one hand augment cerebral perfusion through their 
stimulant effects on the intrinsic cholinergic cerebrovascular innervation, whilst on the 
other hand they may promote vasoconstriction through blockade of nicotinic-receptor- 
mediated autonomic vasodilatation. How can we translate these conflicting data into 
clinical practice?
Factors that may modify the effect of ChEI's on CBF
The net outcome of ChEI treatment on CBF in patients with AD is likely to be influenced 
by many factors that may differ importantly between individuals. Examples of such 
modifying factors include the severity of cholinergic denervation; the presence and 
distribution of cerebral amyloid angiopathy, vessel wall abnormalities, and endothelial 
dysfunction; the status of neurovascular signaling, e.g. astrocytic function; use of 
medication that may alter endothelial function (e.g. drugs that inhibit angiotensin II, 
statins, nitrates) or oxidative stress; the status of the autonomic nervous system; and the 
possible effects of amyloid |3 on endothelial function, neurovascular signaling, and on 
the nicotinic receptor.10, 14
It can thus be hypothesized that the balance of these and other, yet to be identified, 
factors will determine the outcome of cholinergic treatment. This outcome includes 
either an augmented CBF which may enforce cognitive benefit, or an indifferent or even 
negative effect on CBF, which could reduce or oppose any cognitive benefit.
Evidence from clinical trials
Trials that have investigated the effects of ChEI's on cognition, together with their effects 
of cerebral perfusion, support the interpretation that the net outcome of ChEI treatment 
on CBF influences the clinical (cognitive) response.3 When AD patients are divided in 
responders and non-responders, based on the effect of ChEI treatment on cognitive test
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scores (ADAS-cog or MMSE), responders have augmented CBF, whereas non-responders 
show either no effect or a decrease in CBF.3, 15, 16 In other words, if ChEI treatment fails to 
augment CBF, the patient will subsequently show no clinical response to treatment. 
Obviously, by the nature of these studies, it is impossible to exclude that the reverse is 
true, i.e. that the improvement in cognitive function is responsible for the increase in 
CBF. However, several animal and human studies indicate that the increase in CBF 
following administration of ChEI's is not driven by an increase in metabolic demand.3
The effect of ChEI's on the systemic circulation
Association of ChEI's with syncope and arrhythmia
With regard to the effects on the systemic circulation, there is concern from case-reports that 
ChEI treatment may be associated with arrhythmia, syncope, or orthostatic hypotension 
through a negative effect on blood pressure control and cardiac rhythm.17 There are several 
neuropharmacological mechanisms to explain this association. The two components of the 
autonomic nervous system (sympathetic and parasympathetic) both include cholinergic 
neurotransmission. Acetylcholine is a preganglionic neurotransmitter in the sympathetic 
system, and a pre- and postganglionic neurotransmitter in the parasympathetic system. 
Therefore, ChEI's may enhance synaptic activity in both systems. Increased parasympathetic 
activity causes slowing of heart rate and atrioventricular conduction, whereas increased 
sympathetic activity causes a rise in peripheral arterial resistance and blood pressure, and a 
reduction in heart rate variability. In addition, stimulation of central muscarinic receptors may 
induce hypertension.18 A small trial with the ChEI donepezil in AD confirmed that treatment 
caused a shift in autonomic function, as indicated by alterations in heart rate variability. 
This trial also demonstrated a trend towards an increase in blood pressure and in orthostatic 
blood pressure decline following treatment.19 Theoretically, blood pressure instability or 
cardiac arrhythmia can affect functional outcome through postural instability and falls. 
In addition, it may negatively affect cognition through cerebral ischemia. These mechanisms 
could contribute to the heterogeneity in the treatment response to ChEI's.
However, even though syncope and bradycardia have been reported as serious adverse 
events in trials with ChEI's, they had a very low incidence and occurred only slightly more 
frequently than in the placebo groups. A recent meta-analysis concluded that all currently 
prescribed ChEI's have a favorable safety profile.20 In a small prospective trial with 
donepezil in AD, treatment led to a modest reduction in heart rate (from 67 to 62 beats 
per minute).21 This effect was only observed in patients who did not already use 
cardio-inhibitory medication, and was asymptomatic.
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Beneficial effect of ChEI's on hemodynamic control
Reports in the literature on the effects of ChEI's on systemic circulation are conflicting. 
As indicated above, the use of ChEI's in AD has been associated with hemodynamic 
instability. Paradoxically, the ChEI pyridostygmine has been proposed as a treatment for 
patients with autonomic failure, presenting with severe orthostatic hypotension or with 
postural tachycardia syndrome.22 In these patients, the rationale for treatment with 
pyridostygmine is that it may enhance pre- and postganglionic autonomic neuro­
transmission, and partially restore autonomic imbalance between sympathetic and 
parasympathetic activity.23 Indeed, pyridostygmine was able to reduce orthostatic 
decline, as well as postural tachycardia.22
Even though it is not possible to directly compare these - often younger- patients with 
autonomic failure with patients with AD, it remains surprising that a drug used to treat 
hemodynamic instability in one patient group would cause hemodynamic instability in 
another. It is likely that individual patient characteristics, including possible autonomic 
alterations associated with AD, will determine the effects of treatment on blood pressure 
and heart rate variability.
Conclusion
ChEI's are well known for their modest effects on cognition in patients with AD. However, 
because of their additional action on the autonomic nervous system and on intrinsic 
cerebrovascular innervation, these drugs also have direct effects on CBF, blood pressure, 
and cardiac rhythm.
At present, there is only limited information available on the hemodynamic effects of 
ChEI's in AD. Recent technological developments make it possible to perform detailed 
measurements of systemic and cerebral hemodynamics using non-invasive and 
non-obtrusive methods.24 Application of these techniques will aid in disentangling the 
multiple and opposing effects of ChEI's in patients with AD, and may shed light on the 
mechanisms behind the unresolved heterogeneity in the response to treatment.
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Abstract
Cerebral autoregulation (CA) refers to the properties of the brain vascular bed to maintain 
cerebral perfusion despite changes in blood pressure (BP). Whereas classic studies have 
assessed CA during changes in BP that have a gradual onset, dynamic studies quantify 
the fast modifications in cerebral blood flow (CBF) in relation to rapid alterations in BP. 
There is a lack of standardization in the assessment of dynamic CA. This review provides 
an overview of the methods that have been applied, with special focus on the elderly. 
We will discuss the relative merits and shortcomings of these methods with regard to 
the aged population. Furthermore, we summarize the effects of variability in BP on CBF 
in older people.
Of the various dynamic assessments of CA, a single sit-to-stand procedure is a feasible 
and physiological method in the elderly. The collection of spontaneous, beat-to-beat 
changes in BP and cerebral blood flow allows estimation of CA using the technique of 
transfer function analysis.
A thorough search of the literature yielded eight studies that have measured dynamic 
CA in the elderly aged < 75 years. Regardless of the methods used, it was concluded 
from these studies that CA was preserved in this population.
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Introduction
The brain has a high metabolic demand and therefore requires adequate nutritional 
flow. In order to maintain stable cerebral blood flow (CBF), the brain's vasculature must 
respond to changes in arterial blood pressure (BP) or intracranial pressure. Thus, cerebral 
blood vessels have an inherent ability to keep CBF constant over a wide range of systemic 
BP levels, by means of myogenic, neurogenic, or metabolic mechanisms.1, 2 In response 
to a variation in perfusion pressure (mean arterial pressure - intracranial pressure), 
an adaptation in cerebrovascular resistance will cause CBF to return to its baseline. 
This hemodynamic process is known as cerebral autoregulation (CA).2, 3 
The term autoregulation within the cerebral circulation was introduced by Lassen.4 
His review covered more than 200 clinical studies assessing CBF using the inert gas 
method (which measures arterial-venous gas difference), developed by Kety and 
Schmidt, and the indicator-dilution method (which measures the venous dilution of an 
intra-arterially injected indicator), developed by Gibbs, Maxwell, and Gibbs.5 Of note, the 
more recently developed PET-scanning technique enabling, for example, measurement 
of cerebral oxygen metabolism, is founded on these principles.
Lassen's review included the now classic studies regarding static CA (sCA), which 
describes the response of CBF, averaged over a longer period of time, to long term 
changes in BP with gradual onset. By plotting these changes in CBF and BP, it was found 
that CBF remains constant over a wide range of BP changes - the "plateau phase", with 
the upper and lower limits forming the boundaries of CA. It should be noted however 
that this now classic single curve was a composite of many studies, and critical analysis 
of this work brings into question its validity.2 Frequently, a slight slope exists over the 
pressure range where the supposed plateau had been plotted.6 Predictions from a 
physiological computer model are that in between the lower and upper boundaries of 
this plateau phase, CBF actually changes from 80 %  to 120 %  of baseline.7 Nonetheless, 
between these upper and lower limits, autoregulation of CBF is effective. It is important 
to realize that these boundaries are not fixed.2 Chronic hypertension, for example, shifts 
these limits of autoregulation towards higher BP levels. This adaptation protects the 
brain against hypertension, but may also render it more vulnerable to hypoperfusion 
during episodes of hypotension.2
The classical studies of CA are performed in the semi-steady state. The changes in BP 
occur gradually and the measured CBF values reflect the results of adaptation of 
cerebrovascular resistance to the new, stable, BP value. In other words, these studies 
assess the outcome of CA rather than the process of CA itself. In terms of maintaining 
sufficient nutritional blood flow, these semi-steady state studies provide no information
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on whether or not a period of hypoperfusion precedes the eventual return to stable 
perfusion. Furthermore, the clinical applicability of estimation of sCA is limited, because 
it requires pharmacological interventions to establish a sustained period of hypertension 
and hypotension.
More recent technological developments such as transcranial Doppler ultrasonography 
(TCD) and servo controlled finger photoplethysmography (Finapres) have offered 
possibilities to investigate the dynamics of the pressure-flow relationship of the cerebral 
circulation. In contrast to the classic studies, dynamic studies of CA quantify the fast 
modifications in CBF-velocity (CBFV) in a major cerebral artery in relation to rapid 
alterations in BP within the upper and lower limits (plateau phase) of sCA. This approach 
allows differentiation of the CA response to fluctuations in beat-to-beat BP of different 
magnitude and duration. Also in contrast to the classic studies, dynamic studies can 
identify episodes of reduced flow in this major perfusing artery in the period needed for 
CBF to return to baseline following hypotension. However, these dynamic studies are not 
able, at present, to measure flow at brain tissue level. For studies of dynamic CA (dCA), a 
pharmacological intervention is not required, and the method is entirely non-invasive, 
which makes it clinically suitable. Recently, dCA has been shown to be impaired in several 
conditions that are highly prevalent in the elderly, such as ischemic stroke8 and carotid 
stenosis.9 Therefore, the vulnerable brain in these patients is insufficiently protected 
against the effects of rapid BP changes. Furthermore, postprandial hypotension or 
orthostatic hypotension, both common hypotensive syndromes in elderly patients,10 
may lead to cerebral symptoms like syncope, falls, and dizziness.11- 12 Whether or not 
these hypotensive syndromes result in symptoms and clinical signs and thus have clinical 
consequences is largely determined by the process of CA.13' 14
In hypertension, dCA has been addressed only in those < 75 years old. In mild to moderate 
hypertension, dCA is unimpaired,15 and reduction of BP to achieve normotension is not 
associated with cerebral hypoperfusion in middle aged subjects16 and elderly subjects
< 75 years.17 Although the beneficial effects of antihypertensive treatment in preventing 
cardiac disease and stroke are well known,18 whether or not it is similarly safe to treat 
hypertension in the elderly cannot be answered at present.19
In contrast with studies of sCA, no uniform method exists to measure, analyze, and report 
dCA. In fact, the various methods applied differ in the type of BP stimuli (spontaneous or 
induced BP fluctuations), as well as in the model for analysis and interpretation.
Studies describing dCA in the elderly and in diseases affecting older people have used 
different methods to evaluate the dynamic autoregulatory capacity of the brain. 
The important clinical question whether aging affects CA can therefore only be attempt­
ed to be answered after careful interpretation of these different methodologies.
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In this review we will first provide an overview of measurements of the various parameters 
that have been applied to assess dCA. Also, we will discuss the different methods to 
provoke cerebral hemodynamics and allow dynamic assessments of CA. After that, we 
present an overview of dynamic studies of CA in the elderly and we will discuss the 
interaction between CA and disease.
Review of Methods 
Measurements
To evaluate the dynamic process of the autoregulatory capacity of the human brain, 
assessment of BP and CBF with high temporal resolution is essential and photoplethysmo­
graphy (Finapres) and transcranial Doppler ultrasonography (TCD) enable these 
measurements, respectively.20-22 During all measurements of cerebral hemodynamics, 
changes in end-tidal CO2 should be closely monitored.
We will address the measurements of these parameters in more detail below.
Cerebral Blood Flow
The inert gas method and the indicator dilution methods measure global CBF as blood 
flow in volume per unit weight per unit time (e.g. ml/100 g / min). These methods are 
rather invasive and time consuming, and the indicator dilution methods have a low 
temporal resolution.
In contrast, TCD is non-invasive, easy to use, and offers a very high temporal resolution 
(< 0.1 s) to monitor changes in CBF.20 TCD measures flow-velocity, in cm/s, in one of the 
supplying arteries of the brain, usually the middle cerebral artery (MCA). The flow-velocity 
in the MCA measured by TCD is determined by both the flow in the MCA and by its 
diameter, or rather its cross sectional area. Therefore, changes in flow-velocity recorded 
with TCD represent changes in flow, provided that the diameter of the insonated vessel 
remains constant. It has been demonstrated in (neuro)surgical patients that the diameter 
of the MCA does not significantly increase or decrease during, respectively, a mean 
decrease or increase in BP of 30 (SD 16) mmHg.23, 24 Furthermore, in healthy subjects, 
lower-body-negative pressure at 20 or 40 mmHg induced decreases in flow-velocity in 
the MCA, whereas diameter changes did not occur during these tests.25 These hemo­
dynamic changes are similar to those encountered in dynamic tests of autoregulation, as 
will be illustrated later. In this review, consistent with the literature on this subject, flow- 
velocity in the MCA as recorded with TCD is denoted as cerebral blood flow-velocity
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(CBFV), and it is assumed that changes in CBFV reflect changes in CBF. However, in 
contrast with other methods (see above) this representation of CBF does not include 
brain tissue weight. As a further caveat, these measurements only reflect changes in flow 
for the perfused territory. It is conceivable that the perfused territory of the insonated 
vessel (mostly the MCA) might change under pathological conditions such as focal 
cerebral ischemia or vasogenic edema and under non-pathological conditions such as 
hyper- or hypocapnia, and extreme hypoxia.
Some TCD devices include a provision to determine an index of the cross-sectional area 
of the vessel being insonated, according to the backscattered power. In surgical patients, 
the vessel area increased after inhalation of isoflurane, whereas CBFV remained 
unchanged.26 A similar observation was made during combined hypoxia and hyper- 
capnia, whereas during either hypoxia or hypercapnia alone, no change in vessel 
diameter was noted.27 These data suggest that stability of vessel diameter cannot be 
assumed under all conditions.
Arterial Blood Pressure
BP can be measured non-invasively and beat-to-beat with a servo controlled finger 
photoplethysmography as in the Finapres device.22 The obtained BP recordings using 
this device correspond well to invasive BP recordings in the brachial artery under various 
conditions, including during assessment of dCA.21 The combination of Finapres and TCD 
has made it possible to study the dynamic process of CA.
During BP recordings with Finapres, the finger is held at heart level. In autoregulation 
research using Finapres, changes in mean BP measured at heart level are used to estimate 
changes in cerebral perfusion pressure both in the supine position and during standing 
or head-up tilt. However, it has been argued that finger BP does not represent cerebral 
perfusion pressure because of the hydrostatic gradient between finger and brain when 
the subject is sitting or standing. On the other hand, if the heart - brain circulation is 
considered to represent a closed-loop system, the subject's body position should not 
matter. This is based on the assumption that the intracranial and cerebral venous 
pressures are relatively low and constant and that, during standing or sitting, hydrostatic 
components of intracranial and cerebral venous pressure at head level are reduced 
commensurate with arterial pressure as for a closed circulatory system.28 However, 
controversies regarding these assumptions must be recognized.29 Currently, there are 
no experimental data that either unequivocally support or disprove this theory.30
Carbon dioxide
Monitoring of CO2, mostly as end-tidal CO2, is essential in studies on cerebral perfusion
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and autoregulation. CO2 is a very potent cerebral vasodilator and hypercapnia may cause 
a 3 - 5 %  increase in CBF per mmHg rise in end-tidal CO2.31, 32 Hypocapnia induces 
vasoconstriction and can reduce CBF by 2-3 %  per mmHg reduction in end-tidal CO2. 
Thus, changes in respiratory pattern during tests of autoregulation may greatly confound 
measurements of CBF. Moreover, CO2 causes sympathetic activation and may cause a 
substantial rise in BP.31
Methods to induce hemodynamic changes
Essential for the evaluation of cerebral autoregulation dynamics is to observe the 
response of cerebral perfusion to an alteration in BP. There are several potential methods 
to induce oscillations or rapid changes in BP, of which the thigh cuff method was the first 
to be introduced.
Step decreases in blood pressure
Aaslid et al. introduced the thigh cuff method, which induces step decreases in BP by 
rapid deflation of cuffs around both thighs, after an inflation lasting at least two minutes.33 
A different approach to reduce BP is lower-body-negative pressure. If the atmospheric 
pressure surrounding the lower body (which is enclosed in a sealed box) is reduced, this 
reduces the extravascular pressure, which causes dilatation of veins and a lowered 
vascular resistance, increasing the flow to the lower limbs.34
Of interest, even without a change in mean BP, CBFV decreases during lower body 
negative pressure.16, 35 The exact mechanism that is responsible for this reduction in CBFV 
during lower body negative pressure remains uncertain; recently it was shown that it is 
not likely due to cerebral vasoconstriction caused by sympathetic activation.16 
Both the thigh cuff and the lower body negative pressure techniques have been 
developed to allow assessment of dCA in the supine position. This is of relevance in 
patients who are confined to bed, for example in head trauma patients in an intensive 
care unit. The thigh cuff method can be painful36 and is not a method of choice in aged 
subjects, although pain can be reduced if large-sized cuffs are used (R Aaslid, personal 
communication). Lower-body-negative pressure is also an uncomfortable procedure 
that is not well tolerated and cannot be applied in obese subjects. Therefore, both 
techniques are not ideally suited for the assessment of dCA in elderly patients. Since the 
majority of these patients can be tested in an upright position, alternative methods to 
induce oscillations in BP can be employed more efficiently.
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A simple and feasible method used to assess dCA is the Valsalva maneuver, which causes 
characteristic changes in BP as well as in CBFV.37 In this procedure the drop of BP is due 
to elevation of intrathoracic and intra-abdominal pressure induced by straining. With the 
rise in intrathoracic pressure the venous return falls, causing a reduction in cardiac 
output and hence a fall in BP, which in turn leads to baroreflex-mediated vasoconstriction.38 
The increase in intrathoracic pressure also causes an increase in intracranial pressure,39 
leading to a considerably stronger reduction in the cerebral perfusion pressure than 
indicated by the BP decrease. In addition, an increase in end-tidal CO2 pressure during 
the Valsalva maneuver has been observed40 and the effect on cerebral vessels of a change 
in arterial CO2 pressure has to be taken into account. These observations suggest that 
the Valsalva maneuver is too complex a method to quantify the effects of changes in BP 
on CBFV.
Placing a hand in ice water (cold pressor test), as well as isometric exercise such as 
sustained handgrip, result in increased BP by stimulating sympathetic efferent pathways. 
Both methods have been used for the assessment of dCA.41-43 However, the CBFV 
response to these tests is very heterogeneous.
A different stimulator of the sympathetic nervous system is passive head-up tilt.44 CBFV 
decreases during head-up tilt, and this test has been used to assess dCA in patients with 
syncope.45 However, during head-upright tilt in healthy subjects a slight, but significant 
drop in both end-tidal CO2 pressure and CBFV has been observed, without a change in 
the rate of breathing.46 The change in end-tidal CO2 is thought to be due to changes in 
the ventilation-perfusion relationship during tilting.
The role of the sympathetic nerve system in the regulation of CBF remains controversial. 
The cerebrovascular bed is well innervated by both sympathetic and parasympathetic 
nerve fibers,47 but most studies in animals have found that baseline CBF did not change 
after autonomic denervation.48 On the contrary, Zhang et al found that dCA was altered 
markedly after ganglion blockade, suggesting that autonomic neural control of the 
cerebral circulation is involved in beat-to-beat regulation of CBFV.49 Therefore, possible 
direct effects on cerebral vessels of sympathetic activation have to be taken into account 
when using these tests to induce an increase in BP and assess dCA.
A more straightforward technique used to assess dCA is the sit-to-stand procedure, 
which induces a depressor change in BP and CBFV. The reduction in BP (of approximately 
25%), resulting from an immediate and marked fall in total peripheral resistance upon 
standing, is presumably caused by cardiopulmonary baroreflex mechanisms.50 This 
characteristic decrease in BP, named initial orthostatic hypotension, is absent in passive
40
C LIN IC AL A N D  M E T H O D O L O G IC A L  BACKG RO U ND
tilt testing.51 After this initial decrease in total peripheral resistance, the arterial 
baroreceptors respond to the hypotension and the cardiopulmonary receptors react to 
the decline in preload, leading to an increase in total peripheral resistance. In figure 1, we 
present a typical BP and CBFV response in a healthy elderly subject during a sit-to-stand 
maneuver. Standing up causes a small decrease in end-tidal CO2, which cannot, however, 
explain the immediate decrease in CBFV upon standing.52
Figure 1 Blood pressure and cerebral blood flow velocity response during 
a sit to stand maneuver
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Leg en d : Continuous beat-to-beat blood pressure (BP) and cerebral blood flow-velocity (CBFV) 
measurements during a sit to stand maneuver in a healthy elderly subject. Beat-to-beat data were 
resampled at 2 Hz to create an equal time base. The subject starts standing after 30 s.
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When changing position from sitting to standing, the Doppler probe remains in the 
same spatial relation to the heart and Finapres finger cuff throughout the procedure in 
contrast to passive head-up tilt, and thus avoiding the issue of a possible hydrostatic 
effect on cerebral perfusion pressure. The sit-to-stand procedure is a useful and feasible 
method to test dCA in elderly subjects. An additional benefit of this method is that it 
represents a physiological challenge that occurs in daily life.
Oscillations in blood pressure
The techniques described above provide a single step challenge to cerebral hemo­
dynamics. In contrast, periodic squatting,53 oscillatory lower-body-negative pressure,54- 55 
oscillatory thigh cuff inflation and deflation,56 and periodic breathing,57 give rise to 
approximately sinusoidal oscillations in BP. When BP is forced to oscillate at a determined 
frequency, CBFV follows these induced oscillations. These induced periodic variations in 
BP and CBFV can be used for the assessment of dCA.
A disadvantage of the periodic breathing approach is that it may lead to a larger tidal 
volume and induce hypocapnia. Instructing patients to breathe slowly and with small 
tidal volumes can prevent hypocapnia. However, older subjects and subjects with 
cognitive impairment may not be able to adequately perform this technique. The same 
holds true for the technique of periodic squatting. The disadvantages of lower-body- 
negative pressure and thigh cuffs have been described above. A single sit-to-stand 
maneuver is well tolerated in elderly subjects. Therefore, repeated sit-stand maneuvers 
may be easier to perform and better tolerated in the elderly population. However, this 
procedure has never been tested to produce sinusoidal oscillations in BP It could be 
useful to test a well-developed repeated sit-to-stand protocol in experiments in the 
elderly population.
Fortunately, it is also possible to estimate dCA without inducing changes in BP BP 
oscillations ranging from 0.02 Hz to 0.4 Hz occur in humans over daytime and nighttime 
periods without an externally triggered BP manipulation, independent of stimuli of daily 
life.58 If spectral analysis is applied to this BP variability, three frequency ranges are 
noticeable: one around the respiratory frequency showing peaks at twelve cycles per 
minute (the high frequency region, respiratory waves, around 0.2 to 0.4 Hz); one around 
six cycles per minute related to variations in vasomotor tone (mid-frequency region, 
Mayer waves at 0.1 Hz); and the lowest frequency region, of which the cause is speculative, 
around one cycle per minute (low frequency region, 0.02Hz to 0.07Hz; alternatively 
named the very low frequency).59 Similarly, CBFV measured by TCD is not constant over 
time. Lindegaard et al. found individual ranges of spontaneous fluctuations between
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± 15% and ± 35% of the mean flow in patients after carotid endarterectomy.60 
Diehl et al. found oscillations of up to 30% of the mean CBFV with low frequency 
oscillations between 0.4 and 9 cycles/min.61 In conclusion, spontaneous fluctuations of 
BP and CBFV may be useful for the assessment of dCA.61 This mechanism limits the need 
for the above-mentioned methods to induce alterations in BP and seems to be the 
simplest method for assessment of dCA in a clinical setting.
Baseline (resting) measurements of BP are the most physiological situation to assess 
dCA. However, they depend on the magnitude of the spontaneous oscillations. This 
magnitude in turn depends on the variability of BP, which is not always high enough to 
allow estimations of dCA. Furthermore, spontaneous oscillations in the low frequency 
range appear inconsistently. These reasons may explain the lack of coherence between 
BP and CBFV (we will further explain and discuss the coherence below) in approximately 
10% of all spontaneous oscillation recordings.62 In this situation, augmented oscillations 
are expected to increase coherence between BP and CBFV, and it will be necessary to 
induce these oscillations using repeated maneuvers as described above.
Quantifications of Dynamic Cerebral Autoregulation
Following a change in BP, the relationship between CBF and BP has to be quantified. 
Here, we will discuss the methods that are most commonly used in clinical situations. 
These methods approach the relationship between BP and CBF as if it is linear. It should 
be noted that more complex mathematical models have been developed that allow for 
non-linear dynamics.63
In table 1 we provide an overview of the different quantifications discussed below. 
Cerebrovascular Resistance
Linear system analysis facilitates the examination of the transfer of BP oscillations to CBF 
as a measure of autoregulation. It quantifies the extent to which the BP input signal is 
reflected in the CBFV output signal. The regulator between the input and output is the 
resistance of the small cerebral vessels distal to the site of insonation. According to Ohm's 
law, this resistance is defined as mean BP / CBF. Thus, cerebrovascular resistance (CVR) is 
defined by mean BP divided by mean CBF:
Cvr = BPmean 
CBFmean
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The use of CBF to calculate CVR takes into account the brain weight, whereas studies 
that use TCD and measure flow-velocity lack this tissue weight. These studies calculate 
the cerebrovascular resistance index (CVRi), which is defined by the mean BP divided by 
mean CBFV:
CVRi = BPmean 
CBFVmean
Studies that use CBFV ideally would have to take into account the cross-sectional area 
factor between CBF and CBFV in addition to brain tissue weight in their estimates of 
cerebrovascular resistance. Furthermore, it should be emphasized that the use of the 
ratio between BP and CBF(velocity) to represent CVR(i) corresponds to a model where 
the cerebrovascular circulation is characterized by a single parameter. This calculation 
infers from Ohm's law and is based on a number of hypotheses and resistance is not 
measured directly.
Gosling's pulsatility index (PI) is sometimes used to reflect cerebrovascular resistance.64 
This index is defined as the difference between systolic and diastolic extremes of CBFV 
divided by the mean CBFV:
Pl = CBFVsys - CBFVdias 
CBFVmean
The PI changes with alterations in CVRi in the following manner. CVRi and the PI are both 
inversely correlated to CBFV in steady state (e.g. reduction in CVRi causes an increase in 
CBFV and a reduction in PI). Under these stable conditions a quantitative relationship 
indeed exists between CVR and PI. However, during neurally mediated syncope, CVRi 
decreases whereas the PI increases.45 Therefore, the PI cannot serve as an adequate 
parameter to assess dCA.
Another estimate for vasomotor resistance is the critical closing pressure, determined 
from the systolic-diastolic pressure-flow relationship within each heartbeat. The critical 
closing pressure of the cerebral circulation indicates the value of BP at which CBF is 
projected to approach zero.65 This value is obtained by linear extrapolation of the BP and 
CBFV values in the systolic to diastolic range that were obtained within each cardiac 
cycle. The slope of this "intrabeat" BP - CBFV curve is non-linear, however, and therefore 
it remains uncertain if the true critical closing pressure can be accurately predicted by 
linear extrapolation. The critical closing pressure has not been validated in disease states 
or in elderly subjects, and further research will be necessary to determine if it could be a 
useful tool. For a review, we refer to Panerai, 2003.65
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Table 1 Overview of the various dynamic quantifications of cerebral 
autoregulation in the time domain
CA m easurem ent A bbreviation Unit / Value Definition
CerebroVascular
Resistance
CVR mmHg/ml/
min
BPmean
CBFmean
CerebroVascular CVRi mmHg/ BPmean
Resistance Index cm/s CBFVmean
Pulsatility Index PI -- CBFVsys -  CBFVdias 
CBFVmean
Critical Closing 
Pressure
CrCP mmHg The extrapolated value of BP 
at which CBF approaches zero
Rate of Recovery RoR CBFV/s A C VRi/AT  
ABP
Autoregulatory Index ARI 0 - 9 9 models for CA:
0 indicates no autoregualion 
9 indicates very fast regulation
Correlation Coefficient Mx 0 - 1 Pearsons correlation coefficient 
between BP and CBFV
2
Time domain versus frequency domain
A linear system can be described in the time domain or in the frequency domain. We will 
first describe the techniques used in the time domain.
The time domain is used to describe the analysis of physical signals, with respect to time. 
The signal's value is known at various discrete time points and a time domain graph 
shows how a signal changes over time.
Rate of Recovery
The time of CBFV recovery after a single pressor or depressor stimulus is taken as a 
measure for the efficiency of dCA. One of the quantifications used in this approach is the
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rate of recovery. The rate of recovery is defined as the normalized changes in CVRi per 
second during a BP decrease:33
Rate of Recovery = ACVRi / AT 
ABP
This rate uses CVRi in the calculation, but, as mentioned above, this does not take into 
account the cross-sectional area factor between CBF and CBFV and lacks brain weight. 
Furthermore, this method has not been tested specifically in an elderly population.
Autoregulatory Index
Using the alterations in CVRi in relation to the change in BP during thigh cuff maneuvers, 
Tiecks et al. introduced the autoregulatory index.66 For an observed decrease in BP, a 
hypothetical CBFV curve without autoregulation is calculated. Eight other different 
computer models of possible flow-velocity curves are calculated as well, each assuming 
a higher degree of dCA. An autoregulatory index of zero indicates that CBFV passively 
follows BP (in other words, the percentage change in CBFV is equal to that of BP); a value 
of nine indicates that CBFV recovers much faster than BP. Panerai et al. demonstrated 
that this model can also be used to grade autoregulation using baseline recordings of BP 
and CBFV, estimating the impulse response function.67 This function expresses the 
relationship between BP and CBFV after a very short, impulse like, disturbance in BP. 
The autoregulation index has been applied in elderly subjects with hypertension, stroke, 
and carotid sinus syndrome (see section on CA in aging and co-morbidity).
Correlation Index
In patients with head injury, Czosnyka et al. calculated Pearson's correlation coefficients 
between consecutive samples of averaged cerebral perfusion pressure and flow velocity 
for every 3-minute period, determining a correlation index, known as 'Mx'.68 Lang et al. 
demonstrated that this index is valid if BP is used instead of cerebral perfusion pressure 
in these patients.69 This obviates the need for the invasive measurement techniques to 
determine intracranial pressure. Presently, however, the Mx has not been validated in 
non-brain trauma patients, and the proposed cut-off values were not valid in healthy 
subjects.70
The frequency domain
In the frequency domain, physical signals are described with respect to frequency.
In figure 2, we illustrate two signals that show clear repetitive patterns over time. In fact, 
they can be described as two sinusoidal waveforms (oscillations) with a given period, T,
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and amplitude A and B. The frequency in Hertz (Hz) is calculated from the period:
F = ±
T
Giller was the first to use frequency domain analysis to describe the relation between 
oscillatory patterns of BP and CBFV.71
In figure 3A, we present an example of the spontaneous oscillations in BP and CBFV 
recorded in a healthy old subject over a period of 5 minutes of rest in sitting position. 
The signals are composed of several different oscillations with different periods (and 
thus frequencies) and amplitudes. Spectral analysis makes it possible to create the 
frequency domain graph that shows the frequency spectrum of these different 
oscillations that are hidden in the signal. In figure 3B, we illustrate the power spectra of 
the two signals presented in figure 3A. A power spectrum is a frequency graph that 
describes how much of the signal lies within a given frequency.
In the frequency domain analysis, the regulation of CBF in response to changes in BP can 
be described using transfer function analysis. Transfer function analysis makes it possible 
to examine the transfer of the BP oscillations to CBF as a measure of autoregulation. It 
quantifies the extent to which the input signal, BP, is reflected in the output signal, CBF, 
with CA as the regulator between the input (BP) and output (CBF).
The regulation of CBFV is effective in the low-frequency range of BP fluctuations, but not 
in the high-frequency range because of the time delay required to initiate cerebrovascular 
adaptations to changes in perfusion pressure. Therefore, CA functions like a high-pass 
filter, allowing rapid BP changes to be transmitted to CBFV, whereas slow BP changes are 
filtered. CBFV in relation to BP can therefore be expressed by transfer function analysis 
using a high-pass filter model in the frequency range of 0.07 - 0.30 Hz.72- 73
Gain, Phase and Coherence
The transfer function between the oscillations in BP and CBFV in this autoregulatory 
system is characterized by three parameters: gain (or magnitude), phase shift, and 
coherence.
The gain, or transfer magnitude, quantifies the damping effect between the input and 
output of the transfer function. Provided that in figure 2, waveform 1 is the input and 
waveform 2 is the output of the transfer function, the regulator in this system attenuates 
the amplitude of the input (A), yielding a low value for gain.
In the transfer function between BP and CBFV, the gain represents the damping effect of
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00 Table 2 Dynamic cerebral autoregulation in healthy, elderly people
Authors Study sample Measurement Assessment dynamic CA Conclusion
Lipsitz et al. N=10, age 24+/-1 years Continuous cerebral blood flow Transfer function Elderly normotensive and previously
2000 N=10, age 72+/-3 years 
N=10, age 72+/-2 years
velocity (CBFV) and blood pressure (BP) 
measurements during standing and 
steady-state sitting and standing
analysis treated hypertensive elderly 
subjects retain dynamic cerebral 
autoregulation (CA)
Carey et al. 2000 N=27,29 +/- 5 years 
N=27,68 +/- 5 years
Changes CBFV and BP were measured 
during:
Lower body negative pressure release, 
Valsalva maneuvre,
Spontaneous rises,
Thigh cuff test,
Spontaneous falls
Autoregulatory index 
values of each subject 
for each dynamic (de) 
pressor stimulus;
Step response analysis
Dynamic CA is unaffected by aging
Narayanan et al. N=10, age 24+/- 1 CBFV and BP recordings of oscillations Transfer function Dynamic CA in healthy elderly
2001 N=10, age 72+/-3 during sitting and standing analysis subjects is intact in the low 
freguency range
Carey et al. 2003 N= 25, 28+/-8 years 
N=25,69 +/-10 years 
(five very elderly, >75 
years)
Changes in CBFV and BP were 
measured during head-uptilt
Autoregulatory index Dynamic CA during orthostatic stress 
is unaffected by aging
Heckmann et al.
2003
N= 18,29,4+/-4,7 years 
N= 18, 66,5+/-5,8 years
Continuous monitoring of CBFV and 
BP during ergomotor exercise
Pulsatility index Cerebral autoregulatory capacity 
is retained but delayed in elderly 
subjects
Sorondetal. N= 13,30 (7) years 
2005 N= 13, 74 (4) years
Continuous CBFV and BP 
measurements in response to standing 
from a sitting position
Yam et al. 2005
Franke et al.
2006
1=16, age 28+/-5 
1=16, age 54+/-8
1=10, 72+/-1 
1=10, 73+/-2 
1=10,23 +/-1 
1=10,23 +/-1
CBFV and BP recordings of 
spontaneous oscillations
CBFV continuous measurements; BP 
assessment every minute
4*-vo
Rate of recovery
Correlation index
Cerebrovascular 
resistance, pulsatility 
index
Older participants have a similar 
decline in CBFV in both territories 
and a significantly larger CBFV 
decline in the posterior cerebral 
artery compared to the middle 
cerebral artery.
No correlation between age and 
correlation index
Older subjects autoregulate CBFV as 
well as younger subjects regardless 
of fitness
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Figure 2 Transfer function analysis
Period = T (s) 
F  = 1/T Hz
Phase Shift 
W1 - W2
Leg en d : Graphical explanation of the concept of transfer function analysis. Two sinusoidal 
waveforms with the same period (T) are presented. Waveform frequency (F) is defined as 1/T. 
The solid line represents waveform 1 (W1), with amplitude A. The dashed line represents 
waveform 2 (W2), with amplitude B.
The gain is the damping effect between W1 and W2, and the phase shift represesnt the time 
delay between W1 and W2. Provided that W1 is the input and W2 is the output of the transfer 
function, the regulator in this system attenuates the amplitude of the input leading to a lower 
amplitude (gain) of W2. The phase shift of W2 characterizes the displacement in time of this 
waveform relative to W1.
CA on the magnitude of the BP oscillations. The gain of this transfer function marks the 
efficiency of the regulator, which is the response of CA. A low gain indicates an efficient 
autoregulation, whereas an increase in gain represents a diminished efficiency of the 
dynamic process of CA. According to the high-pass filter model of CA, the gain rises with 
increasing frequencies of BP oscillations.55
A specific problem in the interpretation of gain is that absolute measures of gain 
(estimated from transfer function analysis of absolute changes in CBFV and BP) are 
influenced by baseline values of CBFV and BP. Especially for CBFV, interindividual
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Figure 3a Spontaneous oscillations of blood pressure and cerebral blood 
flow velocity
0 50 100 150 200 250 300 
Time (s)
■T . . . . . . . . . . . . . . . . . . . . .
0 50 100 150 200 250 300 
Time (s)
Leg en d : 5 minutes of continuous blood pressure (BP) and cerebral blood flow velocity (CBFV) 
measurements in a healthy elderly subject in sitting position, showing spontaneous oscillations 
in both signals.
2
differences can be substantial, and reflect differences in MCA diameter rather than 
baseline differences in flow. Therefore, normalization of gain has been proposed. This can 
be achieved by substituting gain by the product of gain and cerebrovascular resistance, 
named normalized gain. If the CVRi is determined from averaged baseline values for BP 
and CBFV, normalized gain is mathematically similar to gain calculated from relative 
changes in BP and CBFV.74- 75
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Figure 3b Power spectra blood pressure and cerebral blood flow velocity
Freu q ency  (Hz)
Freq u ency  (Hz)
Leg en d : The power spectra of the blood pressure (BP) and cerebral blood flow (CBFV) data 
presented in figure 3a, obtained after spectral analysis. The power spectra describe how much of 
the BP and CBFV oscillations lie within a given frequency. Note the different scales on the y-axis, 
illustrating the difference of the magnitude of the oscillations in BP and CBFV.
The second parameter of the transfer function we will discuss is the phase shift. 
Synchronous waveforms are "in phase". The phase shift of a waveform therefore represents 
the displacement of this waveform relative to another waveform with the same period 
(Fig 2). The phase shift can be expressed in degrees from 00 to 360°, or in radians from 0 
to 2 n, thus ranging from no phase shift to a phase shift of one full period. The phase shift 
can be recalculated to a time difference between two signals: a 900 phase shift between
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two signals with 10 s periods equals a time delay of 2.5 s between these signals.
The oscillations of CBFV do not occur simultaneous to those of BP. Changes in CBFV 
recover faster than changes in BP, which causes a displacement of CBFV relative to BP in 
such a manner that CBFV oscillations appear to lead BP oscillations. This is interpreted as 
intact dCA.76 In relation to BP, this leftward shift is mathematically negative. However, in 
literature, the phase shift between BP and CBFV is often given as a positive number and 
is defined as a "phase lead". A positive phase indicates an intact CA, whereas in patients 
with a complete loss of CA, the phase shift between CBFV and BP is expected to be close 
to 0° In a clinical population of patients with carotid stenosis or occlusion, phase shifts 
were significantly lower than in normal subjects and could sometimes approach 0 °57- 77 
Phase shifts can be considered surrogate measures for the time delay of the auto­
regulatory response. When we translate the phase shift to the time domain, a phase shift 
of 0 means no time delay between oscillations of BP and CBFV.
The measurement of phase shifts and gain is applicable to all stationary models that 
induce oscillatory BP and CBFV changes, and these parameters have an apparent 
relationship to the rate of autoregulation. During induced oscillations in the three 
frequencies regions (the high, > 0.2 Hz, low, 0.07 - 0.20 Hz, and very low frequencies,
< 0.07 Hz), the gain values increased and the phase shifts decreased with increasing 
frequency.55 Analysis of spontaneous oscillations yielded the same results.72- 73 These 
results all confirm the high-pass filter model of dCA. In assessing dCA, gain should be 
calculated in combination with phase shifts. For the calculation of phase shifts during a 
short, nonstationary BP/CBFV response, multimodal pressure-flow analysis has been 
introduced as a mathematical tool.78
The third parameter of the transfer function, the coherence function, tests the linearity 
of the relation between input and output. Coherence approaching unity in a specific 
frequency range suggests a linear relationship in this domain, whereas coherence 
approximating zero may indicate no relationship between the signals. However, a low 
coherence could also indicate severe extraneous noise in the signals.71, 79 Therefore, for 
the calculation of phase shifts and gain values, thresholds of coherence of > 0.4 or > 0.5 
have been used by most researchers.72' 73 Conversely, low coherence can also be an 
expression of the nonlinear qualities of dCA and the validity of using these cut-off and 
maximum points is debatable.80 A solution to this limitation is to induce oscillatory 
changes in BP and CBFV. Several maneuvers (as described above) induce oscillations. 
These enlarge the power of the oscillations and thereby the coherence of the transfer 
function.55 These maneuvers can be performed in the different frequency regions. 
Another possible solution is non-linear analysis and the use of more complex 
mathematical models.
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In accordance with the high-pass filter model of dCA, in healthy older people values of 
coherence and gain are the highest in the high frequency region of BP oscillations and 
the lowest in the very low frequency region, whereas phase shifts are the highest in the 
very low frequency region and the lowest in the high frequency region.15, 73, 81
Dynamic cerebral autoregulation in elderly subjects 
Healthy elderly
To include all the literature regarding the dynamic process of CA in healthy elderly 
subjects, we performed a literature search with the following search terms: cerebrovascular 
circulation, cerebrovascular disorders, and aged. Furthermore, we used free text words, 
aging, ageing, elderly, and the truncated free text words cerebr* and autoreg*. We found 
eight studies that have investigated dCA in healthy elderly subjects.82-84 These studies 
compared the autoregulatory capacity of healthy young subjects with healthy aged 
people. An overview of these studies is presented in Table 2. The age range was 50 -75 
years. All studies measured BP and assessed CBFV in the MCA, using TCD; one study also 
measured CBFV in the posterior cerebral artery.85 Unfortunately, important methodological 
differences exist among these studies in the measurements and assessments of dCA. 
Different investigators measured spontaneous oscillations of BP and CBFV during sitting 
and standing, and calculated transfer functions (resulting in values of gain, phase shifts 
and coherence) in elderly people.15, 81 Yam et al. also made use of spontaneous BP and 
CBFV recordings in moderately aged people, but these investigators calculated the 
correlation index between BP and CBFV.70 Sorond et al. measured BP and CBFV in elderly 
subjects during a sit-to-stand procedure and evaluated the rate of recovery of CBFV.85 
Carey et al. used lower-body-negative pressure, the Valsalva maneuver, spontaneous 
oscillations, the thigh cuff test, and head-up tilt to induce BP changes and for each test 
they assessed the autoregulatory index.82, 83 These investigators measured dCA in 25 
aged subjects, including five subjects >75 years. Heckmann et al. determined dCA during 
ergomotor exercise in older subjects and calculated the PI.86 Franke et al. assessed the PI 
in two different groups of elderly people; one group of fit elderly subjects and one group 
of frail elderly subjects. They measured CBFV continuously, but assessed BP only once 
every minute.84 To determine dCA, BP should ideally be measured continuously. 
Regardless of the method by which it was assessed, all studies concluded that in healthy 
aged subjects, dCA is preserved during induced drops in BP and during spontaneous
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oscillations in BP in the low frequency range (0.07 - 0.20 Hz). In the high frequency range 
(> 0.15 Hz), dCA is less efficient in both young and older people.15 This is in agreement 
with the concept that the relationship between CBFV and BP can be expressed by 
transfer function analysis using a high-pass filter model (see above). The studies that 
calculated changes in the CVRi and the PI also concluded that cerebral autoregulatory 
capacity is retained, regardless of physical fitness.84, 86 However, these investigators noted 
that the change of the PI in healthy elderly is delayed during ergomotor exercise 
compared to young subjects.86 The CVRi and the PI only have a quantitative relationship 
under stable conditions and therefore these parameters are difficult to interpret during 
exercise.
Most investigators studied dCA in the MCA, but the posterior cerebral artery (PCA) can 
also be insonated with the TCD,20 and dCA can be investigated in the posterior circulation. 
Sorond et al. observed that CBFV in the PCA declined to a greater extent than in the MCA.85 
In both young and aged humans, the characteristics of dCA in the PCA differ from that in 
the MCA. The regulation of CBFV in the PCA to spontaneous BP oscillations acts as a 
high-pass filter, similar to the MCA.87 The phase shifts in the PCA suggest that the latency 
of CA is sufficient, as it is in the MCA territory, but in all frequency ranges the gain values 
in the PCA were significantly higher compared to the values in the MCA. These higher 
magnitudes do not necessarily indicate an inefficient autoregulation in the PCA, 
considering the similar phase shifts. This dissimilarity in gain more likely is reflective of 
the different resonance properties of the two vascular beds, and of the combination of 
different flow and different vessel diameter; flow-velocity in the MCA is approximately 
1.5 times higher than in the PCA.85, 87
In summary, no evidence was found for an effect of aging on dCA in the age ranges 
studied (50-75 years). Whether dCA is preserved at more advanced age (>75) is at present 
unknown.
CA in aging and co-morbidity
With TCD, CBFV can be measured during gradual and prolonged changes in BP, cf. the 
classical method to determine CA.88 Under normal conditions, the upper and lower limits 
of CA are found at 60 and 150 mmHg mean arterial pressure, respectively. The important 
difference between measurement of classical and dynamic CA is that the classical 
measurements are performed in the semi-steady state and the use of vasoactive 
medication is necessary to drive these prolonged changes in BP. In contrast to this
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approach, dCA measures flow changes in response to BP fluctuations that are mostly 
within the limits of autoregulation.
In one study in normal human subjects, dynamic measurement of CA yielded results 
similar to static testing under conditions of intact autoregulation, as well as following 
pharmacologically induced impairment of autoregulation.66 However, very few studies 
have combined estimations of sCA and dCA. Therefore, further research should combine 
sCA and dCA and attempt to describe the behavior of dCA around the lower and upper 
limits of BP as identified by the classic sCA curve.
However, for clinical applications, dynamic measurements of CA are probably the method 
of choice. This practice is non-invasive, less prolonged, could be performed at bedside, 
and pharmacological interventions are not necessary.
Diseases such as acute ischemic stroke may bilaterally impair sCA leaving the brain tissue 
unprotected against the potentially harmful effect of BP changes.2 Stroke is more 
common in older subjects, and 72 - 96 hours after an acute stroke dCA is bilaterally 
impaired, rendering CBFV dependent on BP.8, 89 Rheinhard et al. found no major 
disturbance of dCA after 4 - 48 hours after stroke. However, after 72 - 171 hours, they 
found a trend towards poorer autoregulatory values. Therefore, it could be argued that in 
post-stroke patients, BP should be well controlled to stabilize CBF and to prevent cerebral 
hyperperfusion or ischemia. However, which levels of BP are acceptable in the acute 
stroke phase, and to which level BP can or should be lowered, is still uncertain.90 Further 
research addressing the dynamic pressure-flow relationship in acute stroke may help to 
shed light on this important issue.
For hypertensive patients, estimations of CA offer a simple method to evaluate not only 
the effect of hypertension, but also the effect of antihypertensive treatment on cerebral 
perfusion. Because of an upward shift of the lower limit of the sCA curve towards higher 
pressure and with this, a possible impaired tolerance to a decline in BP, a conservative 
approach in elderly patients with hypertension has been suggested.91 However, classical 
studies of sCA have shown that this rightward shift with hypertension undergoes a 
leftward shift with treatment.92 Indeed, with dCA, middle-aged and elderly (<75) 
hypertensive patients were found to retain the ability to maintain CBFV in the face of 
acute BP changes, assessed by the autoregulatory index during different maneuvers.93 
Using the autoregulatory index during the Valsalva Maneuver, Novak et al. did not find 
any difference between healthy normotensive and hypertensive middle aged subjects.78 
However, when they used the multimodal pressure-flow analysis, they observed a smaller 
phase shift-pointing towards less efficient autoregulation in the hypertensive group. 
In patients with controlled hypertension, the cerebral autoregulatory response was
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preserved.94 In newly diagnosed middle-aged patients with untreated mild-to moderate 
hypertension, dCA was normal. Short- and long-term reduction of BP did not compromise 
dCA.16 Furthermore, in uncontrolled hypertensive patients with a mean age of 72 years, 
6 months of successful, aggressive treatment with antihypertensive therapy increased 
CBFV significantly compared to controlled hypertensive patients and healthy controls.17 
This therapy did not impair dCA assessed with an active sit-to-stand procedure. 
Autoregulation studies can contribute valuable clinical information regarding CBF 
control by identifying or confirming patients at high risk for impaired cerebral perfusion. 
Transient cerebral hypoperfusion can lead to syncope, which is a common medical 
problem in the elderly.95 In addition, many older patients are vulnerable to cerebral 
hypoperfusion following orthostatic BP decreases.11 The combined mechanisms of 
(baroreflex mediated) BP regulation and CA limit the reduction of the cerebral perfusion 
induced by the postural position. However, if, despite these protective mechanisms, 
cerebral perfusion becomes impaired, symptoms of orthostatic hypotension such as 
dizziness and syncope occur.96 For recurrent falls among elderly subjects, orthostatic 
hypotension is an independent risk factor, but orthostatic hypotension alone may not be 
sufficient to produce symptoms like falls in most elderly patients.97 In contrast, decreases 
in standing BP that are smaller than the formal definition of orthostatic hypotension 
(a decrease of 20 mmHg or more) may exceed the threshold for CA in some patients and 
therefore be sufficient to cause cerebral hypoperfusion. In many patients with orthostatic 
hypotension BP remains within the autoregulatory range. Because of CA, the effect of a 
given change in BP on cerebral perfusion cannot be predicted.
Conclusion
Classic studies regarding CA are performed in the semi-steady state, and they measure 
CBF after a persistent change in BP with a gradual onset. In contrast, recent studies have 
investigated the fast modifications of CBF in relation to rapid changes in BP. Technological 
developments, such as TCD and servo controlled finger photoplethysmography, have 
offered the possibilities to investigate more thoroughly the dynamics of the process of 
CA. This dynamic approach is the most promising approach for the clinical evaluation of 
CA. These measurements are less time consuming, entirely non invasive and could be 
performed at bedside.
However, no uniform method exists to assess the dynamic cerebral autoregulatory 
capacity of the human brain. Researchers have introduced several techniques to
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challenge CA, ranging from a single episode of induced hypotension to induced 
oscillatory changes in BP, and additionally have used spontaneous BP oscillations to 
quantify dCA. The quantifications used vary from calculated indices using regression 
analysis, to rate of CVR changes and to transfer function analysis. We have provided an 
overview of the various methods applied to study CA dynamically.
Subsequently, we have reviewed the literature regarding dCA in healthy elderly subjects. 
Regardless of the assessment used, dCA is preserved in healthy elderly subjects < 75 
years. Owing to this intact dCA, a lowering of BP should not influence CBF. However, in 
diseases affecting the elderly, symptoms of cerebral hypoperfusion are frequent. Testing 
the dynamic cerebral autoregulatory capacity could be a promising tool to determine 
the risk of hypoperfusion and ischemia of the brain.
To determine dCA during orthostatic stress, the sit-to-stand procedure is a feasible 
method in elderly patients. Baseline measurements of spontaneous fluctuations in BP 
and CBFV are elegant measurements to assess dCA and ask little of the patient. If the 
magnitude of the spontaneous oscillations in BP is not high enough to assess dCA (i.e., 
coherence is < 0.4), it may be necessary to induce oscillations with any of the methods 
described above. In both situations, CBFV in relation to BP can then be expressed by 
transfer function analysis using a high pass-filter model resulting in values of gain, phase 
and coherence. More clinical studies are necessary to investigate the effect of a truly old 
age (80 and older) and co-morbidity on the dynamic pressure flow-relationship. 
At present, technological developments have given good prospects to study this 
relationship in the elderly population.
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Abstract
The aim of this study was to assess the feasibility and reproducibility of a simple and 
non-obtrusive repeated sit-stand maneuver to assess cerebral autoregulation (CA) in 
healthy old > 70 years. In 27 subjects, aged 76 (SD 4) years we continuously measured 
blood pressure using photoplethysmography and cerebral blood flow velocity in the 
middle cerebral artery (transcranial Doppler ultrasonography) during 5 minutes of sitting 
rest and again during repeated sit-stand maneuvers at 10 s (0.05 Hz) and 5 s (0.1 Hz) 
intervals. In 11 randomly selected subjects these measurements were repeated after 3 
months. Both maneuvers induced substantial periodic oscillations in pressure and flow. 
For example, the maneuvers at 0.05 Hz increased the power spectral density (magnitude) 
of blood pressure and cerebral blood flow velocity oscillations with 16.3 (mmHg)2 and 
14.5 (cm/s)2 , respectively (p < 0.001). These larger oscillations led to an increase in transfer 
function coherence compared to spontaneous oscillations from 0.46 to 0.60 for 0.05 Hz 
maneuvers and from 0.56 to 0.76 for 0.1 Hz maneuvers (p < 0.01), allowing for more 
confident assessment of CA through transfer function phase and gain. This increased 
coherence was not associated with improved reproducibility however. In conclusion, we 
were able to investigate CA in old patients using these repeated sit-stand maneuvers, 
which, compared to spontaneous oscillations, produced a stronger and more clinically 
relevant hemodynamic challenge for CA.
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Introduction
To maintain a stable cerebral blood flow during changes in blood pressure (BP), the 
cerebral circulation has an autoregulatory system based on myogenic, metabolic, and 
neurogenic mechanisms that adapt cerebrovascular resistance in response to alterations 
in BP.1 The rapid regulation of cerebral blood flow in response to fast (within seconds) BP 
modifications is determined by dynamic cerebral autoregulation (dCA). dCA must be 
distinguished from static cerebral autoregulation, which describes the adaptation to 
slower and more gradual (within hours or days) BP changes.2- 3
Studies in healthy aging (< 75) suggest that the regulation of cerebral blood flow is 
preserved and that dCA blunts the effects of rapid BP changes.4 However, data in the 
aging population are scarce, especially for those over the age of 75. In these older 
patients, autoregulation studies can contribute valuable clinical information by 
identifying patients at high risk for cerebral ischemia due to impaired perfusion. In order 
to differentiate between health and disease in aging however, it is essential to be better 
informed of the influence of normal aging on the behavior of dCA. In this population, it 
is essential that methods to assess dCA are minimally obtrusive. As such, the dynamic 
component of cerebral autoregulation is well assessed by beat-to-beat measurements of 
BP and cerebral blood flow velocity (CBFV), facilitated by Finapres and transcranial 
Doppler ultrasonography respectively.5- 6 Transfer function analysis of spontaneous oscil­
lations in BP and CBFV enable the assessment of dCA under resting conditions and 
therefore would seem ideally suited for older subjects.4
Unfortunately, this method has two important limitations. First, in the low frequencies 
where dCA is active (< 0.15 Hz), only a small part of the spontaneous variability in CBF 
can be confidently ascribed to BP variability.7 This most likely reflects effective dynamic 
autoregulation, which reduces the effect of BP variability on CBF variability. In transfer 
function analysis, this is expressed in low values for coherence. Second, the oscillations 
in the frequencies of interest may show considerable variability over time in both 
presence and strength (magnitude) and therefore may not reliably be captured in a short 
period of observation (dCA measurements are often limited to 5 or 10 min for reasons of 
feasibility). These two issues can be addressed by methods that generate a constant 
series of more substantial BP and CBFV fluctuations in the frequency range of interest.4- 8 
None of these currently available methods, which include repeated squatting, cyclic 
thigh cuff inflation/release, cyclic lower body negative pressure, and cyclic tilt table 
testing, however are deemed suitable for clinical application in older patients as they are 
too obtrusive.4
Actively moving from sit to stand as a single maneuver has been utilized in old subjects
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to measure dCA in a simple fashion.9, 10 However, this method produces a single and 
unidirectional hemodynamic challenge (a transient BP reduction), whereas we aim to 
induce periodic changes in BP which include both reductions and increases in BP. 
Sit-stand maneuvers that are repeated at low frequencies could therefore be a straight­
forward and well-tolerated method to evoke BP and CBFV fluctuations in a desired 
frequency. This would then provide a physiological maneuver that is also representative 
of every day hemodynamic challenges.
The aim of this study was to assess the accuracy, reproducibility, and feasibility of 
repeated sit-stand maneuvers to produce robust and clinically relevant BP and CBFV os­
cillations and to assess dCA in old subjects aged > 70 years. We used transfer function 
analysis of spontaneous oscillations as the reference standard against which we 
compared this new method.
Subjects and methods
Ethical approval
The study was approved by the Ethics Committee for Research on Human Subjects of 
the Radboud University Nijmegen Medical Center and all volunteers gave written 
informed consent.
Subjects
We recruited 27 community-dwelling older volunteers (19 men, 8 women; mean age 76 
(SD 4.0) years (range 71 - 86), systolic BP 149 (18.3) mmHg, diastolic BP 83.6 (8.0) mmHg), 
BMI 25.3 (2.6) kg/m2, who responded to a newspaper advertisement. All subjects were 
examined by a geriatrician, and carefully screened with medical history, physical 
examination, and ECG to exclude acute medical conditions. Subjects were active and 
independent, did not smoke, and had no history of cerebrovascular and neurological 
disorders. Four subjects had controlled hypertension and used antihypertensive drugs: 
diuretics (n = 3) and p-blockers (n = 2). A Doppler study of the carotid and vertebral 
arteries was performed and significant stenosis (> 50 % ) was ruled out. Subjects were 
positively evaluated for having an adequate temporal w indow for insonation of the 
middle cerebral artery.
Instrumentation
Subjects were seated. First, they received a three-lead ECG for measurement of the R-R 
interval. BP was measured using a photoplethysmographic cuff on the index or middle
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finger of the left hand (Finometer, Finapres Medical Systems, the Netherlands); this 
method can be used with confidence to assess dCA.11, 12 The hand with the cuff was 
supported by a sling with the hand resting approximately at heart level. Data was 
collected by the Finometer for an uninterrupted period which lasted for a maximum of 7 
minutes. Continuous transcranial Doppler ultrasonography was used to measure CBFV. 
When possible, both the left and right middle cerebral artery were insonated by placing 
a 2-MHz Doppler probe (Multi-Dop, Compumedics DWL, Germany) over the temporal 
window. The middle cerebral arteries were identified according to their signal depth, 
velocity, and wave characteristics.5 The probes were locked at a constant angle and 
position with a customized headband (Spencer technologies, Seattle, Wa) and the 
location of the temporal w indow and the Doppler probe settings (signal depth, sample 
volume) were noted for each subject.
Arterial saturation (SaO2) was recorded with a pulse oximeter and end tidal CO2 (EtCO2) 
using a capnograph (N1000, Nellcor, Boulder Co).
Procedure
From twelve hours before the study, subjects refrained from using caffeinated beverages 
and alcohol, and they used a light breakfast at least two hours before the visit. All 
experiments were performed in the morning, in a quiet environmentally controlled 
laboratory. A subgroup of randomly selected subjects (9 men, 2 women; mean age 77 (5) 
years, range 71-86) underwent the experiments twice, 3 - 4 months apart. This time 
interval was chosen because the evaluation of an intervention - for example, the effect 
of antihypertensive treatment on cerebral autoregulation - generally leads to a similar 
test-retest interval. After at least 30 min of sitting rest, data were collected for 5 minutes 
during sitting. These data were used for spectral and transfer function analysis of 
spontaneous oscillations in BP and CBFV.
To create BP and CBFV oscillations in the frequency range relevant for studying dCA, we 
used repeated sit-stand maneuvers at two distinct frequencies. Subjects were instructed 
to perform repeated sit-stand maneuvers at a frequency of 0.1 Hz (low frequency; 5 s sit 
followed by 5 s stand (5/5s maneuver)) for 4 minutes and 0.05 Hz (very low frequency; 10 
s sit followed by 10 s stand (10/10s maneuver)) for 5 minutes, separated by 10 minutes 
of recovery. Verbal signs were given in this frequency to facilitate stable repeated 
movements.
Data processing and analysis
All data were simultaneously analogue/digital converted and sampled at 125 Hz with 
commercially available data acquisition software (Oxysoft, Artinis Medical Systems, the
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Netherlands) and recorded for offline analysis. Frequency domain analysis was performed 
on beat-to-beat mean BP and CBFV. The changes in mean BP and CBFV were aligned 
with the time of the R wave peaks of the ECG. Heart rate (HR) was assessed from the RR 
interval. The time series were linearly interpolated at 2 Hz to obtain equidistant time 
intervals and then detrended with third-order polynomial fitting. The latter procedure 
ascertains signal stationarity, a prerequisite for spectral analysis, without affecting very 
low frequency oscillations.13 These series were smoothed using the Welch method, with 
a subdivision into 128-segments (64 s) with 50 %  overlap, yielding at least six data 
segments for each recording with a spectral resolution of ~ 0.0156 Hz. Each segment was 
previously windowed with a Hanning window. The data segmentation is based on a 
trade-off between a reduction in spectral variance and keeping sufficient spectral 
resolution. Each Hanning windowed segment was fast-Fourier transformed and the peri- 
odograms were averaged to calculate the autospectrum of BP and CBFV.
Evaluation of autoregulation
We have previously described the relation between oscillations in BP and CBFV using 
transfer function analysis in details.4, 8 In short, the transfer function between these two 
parameters is characterized by the parameters gain, phase shift, and coherence. Gain 
represents the damping effect of dCA on the magnitude of the BP oscillations and marks 
the efficiency of dCA. Phase shifts quantify the displacement of CBFV oscillations relative 
to those of BP. Because changes in CBFV recover faster than changes in BP, CBFV oscilla­
tions appear to lead BP oscillations, which is indicated by a positive phase shift. The last 
parameter of the transfer function, coherence, tests the linearity of the relation between 
BP and CBFV oscillations. Since coherence approaching zero may indicate no relation­
ship between the signals, severe extraneous noise in the signals, or a non-linear relation­
ship, a value of 0.4 is considered the lower limit where transfer function estimates can be 
calculated with confidence.13 By convention, therefore, data with coherence <0.4 are 
excluded from analysis in most published studies. In this study, we will present data both 
with and without exclusion of coherence <0.4.
Transfer function analysis for spontaneous oscillations was carried out in three previously 
defined frequency domains: very low frequency (VLF; 0.02 - 0.07 Hz), low frequency (LF; 
0.07 - 0.2 Hz), and high frequency range (HF; 0.2 - 0.35 Hz).13 For analysis of the induced 
oscillations, the ranges surrounding the dominant frequency peaks in the power spectra 
around 0.05 and 0.1 Hz were selected for analysis (0.016 - 0.078 Hz and 0.07 - 0.13 Hz 
respectively).
To assess the accuracy of the repeated sit-stand maneuvers, spectral and transfer 
estimates of the sit-stand maneuvers were compared to those of the spontaneous oscil­
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lations in the same frequency range, i.e. the 10/10s maneuver to the VLF and the 5/5s 
maneuver was compared to the LF range.
If two signals were available, we averaged the different values of CBFV and the transfer 
function parameters of both sides for each subject; otherwise we included the available 
signal for group analysis. All analyses were performed with commercially available 
software (DADiSP, DSP Development, Cambridge, MA).
Statistical analysis
Data are presented as mean (SD). We tested normal distribution using q-q plots. Normal 
distribution could be assumed for baseline hemodynamic parameters, but not for 
spectral and transfer function analysis parameters. Repeated measures ANOVA or the 
non-parametric Friedman test with Bonferroni correction for multiple comparisons were 
applied to compare the variables between spontaneous oscillations and the sit-stand 
maneuvers.
For analysis of reproducibility group averages of the two different measurements were 
compared using the Wilcoxon signed rank test. Differences between the two measure­
ments are presented as the typical error expressed as coefficient of variation (CoV).14 The 
amount of intra-subject variability in relation to corresponding values of inter-subject 
variability was expressed using an intraclass correlation coefficient (ICC).14
Results
General results
All subjects underwent baseline measurements but because of orthostatic hypotension, 
one subject was excluded for the repeated sit-stand maneuvers. The experiments were 
well tolerated by all subjects. Average BP, HR, CBFV, and EtCO2 in rest and during the 
repeated sit-stand maneuvers are presented in Table 1. Maneuvers increased BP, HR, and 
CBFV relative to resting conditions (p < 0.05). BP was higher in the 5/5s maneuver than 
in the 10/10s maneuver (mean difference 4.8 mmHg, p < 0.05). EtCO2 decreased slightly 
(0.8 mm Hg, p < 0.05) during the 10/10s maneuver compared to sitting rest.
Spectral analysis
Figure 1 shows examples of the BP and CBFV oscillations during sitting rest (figure 1a), 
and during the 10/10s and 5/5s repeated sit-stand maneuver (figure 1b and 1c, respec­
tively). Figures 2a and 2b demonstrate that the magnitude of spontaneous oscillations of 
both BP and CBFV was highest in the very low frequency and declined with increasing
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Figure 1 Example of blood pressure and cerebral blood flow velocity oscillations 
in sitting rest and during the 5/5s and 10/10s repeated sit-stand 
maneuvers in one subject
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Legend: Data from one subject, showing beat-to-beat variability in blood pressure (BP) 
(left panel) and cerebral blood flow-velocity (CVBFV) (right panel), in sitting rest (a) and the 
repeated sit-stand maneuvers, 10/10 s (b) and 5/5s (c). Note the enhanced amplitude and 
consistency of the oscillations induced by repeated maneuvers.
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Figure 2 Power spectra of blood pressure and cerebral blood flow velocity
oscillations in sitting rest and 10/10s and 5/5s repeated sit-stand maneuvers
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Legend: Results of spectral analysis of spontaneous and induced oscillations in BP (top panel) 
and CBFV (bottom panel) in power spectral density plots. Note the differences on the y-axis, 
representing the difference in magnitude of the oscillations. PS BP = power spectrum of blood 
pressure; PS CBFV = power spectrum of cerebral blood flow velocity. The solid line represents 
the spectra of the spontaneous oscillations, the dotted line of the oscillations induced with 
the 10/10s repeated sit-stand maneuver, and the dashed line of the oscillations induced with the 
5/5s maneuver.
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frequency (p < 0.01).The repeated sit-stand maneuvers resulted in BP and CBFV oscilla­
tions with large magnitudes at the intended frequencies 0.05 and 0.1 Hz. The magnitude 
of these induced BP and CBFV oscillations was significantly higher than the spontaneous 
oscillations (10/10s maneuver mean difference BP 16.3 mmHg2, CBFV 14.5 (cm/s)2, 5/5s 
maneuver mean difference BP 14.8 mmHg2, CBFV 5.1 (cm/s)2, p all < 0.001). Furthermore, 
figure 2 shows that the 10/10s maneuver induced stronger oscillations in BP and CBFV 
than the 5/5s maneuver (BP: p < 0.001; CBFV: p = 0.033). Additionally, figure 2 shows that 
the repeated 5/5s maneuver does not only produce oscillations in BP and CBFV at 0.1 Hz, 
but also at 0.2 Hz.
Transfer function analysis
Figure 3 gives an overview of the transfer function parameters phase, gain, and coherence, 
for spontaneous oscillations in BP and CBFV during sitting rest (left panel) and for induced 
oscillations during the 10/10s and 5/5s sit-stand maneuvers (right panel). Regarding the 
spontaneous oscillations, phase decreased whereas gain and coherence increased with 
higher frequency of oscillations (p all < 0.05). Coherence increased from 0.46 to 0.60 in 
the 10/10s maneuver compared to the VLF spontaneous oscillations, and from 0.56 to 
0.76 in the 5/5s maneuver compared to the LF spontaneous oscillations (p < 0.01). Ad­
ditionally, coherence was significantly higher in the 5/5s maneuver compared to the 
10/10s maneuver (p < 0.01). Exclusion of data with coherence < 0.4 did not alter the 
group average results (Fig 3). Eight, 6, and 3 subjects were excluded for the analysis of 
the VLF, LF, and HF frequency range respectively because of coherence < 0.4. In the 
10/10s maneuver only two subjects had coherence < 0.4 and in the 5/5s sit-stand 
maneuver none of the subjects had coherence < 0.4.
Reproducibility
Measurements were performed twice, 3 months apart, in 11 subjects, with mean BP 76.1 
(12.0) mmHg, BMI 25.4 (2.8) kg/m2, CBFV 45.9 (14.3) cm/s. For BP measurements the CoV 
and ICC were 12.0 %  and 0.32; for CBFV measurements 17.5 %  and 0.73. Regarding the 
estimates of phase and gain in the three frequency ranges (VLF, LF, and HF) of spontaneous 
BP and CBFV oscillations and the two induced oscillation frequencies, group averages 
did not change between first and second measurements (Wilcoxon signed rank test, p > 
0.1). Table 2 demonstrates the values of CoV and ICC for the different assessments of 
phase and gain. Both for spontaneous and induced oscillations, reproducibility was only 
acceptable in the low frequency range (i.e. CoV < 25 %  and ICC > 0.7).
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Figure 3 Bar graphs of the estimates of the transfer function analysis of spontaneous 
and induced blood pressure - cerebral blood flow velocity oscillations
all data
data if coherence > 0.4
Legend: Bar graphs show the values of phase (top panels), gain (panels in the middle), coherence 
(bottom panels) for the spontaneous oscillations in the three different frequency ranges 
(VLF= very low frequency, 0.02 - 0.07 Hz, LF = low frequency, 0.07 - 0.2 Hz and HF = 
high frequency, 0.2 - 0.35 Hz) and the two repeated sit- to-stand maneuvers (10/10 s frequency = 
0.05 Hz, 5/5s - frequency = 0.1 Hz) Data are mean ± SD. * refers to statistical significance if LF was 
compared to VLF, ** refers to statistical significance if HF was compared to LF.
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Discussion
The aim of this study was to improve the application of dCA assessments in older patients 
by introducing a non-obtrusive method to study cerebral hemodynamics. In communi­
ty-dwelling old subjects aged 71 - 86 years, we successfully induced enhanced periodic 
oscillations at predefined frequencies in BP and CBFV using well tolerated repeated 
sit-stand maneuvers. These maneuvers led to oscillations that were consistently present 
throughout the measurements and had a clearly increased magnitude compared to 
spontaneous oscillations, which translated into enhanced coherence of the transfer 
function analysis.
Estimates of dCA in aging based on spontaneous oscillations
Baseline measurements of spontaneous changes in BP and CBFV provide in the least 
obtrusive method to calculate transfer function parameters. Using these spontaneous 
changes, an intact dCA is characterized by a high pass filter, i.e., phase decreases and 
gain increases with higher frequency oscillations.4 Consistent with this model, Lipsitz et 
al., using measurements of spontaneous oscillations, observed larger phase shifts and 
lower gain in the low-frequency oscillations (0.04 - 0.15 Hz) compared to the high 
frequency oscillations (0.15 - 0.40) in 10 old subjects aged 72 (3) years.9 Therefore, we 
included transfer function analysis of spontaneous oscillations in the present study, 
which adds to the previous study as it describes a much larger number of subjects with 
a wider age range and thus provides a robust confirmation of these previous observa­
tions by Lipsitz et al. that dCA acts as a high pass filter over three established frequency 
ranges in community-dwelling (very) old, indicating that dCA remains intact with aging.9 
In addition, the values of phase shift in the HF range reach approximately zero which 
indicates that the CBFV oscillations passively follow those of BP, and that dCA is no longer 
active in the frequencies > 0.2 Hz in both young 13 and (very) old subjects.
Estimates of dCA in aging based on repeated sit-stands
Between the 10/10s maneuver and the 5/5s maneuver, phase and gain did not show the 
changes as expected from the classic high pass filter model. This is explained by the 
selected frequency range for the transfer function analysis. The 5/5s maneuvers were 
analyzed in the lower part of the spontaneous LF band around the peak oscillation 
induced by this maneuver (0.1 Hz). The upper part of the LF band will contribute sub­
stantially to the normally observed higher gain and lower phase. Analysis which excludes 
this part of the LF frequency band will thus result in higher phase and lower gain. The 
stronger and more coherent signal induced by the repeated maneuvers allows such
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small bandwidth analysis, however under conditions of spontaneous oscillations this is 
unjustified as it reduces the signal to noise ratio. Our data suggest that with aging, auto­
regulation is well maintained up to frequencies of 0.1 Hz and our results of the transfer 
function analysis of the spontaneous oscillations are in accordance with the literature on 
dCA in healthy young and old subjects. Whether this suggests that with aging, the 
boundary frequency for the high pass filter is shifted towards higher frequencies cannot 
be determined from this study. Answering this question will require testing of younger 
and middle aged subjects using this same protocol.
Repeated sit-stand maneuvers
More powerful oscillations offer the important advantage that they further challenge 
dCA and thus enhance clinical significance of autoregulation tests. These oscillations 
also increase the coherence of the transfer function and the reliability of the assessment.13- 
15 Repeated squat-stand maneuvers were shown to provide powerful periodic BP and 
CBFV oscillations in a much less obtrusive manner than previous attempts that have 
used oscillatory lower body negative pressure, cyclic thigh cuff inflation-deflation, or 
repeated tilting.4- 8- 16-19 Nevertheless, these squat stand maneuvers may not be suitable 
for and feasible in many (frail) older patients. For this reason, we have aimed at introducing 
a less obtrusive technique to induce enhanced hemodynamic oscillations. We have 
considered using periodic breathing as an alternative for the squat stand maneuvers. 
Respiratory cycles, through changes in intrathoracic pressure, generate a periodic 
variation in BP and paced deep breathing has been used to induce periodic oscillations 
in the low frequency (0.1 Hz).20, 21 This method has the disadvantage however that it 
cannot induce oscillations in the very low frequency. Moreover, paced breathing may 
lower etCO2 which will importantly reduce CBFV and confound TFA estimates. Finally, BP 
and CBFV spectral powers induced by deep breathing are much smaller than what we 
obtained using the repeated sit-stand maneuvers.20, 21
A single sit-stand maneuver has effectively been used in old subjects, with recent confir­
mation that it represents a suitable and reliable measure for dCA using calculations of 
the autoregulatory index.9 10 22 23 For such calculations the single sit-stand maneuver 
showed much lower intra-subject variability than the thigh cuff technique.23 An active 
sit-to-stand results in an initial transient fall in BP, which is associated with active rising 
and which is not seen in passive tilting (for detailed review see Wieling et al. 2007).24 Ad­
ditionally, the single sit-stand maneuver causes a larger drop in CBFV than thigh cuff 
deflation.23 For these reasons, we hypothesized that sequential sit stand maneuvers, 
similar to squat stand maneuvers, might generate periodic oscillations in BP. Moreover, 
we believed that these repeated sit-stand maneuvers would be much less strenuous and
81
C H A PTER  3
therefore more widely applicable in older subjects then other repeated maneuvers that 
had been tested to date (see above). We selected the frequencies of 0.05 Hz (10/10s 
maneuver) and 0.1 Hz (5/5s maneuver) because these are the frequencies where dCA is 
active and other repeated maneuvers8, 17 18 had been successful in inducing large oscilla­
tions with increased coherence at these frequencies. Indeed, both repeated sit-stand 
maneuvers effectively induced oscillations at the intended frequencies and led to 
increased coherence. Moreover, the 10/10s maneuver induced more powerful oscilla­
tions than the 5/5s maneuver, in accordance with previous studies.8, 18
Practical aspects of repeated sit-stand maneuvers
Feasibility in old subjects
Sit-stand maneuvers were very well tolerated, making it a feasible method to induce BP 
oscillations. Particularly the 10/10s sit-stand maneuver, which has a longer time-interval 
between sitting and standing, could be feasible even in frail, old patients. BP and HR 
increased only slightly (< 20 %  ) in both maneuvers relative to measurements in rest 
(Table 1). These changes were not progressive during the maneuver and do not indicate 
strenuous exercise. Since strenuous exercise would impair dCA, in contrast with mild or 
moderate exercise, this make the sit-stand maneuvers a preferable method in elderly 
patient groups.25
Influence of breathing
A small change in arterial CO2 may cause alterations in CBFV26 and hypocapnia induces 
vasoconstriction which reduces cerebral blood flow by 2 - 3 %  per mmHg reduction in 
etCO2.27 For the 5/5s sit-stand maneuver etCO2 did not change, but for the 10/10s 
sit-stand maneuver, EtCO2 showed a small but significant decrease compared to sitting 
rest. The reasons for this decrease in EtCO2 cannot be determined in this study, but may 
well be a consequence of a reduced CO2 return (due to a reduced venous return with 
repeated standing) with maintained alveolar ventilation.28 Whatever the cause, the 
observed decrease in this study of 0.8 mmHg etCO2 is estimated to explain only 2 %  
change in cerebral blood flow.27
The breathing pattern during the repeated sit-stand maneuvers could also have 
influenced the BP and CBFV oscillations. For the 5/5s sit-stand maneuver a change in 
breathing pattern during the repeated tests could explain the observed extra peak, at 0.2 
Hz, in both the power spectra (BP and CBFV, figure 3a and 3b). However, the magnitude 
of the oscillation at 0.1 Hz, which we used for the transfer function analysis, was still 
higher (as can be seen in figure 3) and it is equally possible that the peak at 0.2 Hz is
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Table 1 Hemodynamic response to repeated sit-stand maneuvers (N = 26)
Sitting rest Repeated Sit-stand P-value*
10/10s 5/5s
BP (mmHg)'
HR (bpm)
CBFV (cm/s)
EtCO2 (mmHg)
80.9 (11.5) 89.7 (14.6)
62.7 (7.7) 71.5 (9.0) 
41.5 (9.8) 45.3 (9.0)
34.7 (2.8) 33.9 (2.3)
95.5 (12.2) 0.003 
76.3 (7.8) 0.003
46.5 (8.8) 0.002 
34.2 (2.0) 0.025
Legend: This table presents the average data of blood pressure (BP), heart rate ( HR), cerebral 
blood flow velocity (CBFV), and end-tidal CO2 (EtCO2) in rest and during the repeated sit-stand 
maneuvers. BP expressed as mean arterial pressure, CBFV expressed as mean flow velocity.
The repeated sit-stand 10/10s and 5/5s maneuvers represents maneuvers during which 10 or 5 s 
sit is followed by 10 or 5 s stand respectively. Values are presented as mean (SD).
* P values are derived from repeated measures analysis of variance with Bonferoni correction 
f BP as measured by Finapres measurements.
3
merely resonance of the 0.1 oscillations. The 10/10s repeated sit-stand maneuver does 
not show an extra peak in the frequency analysis, and generates such strong oscillations 
that the influence of the breathing pattern is relatively small.
BP measurements
It has been argued that finger BP does not represent cerebral perfusion pressure because 
of the hydrostatic gradient between finger and brain when the subject is sitting or 
standing. On the other hand, if the heart - brain circulation is considered to represent a 
closed - loop system, the subject's body position should not matter. Controversies 
regarding these assumptions must be recognized29 and currently there are no 
experimental data that either unequivocally support or disprove this theory.30 However, 
in contrast to tilting, a sit-stand maneuver avoids the issue of this possible effect because 
the Finapres finger cuff remains in the same spatial relation to the heart and the Doppler 
probe.
Reproducibility
In the subgroup tested for reproducibility using a test-retest approach, this study obtained 
acceptable values of reproducibility (CoVa and ICC) for the assessment of gain and phase in 
the low frequency range for both spontaneous and induced oscillations (Table 2). However,
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reproducibility of phase and gain in the very low and high frequency range showed high 
CoVa and low ICC values. This suggest that intra-subject variability is larger in VLF and HF 
than in LF. The sit-stand maneuvers, despite raising coherence, did not improve 
reproducibility. Again, this suggests that the poor reproducibility may be due to biological 
variability especially in VLF and HF rather than due to measurement error.
Table 2 Coefficient of variation and intraclass correlation of repeated measurements
CoV (%) ICC
BP 12.5 0.32
CBFV 16.6 0.73
Spontaneous oscillations (n = 11)
Phase VLF 70.2 0.167
LF 22.6 0.859
HF 213 -0.149
Gain VLF 37.6 0.436
LF 16.9 0.717
HF 30.4 0.229
Induced Oscillations (n = 10)
Phase 10/10s 84.7 0.000
5/5s 13.5 0.732
Gain 10/10s 38.7 0.366
5/5s 21.5 0.640
Legend: This table presents the values of the standard error expressed as a coefficient of variation 
(CoV) and intraclass correlation (ICC) for repeated tests of dynamic cerebral autoregulation using a 
test-retest interval of 3 months. BP = blood pressure expressed as mean arterial pressure (mmHg); 
CBFV = cerebral blood flow velocity expressed as mean flow velocity (cm/s); VLF = very low 
frequency (0.02 - 0.07 Hz); LF = low frequency (0.07 - 0.2 Hz); HF = high frequency (0.2 - 0.35 Hz).
In the high frequency range, we expect the variability of repeated dCA assessments to 
be high due to the variability in the cardiac cycle which can significantly influence the 
assessment of dCA. In addition, above 0.2 Hz values of phase reach zero indicating that 
dCA is absent, leading to dependency of CBFV on BP, which has a high day-to-day
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variability. In the very low frequency range we propose that the high intra-subject 
variability is due to counter regulation of biological control systems, such as the 
baroreflex, which also has been shown to be a noisy controller.31 Another possibility is 
that in the very low frequency, changes in CBF are to a larger extent determined by 
factors outside BP.7 However, if this was the case, reproducibility should have been 
improved for the repeated sit-stand maneuvers since these led to increased coherence 
between BP and CBF.
Using spontaneous oscillations and the calculation of the autoregulatory index, Brodie 
et al. found good reliability and these authors obtained higher reproducibility for BP and 
CBFV measurements.32 The autoregulatory index however cannot be directly compared 
to the more complex transfer function analysis. The same holds true for the study of 
Sorond et al, using the single sit-stand procedure, which shows data with a lower intra­
subject variability.23 The analysis of the effects on BP and CBFV of a single maneuver 
cannot be directly compared to transfer function analysis oscillations induced by 
repeated maneuvers. Moreover, the subjects in the present study are much older (mean 
age Brodie et al. 38 years, mean age Sorond et al 50 years).23, 32 Older subjects have 
higher day to day variability in BP. Moreover, the test-retest interval in the present study 
was longer. Indeed, Reinhard et al found similar reproducibility with a test-retest interval 
of 4 months using deep-breathing to assess dCA.21 Birch et al. obtained relatively good 
repeatability on 8 measurements during 3 months in 5 subjects using lower body 
negative pressure.33 However, to obtain this, they had to use high vacuums which cannot 
be used in (old) patients.33 In our small subgroup, group-average data were very similar 
and reproducible with repeated testing after 3 months. This suggests that in intervention 
studies, repeated assessment of dCA can be performed at the group-average level but 
intra-individual changes however can only be assessed reliably in the low frequency range.
Possible limitations
The limitations of the transcranial Doppler, which measures CBFV instead of cerebral 
blood flow, have been discussed in detail.48 The assumption made in this study is that 
changes in diameter of the middle cerebral artery are minimal and that changes in CBFV 
represent changes in cerebral blood flow. A disadvantage is that these maneuvers 
proposed in this study cannot by performed in critical ill patients and in ventilated 
patients, i.e. traumatic brain injury patients. In such patients it is preferable to induce BP 
oscillations using deep breathing.
In conclusion, we have demonstrated that repeated sit-stand maneuvers are able to 
induce strong oscillations in both BP and CBFV in predefined frequencies. This is the first
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study that was successful in inducing enhanced oscillations in both the very low and low 
frequency ranges in this age group using a non-invasive, non-obtrusive method. The 
oscillations we induced were less powerful than those obtained by repeated squat stand 
maneuvers, however, the repeated sit stand maneuvers are easier to perform and can 
therefore be more readily applied in old subjects. Moreover, their power compares 
favorably to that of other, more obtrusive methods to induce periodic oscillations. The 
magnitude of changes in BP and CBFV induced by these repeated sit stand maneuvers is 
much larger than those of spontaneous oscillations, and resembles the changes observed 
in daily life e.g. in conditions of orthostatic hypotension, post prandial hypotension, or 
carotid sinus syndrome. This enhances the clinical significance of this new autoregulation 
test, as the autoregulatory system is challenged with changes in BP that must be handled 
by older subjects in real life. We have shown that our new technique to assess dCA was 
feasible and accurate in these older control subjects. Additionally, we have confirmed 
that dCA, as assessed by the accepted method of transfer function analysis of spontaneous 
BP and CBFV oscillations, acts as a high pass filter in healthy (very) old subjects and we 
have addressed the issue of reproducibility. For the spontaneous oscillations and for 
both repeated sit-stand maneuvers, group average values did not change and were 
reproducible for a test-retest interval of 3 months. Intra-individual reproducibility 
however was acceptable only in the low-frequency range, and was not improved by the 
repeated sit-stand maneuvers, despite the enhanced coherence between BP and CBFV, 
suggesting strong biological variability in the very low frequency.
We propose that these repeated sit-stand maneuvers provide a robust and clinically 
relevant method to further investigate the dynamic pressure-flow relationship in older 
patients.
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Abstract
The breath hold maneuver is a convenient and frequently used method to assess cere­
brovascular reactivity (CR) in diseases that are common in aging. The validity of this 
method in older subjects however is unknown. We addressed the feasibility and repro­
ducibility in healthy older subjects. 25 healthy volunteers, aged 75 (SD 4) years, performed 
2 consecutive breath holds after careful instruction. Blood pressure (BP - Finapres), 
cerebral blood flow velocity (CBFV - Transcranial Doppler) and end-tidal CO2 
(capnography) were measured continuously. As a reference standard, CR was determined 
by hyperventilation and CO2 -inhalation. To assess reproducibility, these measurements 
were repeated after 3 months in 11 randomly selected subjects who agreed to do so. 
Despite apparent compliance with the instructions during performance of breath 
holding, only 29 of the 50 breath holds (58%) had been accurately executed. 15 breath 
holds (30%) had to be excluded because subjects performed a Valsalva-maneuver (8%) 
or secretly exhaled during the breath hold (22%), which was identified only from the BP 
and end-tidal CO2 measurements. Incorrect breath holds led to underestimation of CR. 
For valid breath holds, reproducibility was comparable to the reference method 
(coefficient of variation 18.4% and 14% respectively). In conclusion, the number of 
inaccurate breath holds was unacceptably high, moreover, these could not be identified 
from CBFV registrations alone. Therefore, reports of CR based on breath holds in older 
subjects without co-registration of BP and either end-tidal CO2 or chest-expansion, 
should no longer be acceptable.
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Introduction
Cerebral blood vessels are unique in their strong response to changes in arterial carbon 
dioxide concentration [PaCO2], referred to as cerebrovascular reactivity (CR).1 CR has 
been widely employed as a non-invasive measure of cerebrovascular function in both 
research and clinical practice.2-4 Most often, transcranial Doppler ultrasonography (TCD) 
is used to record cerebral blood flow velocity (CBFV) in one of the major cerebral arteries 
during changes in [PaCO2], with less frequent use of MRI or PET to measure cerebral 
blood flow (CBF). Several methods have been employed to induce changes in CO2, such 
as hyperventilation to cause hypocapnia, and CO2 inhalation, breath hold, or rebreathing 
to cause hypercapnia.3, 5 6
The breath hold method is fast and easy to use since it only requires measurements of 
CBF(V) and an instruction to subjects to hold their breath. Therefore, it is the preferred 
method to measure CR in MRI studies.78 In functional magnetic resonance imaging 
(fMRI) studies, the cerebrovascular response to breath holding has also been used to 
probe characteristic differences in hemodynamic response patterns9 and to normalize 
the blood oxygen level dependent (BOLD) response between different subjects and 
brain regions.10-12
Both TCD and MRI studies investigating the reliability and reproducibility of the breath 
hold method to assess CR have focused on healthy and diseased young to middle aged 
subjects (i.e. age all < 70 years).3' 8 13 However, diseases in which CR may be impaired and 
therefore where breath holds have been employed, such as hypertension, cerebral small 
vessel disease, carotid stenosis and cognitive impairment, primarily affect subjects older 
than 70 years.2, 4 14 15 The correct execution of a breath hold could be a challenging task 
for this age group.
The influence of CO2 on CBF is confounded importantly by the effects of CO2 on blood 
pressure (BP).5 Therefore, in order to carefully interpret CR, concomitant measurements 
of blood pressure (BP) and end-tidal CO2 (etCO2) are required. We have used TCD to 
measure CBFV, together with continuous measurements of BP and etCO2 to assess CR 
during breath holding. Under the assumption that the cross-sectional area of the 
insonated vessel does not change during hypo- or hypercapnia, CBFV can be used as an 
index of CBF.16-18
The aim of this study was to determine whether the breath hold method provides a 
reliable estimate of CR in this older age group, using the hyperventilation combined 
with CO2 inhalation method as reference standard.4
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Methods
Participants
We recruited 25 healthy volunteers aged > 70 years who responded to a newspaper 
advertisement. All subjects were examined by a geriatrician and carefully screened by 
medical history taking, physical examination, routine laboratory tests, ECG, and MRI to 
exclude acute and chronic medical conditions. Cognition was screened using the Mini 
Mental State Examination (range 0 - 30, max 30), and a score < 26 was an exclusion 
criterion. They were all leading an active and independent life, did not smoke, and had 
no history of cerebrovascular, neurological, or systemic disorders. A Doppler study of the 
carotid and vertebral arteries was performed. Subjects with stenosis (>50%) or who did 
not have an adequate temporal w indow for insonation of the middle cerebral artery 
were excluded. The study was carried out in accordance with the Declaration of Helsinki 
(2000) of the World Medical Association and was approved by the Ethics Committee for 
Research on Human Subjects of the Radboud University Nijmegen Medical Centre. All 
volunteers gave written informed consent.
Instrumentation
Subjects were in sitting position during the whole procedure. BP was measured using a 
photoplethysmographic cuff on the index or middle finger of the left hand, held at heart 
level (Finometer, Finapres Medical Systems™, the Netherlands). TCD was used to 
continuously and bilaterally measure CBFV in the cerebral arteries which were insonated 
by placing a 2-MHz Doppler probe (Multidop, DWL medical systems™, Germany) over 
the temporal window. The middle cerebral arteries were identified according to their 
signal depth, velocity, and wave characteristics.19 The probes were locked at a constant 
angle and position with a customized headband (Spencer technologies™, Seattle, Wa, 
USA). Depth, velocity, and location of temporal window, were noted for each subject. 
If only one signal was available due to one-sided temporal w indow failure, we included 
this available signal for analysis. EtCO2 as a measure for [PaCO2] was recorded using a 
capnograph and arterial O2 saturation using a pulse oximeter (both N1000, Nellcor™, 
Boulder, CO, USA).20 A three-lead ECG was used for measurement of the R-R interval.
Procedure
From 12 hours before the study, subjects refrained from caffeinated beverages and 
alcohol. They only used a light breakfast at least 2 hours before the visit. All experiments 
were performed in the morning, in a quiet environmentally controlled laboratory. Out of 
a randomly selected subgroup , 11 subjects (9 men; mean age 76 ± 5 years) agreed to
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undergo the experiments twice, 3-4 months apart. This time interval was chosen because 
the evaluation of an intervention generally leads to a similar test-retest interval. 
The same temporal w indow and depth of the transcranial Doppler were used to ensure 
insonation of the same middle cerebral artery segment.
After at least 30 min of sitting rest, data were collected for 5 minutes during sitting rest 
and spontaneous breathing to assess baseline hemodynamics. The breath hold 
procedure was explained and this was repeated until subjects were familiar with the 
procedure. They were carefully instructed to hold their breath as long as possible 
following a normal inspiration, and to avoid performing a Valsalva-maneuver. If necessary, 
breath holding was practiced before the actual measurements until maximal cooperation 
was achieved. Subjects started breath holding on a sign of the researcher, which was 
given after inspiration during normal breathing, to minimize the possibility of a Valsalva- 
maneuver. The start and end of the breath hold were marked on all registered signals. 
Subjects performed 2 breath holds (interval 2 min). Subjects were not able to see their 
own measurement results, however, with our experimental set-up, the subject could be 
extensively supported and accompanied by the researcher during the complete 
measurements and breath hold periods.
After a pause, subjects were coached to perform 30 s of hyperventilation (maximal deep 
breaths, duty cycle: 1 s). Next, after 2 minutes of spontaneous breathing, subjects were 
asked to inhale a gas mixture containing 7 %  CO2, 21 % O 2 and 72 %  N2 through a tightly 
fitting mouthpiece until a stable plateau of CBFV had been reached.
Data processing
All data were simultaneously analogue/digital converted and sampled at 200 Hz with 
commercially available data acquisition software (Acknowledge Software, BIOPAC 
Systems™, Inc, Goleta, CA, USA) and recorded for offline analysis. The changes in mean BP 
and CBFV were aligned with the R-R interval of the ECG to assess beat to beat values.
Evaluation of Cerebrovascular Reactivity to CO2
For the breath hold method, CR was quantified by the breath hold index (BHI).3 
This index is the percentage increase in mean CBFV occurring during or immediately 
after breath-holding divided by the length of the breath hold in seconds:
{CBFVmax[breathhold] - CBFV[rest]}
BHI = IQQx--- 7^ 7777— ;— :--- „---- r,— tt,---CBFV [rest] x time [breathhold]
95
C H A PTER  3
As the reference standard, the full range of CR was used (FCR).4 This is the percentage 
change in CBFV (cm/s) from hypocapnia (induced by hyperventilation) to hypercapnia 
(induced by 7 %  CO2 inhalation):
100x [CBFVmax[inhalationsCO2] - CBFVmin[hyperventilation]}
FCR = CBFV [rest]
For the purpose of this study, we did not perform additional calculations to account for 
the changes in BP because the breath hold method, as normally applied, does not take 
BP measurements into consideration.5
Statistical analysis
Data are presented as means (SD). We tested normal distribution using q-q plot and 
could only be assumed for baseline parameters. Breath hold indices between different 
subgroups of subjects were compared with the Mann-Whitney U test. Bonferroni 
correction for multiple comparisons was applied to compare the variables between 
baseline measurements, hyperventilation and CO2 inhalation. Correlation between the 
breath hold method and CO2 inhalation/hyperventilation procedure (the reference 
method) was assessed using Spearman rank correlation coefficient. For analysis of the 
repeated measurements, group averages of the two measurements were compared 
using the Wilcoxon signed rank test. Long term reproducibility was assessed for the 
breath hold method and the full range of CR using the typical error, expressed as a 
coefficient of variation, and an intraclass correlation coefficient.21 The typical error is 
quantified as the standard deviation in each subject's measurements between tests, 
related to changes in the mean. The coefficient of variation than is the typical error 
expressed as a percentage of the subject's mean score. Its major advantage is that it 
represents a scale invariant measure of inequality. The intraclass correlation coefficient 
represents the amount of intra-subject variability in relation to corresponding values of 
inter-subject variability. It expresses how consistent the outcome of a subject's 
measurements are relative to the rest of the group over different sessions.21 Statistical 
significance was set at p < 0.05. All statistical analysis were performed using statistical 
software (SPSS version 16.0, SPSS Inc, Chicago, Ill).
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Results
General results
The baseline characteristics of the participants are presented in Table 1. Table 2 provides 
the estimates of CR based on the breath hold method and the reference method of 
hyperventilation and CO2 inhalation. As expected in these healthy subjects, both 
methods were indicative of normal CR (normal value FCR: 85 %  (SD 15 %), cut off value 
normal BHI: 0.69).4 22 All subjects were able to hyperventilate for 30 s and tolerated the 
inhalation of the gas mixture well. For this reference method, data from all 25 subjects 
were suitable for analysis of CR, whereas for the breath hold method, CR could only be 
determined in 17 of the 25 subjects. Two subjects were unable to perform the maneuver, 
and breath holds in 6 subjects needed to be excluded from analysis because of inaccurate 
breath holding, as evidenced by the results (see below).
Table 1 Baseline characteristics
N = 25
Age (years) 75 (3.9)
Sex (male : female) 19 : 6
Antihypertensive drugs (number of subjects) 4
Diuretics (n) 3
ß blockers(n) 2
BMI (SD) kg/m2 25.4 (2.5)
Systolic BP (SD) mmHg 149 (18.3)
Diastolic BP (SD) mmHg 83.6 (8.0)
Heart rate (SD) bpm 62.8 (9.9)
MMSE (range). Range 0-30 29.2 (27 - 30)
Abbreviations: BMI = body mass index, BP = blood pressure, bpm 
MMSE = Mini Mental State Examination
= beats per minute,
Breath holds
During testing, the subjects appeared compliant with the instructions for proper 
performance of the breath holds. However, off-line analysis revealed that many breath 
holds had in fact been incorrectly performed. Figure 1a shows a correctly performed
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Table 2 Number of subjects included for analysis and the estimates of 
cerebrovascular reactivity
Breath Hold Reference Method
1st
N 17 
Breath Hold Index 1.39 (0.50)
Duration (s) 41.6 (11.2)
2nd
12
1.22 (0.35) 
48.7 (12.5)
Combined*
17
1.33 (0.40) 
44.6 (11.4)
N 25 
Full range of CR 116.5 (40.5)
(%)
Legend: * Average value of breath hold 1 and 2, if only one breath hold was performed, this breath 
hold was included. Duration: length of breath hold. Reference method: hyperventilation to induce 
hypocapnia, followed by CO2 inhalation to induce hypercapnia, expressed as %  change in CBFV 
from hypocapnia to hypercapnia.4 Only 12 of 25 subjects produced 2 correct breath holds, and 
8 subjects had no valid breath hold (see text for details).
Abbreviations: CR = cerebrovascular reactivity
breath hold. The end-tidal CO2 signal shows that there is no respiration during the breath 
hold and that upon expiration, end-tidal CO2 is elevated consistent with a rise in [PaCO2] 
due to the breath hold. As a result, CBFV and BP progressively increase during breath 
hold. Figure 1b is a typical example of an inadvertently performed Valsalva-maneuver 
during the breath hold. There is a transient increase followed by a prolonged reduction 
in both BP and CBFV, with an overshoot in BP and CBFV upon expiration.23 In figure 1c, 
the end-tidal CO2 measurements show that the subject secretly exhaled during breath 
holding, which reduces the rise in end-tidal CO2 and thereby the rise in CBFV and BP.
In total, the protocol could have yielded 50 breath hold indices, two in each of the 25 
subjects (n=50). However, 15 breath holds had to be excluded because of performance 
of a Valsalva-maneuver (n =4) and 'concealed' expiration (n = 11). In addition, two 
subjects were not able to hold their breath and could not be instructed properly (n = 4), 
one subject was only able to perform 1 breath hold, and in one subject the CBFV signal 
was partially lost during the second breath hold, which made it impossible to determine 
any change in CBFV. The latter subject however was able to perform the complete breath 
hold task. Of note, the reference method did allow reliable estimation of CR in these 
subjects. Seventeen subjects performed one correct breath hold, and twelve performed 
a second correct breath hold. In total, only 29 of the 50 breath hold indices could be 
calculated and included for analysis.
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Figure 1 Example of different breath hold performance
0 20 40
Time (s)
20 40 60 80 100 
Time (s)
0 20 40 60 80 100 
Time (s)
Legend: Data from three subjects, showing a correctly performed breath hold (A- left panel), 
a breath hold with unintentional Valsalva maneuver (B - middle panel), and 'concealed expiration' 
during breath hold (C - right panel). The upper panel presents blood pressure, the middle panel 
cerebral blood flow velocity and the bottom panel end-tidal CO2 . The horizontal lines mark the 
duration of the breath hold procedure.
Estimates of CR differed importantly between correctly and incorrectly performed 
breath holds. Breath holds where a Valsalva-maneuver was identified had a breath hold 
index of only 0.46 (SD 0.12) compared to 1.39 (SD 0.50) for correct breath holds (p = 
0.012). For procedures during which 'concealed' expiration was identified, the mean 
index was 1.22 (SD 0.18) / s (p = 0.54). Three subjects performed a correct first breath 
hold and a second breath hold with 'concealed' expiration. In these subjects, the index 
for the correct breath hold was 1.73 (SD 0.17) / s, compared to 1.30 (SD 0.20) / s for the 
incorrect breath hold (p = 0.10)
A B C
3
99
C H A PTER  3
Hyperventilation and CO2 inhalation
On average, hyperventilation reduced CBFV by 41 %, and CO2-inhalation increased CBFV 
by 71 %. Table 3 presents the systemic and cerebral hemodynamics during hyperventila­
tion and hypercapnia. BP decreased 14.0 (SD 6.7) mmHg and increased 19 (SD 15.7) 
mmHg respectively, with a difference of 33 (SD 16.0) mmHg between hyperventilation 
and CO2 inhalation. The CR index (the full range of reactivity divided by the total change 
in end-tidal CO2), corrected for these changes in BP, was 5.01 (SD 4.0) %/mmHg EtCO2.
Table 3 Systemic and cerebral hemodynamics during hyperventilation and 
CO2 inhalation
Measurement Baseline* Hyperventilation 1 CO2 1
BP (mmHg) 95.4 (11.2) 81.4 (13.8) * 114.3 (20.6) *
HR (bpm) 64.6 (9.8) 66.1 (9.1) 71.4 (12.1) *
CBFV (cm/s) 42.5 (10.1) 24.7 (6.1) * 72.6 (18.1) *
Change in etCO2 (mmHg) NA 11.5 (3.6) * 24.4 (11.3) *
Legend: * average of mean beat-to-beat values during 30 s of sitting rest, before start of 
hyperventilation f average value of 5 beats surrounding lowest or highest values during 
hyperventilation or CO2 inhalation, respectively. * significantly different from baseline values, 
p = 0.009 after Bonferroni correction.
Abbreviations: BP = blood pressure, CBFV = cerebral blood flow velocity, HR = heart rate, 
bpm = beats per minute, etCO2 = end tidal CO2
Comparison between breath hold and the reference method
There was a weak correlation between CR estimates from breath hold indices and CR 
estimates from the reference method (Spearman rho 0.47, p = 0.06). All subjects had 
normal CR according to the reference method. Subjects with low breath hold index all 
had incorrectly performed breath hold maneuvers, correctly performed breath holds 
indicated normal CR. CR as estimated by the reference method (FCR) was 124 (SD 41) %  
for the subjects who performed a correct breath hold, and 116 (SD 43) %  for subjects 
who performed an incorrect breath hold (p = 0.66).
Reproducibility
For the repeated measurements, data from all 11 subjects could be analyzed for the 
reference method, whereas only 9 of the 11 subjects performed at least one correct
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breath hold maneuver. If two correctly performed breath holds were available for the 
repeated measurements, the average of the two was used for analysis of reproducibility. 
For the repeated measurements with an interval of 3-4 months, there was no difference 
in the average duration and index of the breath hold, nor in the average full range of CR 
to CO2. For the breath holds (n=9), the typical error expressed as intra-individual 
coefficient of variation was 16.4 %  (lower and upper 95%-confidence limit: 11.3 %  - 31.5 
% ) for the duration of breath hold, and 19.4 %  (13.3 %  - 37.5 % ) for the breath hold index. 
For the reference method (FCR, n=11) this was 14.1 %  (10.1 %  - 24.2 %). The intraclass 
correlation for the breath hold was 0.89 (95%CI: 0.63 - 0.97) for the duration and 0.81 
(0.42 - 0.95) for the index of the breath hold. For the full range of CR the intraclass 
correlation was 0.76 (0.40 - 0.92).
Discussion
This study investigated the breath hold technique as a method to assess CR in subjects 
aged 70 years and older. If performed correctly, the breath hold method had acceptable 
reproducibility and correctly indicated normal CR, similar to the more complicated 
reference standard which measures CR using a combination of hyperventilation and 
inhalation of CO2. However, the correlation between the breath hold method and the 
reference standard was poor. An alarming finding is that an unacceptably high amount 
of breath holds had been incorrectly executed, leading to inaccurately low values for the 
associated breath hold index, and thus to underestimation of CR in these subjects. Most 
importantly, these incorrectly performed breath holds could only be identified because 
this study applied concomitant registration of BP and end-tidal CO2 during breath holds. 
Since these measurements are not normally made in most studies that use breath holds 
to estimate CR these errors will go unnoticed and may seriously confound results.
To explain these findings, we must first consider differences in the level of cooperation 
in older subjects. Despite careful instructions, practice if necessary, and coaching during 
the breath holds, almost half of all breath holds (42%) were not performed correctly. The 
screening process made cognitive impairment or frailty very unlikely as a cause of non­
compliance. This suggests that it may be inherent to the procedure that the breath hold 
method will be inaccurately performed in a substantial number of older subjects.
Some breath holds had to be excluded for analysis because BP and CBFV changes were 
characteristic for a Valsalva effect. Upon straining, a drop of BP and CBFV occurs due to 
elevation of intrathoracic and intra-abdominal pressure. In addition, the increase in 
intrathoracic pressure also causes an increase in intracranial pressure, leading to a
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considerably stronger reduction in cerebral perfusion pressure than is indicated by the 
BP decrease alone.24 Due to these effects, the performance of a Valsalva-maneuver leads 
to a lower value of the breath hold index, and thus to underestimation of CR.
Other breath holds were excluded because 'concealed' expiration was observed. 
The difference between correct breath holding and 'concealed' expiration is a smaller 
increase in BP and CBFV during expiration. Therefore, 'concealed' expiration could only 
be seen because etCO2 measurements were available in this study. These tracings 
revealed that subjects had exhaled during the breath hold, before indicating that they 
were ending the breath hold. 'Concealed' expiration during the breath hold procedure 
will lead to a lower [PaCO2] compared to maximum breath holding and again will 
underestimate CR. Especially in diseased or cognitively impaired old subjects, who are 
even more susceptible to false performance of the breath hold method, this risk of un­
derestimation of CR has to be seriously taken into account.
Besides the objection of the use of breath holding because of patient's compliance, the 
applicability of breath holding, and more general the measurements of CR, are also 
determined by the influence of BP and the non-linear relationship between etCO2 and 
CBFV.5- 25' 26 If cerebral autoregulation is efficient, and the BP changes are slow and gradual 
and stay between these autoregulation limits, then it can be argued that CO2 reactivity 
and the change in CBFV may be independent of BP. However, if BP changes fall outside 
this range, or if they occur more rapidly (e.g. within the 30-40 s during a breath hold), or 
if cerebral autoregulation is impaired (e.g. due to the rise [PaCO2]), the changes in CBF 
are in fact in part the result of CBFV passively following the blood pressure increases, 
rather than active vasodilation due to the rise in [PaCO2]. Apart from BP variability, 
[PaCO2] has an even bigger influence over CBFV variability, as the relation between 
changes in etCO2 and CBFV is non-linear.5' 27 It is therefore the interplay between BP, 
etCO2, and CBFV that needs to be considered and requires investigation in the assessment 
of CR.
The assessment of CR using the breath hold method requires only measurements of 
CBF(V). This makes it a preferred method when large groups of patients are studied, and 
its simple instrumentation makes it an ideal method to combine with MRI. For example, 
with advanced MRI techniques, CBF and oxygenation changes can be detected with a 
high spatial resolution during breath holding.28-30 These changes have been used to 
evaluate CR,8 to map regional hemodynamic responses, and to calibrate the BOLD 
signal.9-12 However, the present study indicates that incorrectly performed breath holds 
can only be identified if measurements of BP and EtCO2 are made. Therefore, we suggest 
that when a breath hold procedure is used in MRI, it should be practiced before the
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actual measurement, and executed using etCO2 or chest expansion measurements. 
Moreover, it should be kept in mind that the fact that CO2- induced BP changes cannot 
be monitored non-invasively and continuously in MRI, is a major limiting factor in 
interpreting CR. Feasibility and reliability studies in old subjects are necessary before 
these combined measures can be used in clinical studies.
In theory, part of the problem of inaccurately performed breath holds could be overcome 
by performing breath holds after expiration.8 The advantage is that this lowers the risk of 
a possible Valsalva effect.29 It gives however rise to a more rapid decrease in [PaO2] and 
a more rapid rise in [PaCO2], and thus stimulates the subject earlier to breathe again, 
leading to more distress and discomfort for the subject and this combination of factors 
likely to have confounding effects on BP.
In conclusion, in contrast to the reference method, correct breath holding was difficult 
for healthy older subjects with an average age of 75 years and is likely to be even more 
challenging in those who are cognitively impaired. If performed correctly, the breath 
hold method is a reproducible and simple method to evaluate CR in older subjects 
regardless which method is used to measure CBF, i.e. TCD, MRI, or PET. Unfortunately, co­
registration of EtCO2 and BP is required to ascertain such correct performance, which 
will complicate performance of this method to the extent that its advantages over other 
methods such as the reference method are lost. Nevertheless, we propose that reports 
of CR based on breath holds in older subjects, without information on end-tidal CO2 and 
BP, should no longer be acceptable as these are prone to confounding and error. The 
reference method had better performance in terms of accuracy, feasibility, and tolerability 
and should remain the method of choice even if inhalation of CO2 is difficult to execute 
using MRI.
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Summary
In Alzheimer's Disease (AD), the structural integrity of the cerebral vasculature and, 
consequently, cerebrovascular function are at risk. Transcranial Doppler, near-infrared 
spectroscopy, and photoplethysmography are non-invasive methods to measure, with 
high temporal resolution, cerebral blood flow velocity (CBFV) and cerebral frontal 
cortical oxygenated haemoglobin ([O2Hb]) together with beat-to-beat changes in blood 
pressure (BP). In 21 patients with mild - moderate AD and 20 age-matched controls, we 
investigated how oscillations in CBFV and O2Hb are associated with oscillations in BP 
during spontaneous oscillations in sitting rest and during more powerful hemodynamic 
oscillations induced through repeated sit-stand maneuvers at very low (VLF = 0.05 Hz) 
and low frequencies (LF = 0.1 Hz). We applied spectral and transfer function analysis to 
quantify dynamic cerebral autoregulation for pressure, flow, and brain tissue oxygenation. 
Oscillations in flow and oxygenation could be causally related to BP under all conditions. 
In AD, cerebrovascular resistance was substantially higher (34 %, AD vs. Control : A = 0.69 
(0.25) mmHg/cm/s, p = 0.012) and the transmission of VLF CBF oscillations into [O2Hb] 
differed, with increased phase lag and gain (AD: phase - 1.13 (0.44) rad, control: -0.81 
(-0.29), p = 0.039; AD: gain 0.13 (0.05) pmol/cm/s, control: 0.076 (0.02), p = 0.011). These 
findings suggest that brain cortical [O2Hb] is profoundly affected by changes in CBF that 
occur during routine changes in body posture. In AD, elevated cerebrovascular resistance 
and impaired dynamic microcirculatory autoregulation indicate a compromised cerebral 
microcirculation that is less able to maintain brain tissue oxygenation homeostasis.
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Introduction
In patients with Alzheimer's disease (AD) and in mouse models of AD, the structural 
integrity of the cerebral vasculature, especially of cortical microvessels, is markedly 
compromised.1 Additionally, cerebral autoregulation, the vascular mechanism which 
aims to stabilize brain perfusion, is impaired in mouse models of AD.2- 3 Whether cerebral 
autoregulation is also altered in human AD remains unknown. Recently, we have shown 
that patients with early stage AD have a reduced cerebral blood flow velocity (CBFV) and 
an increased cerebrovascular resistance (CVR) compared to aged matched healthy 
controls. Additionally, the magnitude of spontaneous CBFV oscillations was reduced in 
AD, associated with a reduction in transfer function gain, a parameter that quantifies 
dynamic cerebral autoregulation and describes how changes in blood pressure (BP) are 
transferred to changes in CBFV.4 These results associate AD with cerebral vasoconstric­
tion, leading to an altered dynamic pressure-flow relationship. Notably, changes in CBFV 
were measured using transcranial Doppler (TCD) in the middle cerebral artery (MCA), 
reflecting global changes in cerebral blood flow (CBF) but not necessarily changes that 
occur at brain tissue level.5
Near-infrared spectroscopy (NIRS) and functional MRI have revealed that cerebral cortical 
oxygenation displays spontaneous oscillatory changes6 and that these oscillations appear 
similar to those observed in CBFV and BP7 However, the precise relationship between 
dynamic changes in CBFV measured in the basal cerebral arteries and brain tissue 
oxygenation remains unknown. It is possible that oscillations in brain tissue oxygenation 
are induced by changes in global CBF and that the dynamic relationship between these 
variables reflects not only the function of the cerebral vasculature to deliver oxygen to the 
brain tissue, but also brain tissue oxidative metabolism.8 We hypothesized that the presence 
of vascular abnormalities in AD may alter this relationship.
CBFV in the middle cerebral artery changes dramatically as a consequence of large changes 
in arterial pressure induced during changes in body posture from sitting or squatting to 
upright standing.9,10 This provides a model to study the relationship between CBF and 
cerebral cortical oxygenation. The aim of this study was to test the hypothesis that oscillations 
in BP and CBFV, associated with changes in body posture, are transmitted into changes in 
brain cortical oxygenation and that this relationship is altered in patients with mild - moderate 
AD. For this purpose, beat-to-beat changes in BP, CBFV and changes in concentration of 
frontal cortical oxyheamoglobin [O2Hb] and deoxy-heamoglobin [HHb] were measured 
continuously using TCD and NIRS during repeated sit-stand maneuvers in newly diagnosed 
patients with AD. Fourier spectral and transfer function analysis were used to quantify the 
magnitude of oscillations and the dynamic relations between these variables.
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Materials and methods
Subjects
We recruited 21 AD patients, aged 65 years and older. All patients had been newly 
diagnosed with AD in the memory clinic at Radboud University Nijmegen Medical 
Centre. Patients were diagnosed with mild or moderate AD (NINCDS-ADRDA), Clinical 
Dementia Rating (CDR) 0.5 - 2.11 They were not yet treated with cholinesterase inhibitors. 
As a control group, 20 age-matched healthy elderly were selected from a group of 
volunteers that responded to a newspaper advertisement. All patients and volunteers 
were carefully examined by a geriatrician, including physical examination, laboratory 
evaluation, CT (n = 2) or MRI-scan (n =39) of the brain, and neuropsychological testing. 
All controls and randomly selected patients (n = 10), underwent a Doppler study of the 
carotid and vertebral arteries to rule out significant stenosis (> 50 %).
The study was approved by the Ethics Committee for Research on Human Subjects, Radboud 
University Nijmegen Medical Centre, and all volunteers and primary caregivers of the AD 
patients gave written informed consent, AD patients themselves gave verbal consent.
Cerebral blood flow velocity (CBFV) measurements
Using TCD, CBFV was measured in the middle cerebral artery (MCA). Changes in CBFV 
represent changes in flow, under the assumption that the diameter of the insonated 
vessel remains constant. The MCA is one of the major conduit arteries of the cerebral 
circulation and branches directly from the common carotid artery. Many studies have 
demonstrated that the diameter of the MCA does not change appreciably even during 
moderate alterations in BP and end-tidal CO2.12-14 Therefore, changes in CBFV should 
represent predominately changes in CBF in this study.
NIRS measures cerebral cortical changes in [O2Hb] and [HHb]. The basic principle of NIRS 
is that near-infrared light penetrates the skull and brain, and is absorbed by the 
chromophores O2Hb and HHb, that have different absorption spectra. Assuming 
constant scattering, changes in concentration of these chromophores can be deduced, 
using the modified Lambert-Beer Law.15' 16 We applied a continuous-wave NIRS device 
with 3 light bundles with wavelengths of 775 nm, 845 nm, and 904 nm (Oxymon, Artinis 
Medical Systems™, The Netherlands). A fixed differential path length factor (DPF) of 6.6 
(corresponding to age 50) was used in all subjects, which accounts for the increased 
distance travelled by light due to scattering.15 At present, no data are available on the 
actual variation of the DPF with age above 50 years. Our control and patient group, 
however, were age-matched, which should reduce any systemic measurement bias 
induced by using a fixed DPF.
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Data acquisition
Subjects were in sitting position and received first a three-lead ECG for measurement of 
the R-R interval. BP was measured using a photoplethysmography cuff on the index or 
middle finger of the left hand (Finometer, Finapres Medical Systems, the Netherlands), 
with the hand resting approximately at heart level supported by a sling. Data was 
collected by the Finometer for an uninterrupted period which lasted for a maximum of 
5 minutes. Transcranial Doppler ultrasonography was used to measure CBFV. The left 
and right middle cerebral artery were insonated by placing a 2-MHz Doppler probe 
(Multi-Dop, Compumedics DWL, Germany) over the temporal window. The middle 
cerebral arteries were identified according to their signal depth, velocity, and wave char­
acteristics.17 If only one signal was available due to one-sided temporal w indow failure, 
we included this available signal for analysis. The probes were locked at a constant angle 
and position during data collection with a customized headband (Spencer technologies, 
Seattle, Wa). The NIRS optodes were placed and tightly fixed over the left and right 
frontal cortex (Fp1 and Fp2 according to the 10-20 system) in the same headband that 
locked the Doppler probes. An interoptode distance of 5.0 cm was used to minimize 
contamination from the extra-cerebral circulation and to maximize the signal intensity.15 
NIRS cables and optodes were tightly fixed to prevent movement artefacts. Arterial 
saturation (SaO2) was recorded with a pulse oxymeter and end tidal CO2 (EtCO2) using a 
capnograph (N1000, Nellcor, Boulder Co). All data were sampled at 125 Hz.
Protocol
From twelve hours before the study, subjects refrained from caffeinated beverages and 
alcohol. They had a light breakfast at least two hours before the visit. All experiments 
were performed in the morning, in a quiet environmentally controlled laboratory. After at 
least 30 min of sitting rest, spontaneous oscillations data were collected for 5 minutes. To 
assess the dynamic pressure-flow as well as the flow-brain tissue oxygenation relationship, 
spontaneous BP and CBFV oscillations were augmented using repeated sit-stand 
maneuvers at two different frequencies.9. Subjects were instructed to perform repeated 
sit-stand maneuvers at 0.05 Hz (10 s sit followed by 10 s stand) for 5 min and at 0.1 Hz (5 s 
sit followed by 5 s stand) for 4 min. Verbal signs were given to facilitate repeated changes 
in body posture. The maneuvers were separated by 10 min for recovery.
Data processing
All data were simultaneously recorded for offline analysis (Oxysoft, Artinis Medical Systems, 
the Netherlands). A running average filter of 1 s was applied to the O2Hb and HHb signals to 
increase the signal to noise ratio, and to reduce the heart beat and high frequency noise.15, 16
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Spectral analysis was performed on beat-to-beat mean BP, CBFV, [O2Hb], and [HHb] 
changes. The signals were aligned with the time of the R wave peaks of the ECG. The 
time series were then linearly interpolated at 2 Hz to obtain equidistant time intervals 
and detrended with third-order polynomial fitting. These data then were subdivided 
into 128-segments with 50% overlap and a Hanning-window was applied for spectral 
estimation. This data segmentation is based on a trade-off between a reduction in 
spectral variance and keeping sufficient spectral resolution. Each Hanning-windowed 
segment was fast-Fourier transformed and the periodograms were averaged to calculate 
the autospectrum of BP, CBFV, [O2Hb], and [HHb].18 For spectral analysis the following 
frequency ranges were chosen: the very low frequency range: VLF = 0.02 - 0.07 Hz for 
spontaneous oscillations and for the induced 0.05 Hz maneuver, and the low frequency 
range: LF = 0.07 - 0.13 Hz for spontaneous oscillations and for the 0.1 Hz maneuver.9 
Spectral power of oscillations was calculated as area under the curve (AUC) of the power 
spectral density plots. For comparisons, power spectral density plots of BP, CBFV, [O2Hb], 
and [HHb] were included if data on all signals were available for sitting rest and during 
both repeated sit-stand maneuvers.
Transfer function analysis during the repeated sit-stand maneuvers was applied to the 
relationship between the following signals: BP - CBFV and CBFV - [O2Hb]. We did not include 
the calculation of transfer function during spontaneous oscillations and between CBFV-[HHb] 
since oscillations in the [HHb] signal were too weak for a reliable calculation of transfer 
function estimates . Mean values of phase, gain, and coherence of the transfer function were 
analysed in the same VLF and LF as described above. We have previously described the 
explanation of these estimates in detail.5, 9 10 In short, the phase shift quantifies the 
displacement in time of a signal relative to another. The transfer function gain determines 
the magnitude relationship between two signals. Coherence tests the linearity of the 
relationship between these signals. Coherence approaching unity in a specific frequency 
suggests a linear relationship, whereas coherence approaching zero indicates no relationship 
between the signals, severe extraneous noise or a non-linear relationship.19 A coherence of 
0.4 is considered the lower limit where transfer function estimates can be calculated with 
confidence.18 Estimates of phase, gain, and coherence were therefore only included if 
coherence was > 0.4 in this study. All analyses were performed with commercially available 
software (DADiSP, DSP Development, Cambridge, MA).
Statistical analysis
Data are presented as mean ± SD. Normal distribution was tested using Q-Q plots and 
could not be assumed for power spectral data. Comparisons between the control and 
patient group were made using the independent samples T-test and the Mann-Whitney
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U test. For the comparisons of the transfer function estimates between both 0.05 Hz and 
0.1 Hz maneuvers a paired samples T-test was applied. Statistical significance was set at 
p < 0.05. All statistical analysis were performed using statistical software (SPSS version 
16.0, SPSS Inc, Chicago, Ill).
Results
Patients and controls were matched for age and blood pressure level at screening (Table 1). 
Specifically, 15 out of 21 AD patients and 14 out of 20 controls were hypertensive 
(BP > 140/90) at screening. More AD patients however, used antihypertensive medication 
(12 vs 4). As expected, patients had substantially lower cognitive tests scores and more 
hippocampal atrophy. The difference in age related white matter score was not significant 
(A 1.9 on the 30 point scale, p = 0.089).
Baseline hemodynamic measurements
Table 2 provides an overview of the baseline hemodynamics under resting conditions. HR 
and BP data could be obtained in all controls and patients. In 1 control and 4 AD patients, 
data on CBFV could not be obtained due to an insufficient temporal window. Additionally, 
in 1 AD patient the NIRS measurement had to be excluded because of a low signal to noise 
ratio. Although systolic and diastolic BP (sphygmomanometry) were comparable between 
AD and controls at screening, mean arterial pressure as obtained from the average of 5 min 
recording at rest using Finometer was higher in AD. Moreover, resting heart rate and 
spontaneous BP oscillations at the LF range of 0.1 Hz were higher in AD.
In patients with AD, despite the higher BP, CBFV was reduced by 10 %  compared to 
controls. Consistently, there was a 34 %  increase in cerebrovascular resistance index in 
AD (difference = 0.69 (0.25) mmHg/cm/s, p = 0.012) (Table 2). Alzheimer patients also had 
larger spontaneous oscillations in CBFV and [O2Hb] at the LF range (Table 2).
Repeated sit-stand maneuvers
Representative changes in BP, CBFV, and [O2Hb] and [HHb] during baseline, and the 0.05 
Hz and 0.1 Hz sit-stand maneuvers, are presented in figure 1. Note that, as expected, 
[O2Hb] and [HHb] oscillate in counter-phase, and further that these oscillations appear 
clearly related to the oscillations in BP and CBFV.
Figure 2 shows the group averaged power spectra of controls and AD. The repeated 
sit-stand maneuvers induced oscillations in all signals (BP, CBFV, [O2Hb], and [HHb]), and 
the spectral power of these oscillations was significantly larger than for spontaneous
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Table 1 Baseline characteristics of healthy controls and Alzheimer patients
Healthy Controls Alzheimer patients
Age (years) 74.5 (2.8) 72.3 (5.7)
Gender (male : female) 14 : 6 9 : 12
BMI (kg/m2) 24.8 (2.5) 24.5 (3.1)
BP sys (mmHg) 148.3 (20.0) 150.5 (18.9)
BP dias (mmHg) 83.3 (8.9) 80.1 (9.7)
CDR (range) 0 1.0 (0.5 - 2.0)
MMSE 29.3 (1.2) 21.3 (4.7) *
CamCog NA 67.4 (13.4)
Use of antihypertensive medication N = 4 N = 12**
Antihypertensive medication
Diuretic 3 5
ACE Inhibitor - 4
CA-Channel Blocker - 2
Beta Blocker 2 7
AT II Antagonist - 1
Smoking N = 3 N = 2
Diabetes (Type 2) N= 0 N = 5**
MRI
MTA 0.44 (0.61) 2.00 (0.80)*
ARWMC 3.35 (3.12) 5.25 (3.09)
Legend: Values are presented as means, with standard deviation between brackets; CDR is 
presented as mean and range since the score is an ordinal value; * p < 0.001, ** p < 0.05 
Abbreviations: BMI = body mass index, BP sys and dias = systolic and diastolic blood pressure 
measured with sphygmomanometry at screening, CDR = clinical dementia rating, MMSE = 
mini mental state examination, CamCog = cognitive and self-contained part of the Cambridge 
Examination for Mental Disorders of the Elderly. MTA score = medial temporal lobe atrophy 
(Scheltens), range 0-4. ARWMC score = age-related white matter changes (Wahlund), range 0-30.
oscillations in the corresponding frequency range (Table 3). Notably, the 0.05 Hz repeated 
maneuver induced the most powerful oscillations. Power spectra for BP, CBFV, and [HHb] 
were similar in AD and controls. However, there was a trend towards larger oscillations in 
[O2Hb] in AD during the 0.05 Hz maneuver (p = 0.066) (Table 3).
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Table 2 Baseline hemodynamics in healthy controls and Alzheimer patients
Healthy Controls Alzheimer patients
Mean HR (bpm) 61.3 (5.8) 69.7 (11.8)*
Mean BP (mmHg) 78.8 (10.4) 87.6 (18.8)*
Mean CBFV (cm/s) 42.1 (9.9) 37.7 (14.7)
CVRi (mmHg/cm/s) 2.00 (0.55) 2.68 (0.97)*
PetCO2 (mmHg) 34.7 (3.1) 35.2 (2.5)
BP VLF (mmHg2) 4.62 (1.8) 7.42(4.8)
BP LF (mmHg2) 1.19 (0.6) 2.29 (1.8)*
CBFV VLF ((cm/s)2) 2.43 (1.3) 3.49 (1.3)
CBFV LF ((cm/s)2) 0.55 (0.3) 1.29 (1.0)*
[oxyHb] VLF ((pmol/l)2) .038 (0.012) 0.084 (0.1)
[oxyHb] LF ((pmol/l)2) 0.0091 (0.006) 0.037 (0.08)*
[HHb] VLF ((pmol/l)2) 0.016 (0.009) 0.036 (0.05)
[HHb] LF ((pmol/l)2) 0.0036 (0.003) 0.011 (0.02)
Legend: Average of 5 minutes measurement during sitting rest. For CBFV either the average of 
left and right, or the available signal were included for analysis. Values are presented as means, 
with standard deviation between brackets; BP = blood pressure, HR = heart rate, CBFV = cerebral 
blood flow velocity, PetCO2 = pressure of end-tidal CO2, CVRi = cerebrovascular resistance index 
(mean BP/CBFV), [O2Hb] and [HHb] = changes in concentration of frontal cortical oxygenated and 
deoxygenated hemoglobin, respectively. BP VLF, BP LF, CBFV VLF, CBFV LF, [oxyHb] VLF, [oxyHb] LF, 
[HHb] VLF, [HHb] LF, spectral power of BP, CBFV, [oxyHb] and [HHb] in the very low frequency and 
low frequency range (VLF = 0.02 - 0.07 Hz, LF = 0.07 - 0.13 Hz).
Figure 3 provides an example of the relation between the oscillations in BP and CBFV, 
and of the oscillations between CBFV and [O2Hb] during 0.05Hz sit-stand maneuvers. 
During the maneuvers, oscillations in CBFV lead those of BP, whereas oscillations in 
[O2Hb] follow those of CBFV (phase lag), suggesting a time delay between changes in 
CBF and brain tissue oxygenation.
Transfer function gain between CBFV and [O2Hb] was higher in AD during the 0.05 Hz 
repeated sit-stand maneuver, and the phase lag between CBFV and [O2Hb] was larger 
(Figure 4). The use of antihypertensive medication in the control and AD group did not 
lead to within-group differences in gain and phase between CBFV and [O2Hb] (p all > 
0.1). The within-group differences for diabetes in the AD group could not be assessed, 
since 3 diabetic patients were excluded from transfer function analysis due to low
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Figure 1 Example of blood pressure, cerebral blood flow velocity, and cortical frontal 
oxy- and deoxygenated hemoglobin oscillations in sitting rest and during 
the 0.05 Hz and 0.1 Hz repeated sit-stand maneuvers in one subject
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Legend: Data from one healthy subject, variability in blood pressure (BP - upper panel), cerebral 
blood flow-velocity (CBFV - middle panel) in the left middle cerebral artery, left frontal cortical 
oxygenated and deoxygenated hemoglobin ([O2Hb], solid line, and [HHb], dashed line, - both 
bottom panel), during baseline measurements in sitting rest (left panel) and the repeated sit-stand 
maneuvers at 0.05 Hz (middle panel) and 0.1 Hz (right panel). Note the enhanced amplitude and 
consistency of the oscillations induced by the 0.05 Hz repeated sit-stand maneuvers.
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Figure 2 Group averaged power spectra of blood pressure, cerebral blood flow 
velocity, and cortical frontal oxy- and deoxygenated hemoglobin 
oscillations in sitting rest and during repeated sit-stand maneuvers
Baseline 0.05 Hz 0.1 Hz
NX
X
CL
CÛ
1400
1200
1000
800
600
400
200
0V
_____-v.
_Qx ^
E l ^xO- 2
à |CN ^£ ~
f k .
t»%H+•?»
is
A
.A.
0.0 0.1 0.2 0.3 0.4 0.0 0.1 0.2 0.3 0.4 0.0 0.1 0.2 0.3 0.4
Frequency (Hz) Frequency (Hz) Frequency (Hz)
Legend: Results of spectral analysis of blood pressure (BP - upper panel), cerebral blood flow 
velocity (CBFV- middle panel), and frontal cortical oxygenated and deoxygenated hemoglobin 
([O2Hb], black line, and [HHb], grey line - both bottom panel) during sitting rest (left), 
the 0.05 Hz repeated sit-stand maneuver (middle) and the 0.1 Hz repeated sit-stand maneuver 
(right). The solid lines represent the spectra of the oscillations in healthy controls, the dotted lines 
are for the Alzheimer patients.
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Table 3 Hemodynamics in healthy controls and Alzheimer patients during two 
repeated sit-stand maneuvers
Healthy Controls Alzheimer Patients
0.05 Hz 0.1 Hz 0.05 Hz 0.1 Hz
Number of Subjects* 16 17 15 15
HR (bpm) 68.18 (7.3) 73.50 (7.0) 79.21 (13.5)* 85.45 (14.5)*
BP (mmHg) 91.27 (14.7) 93.05 (13.5) 105.64 (21.1)** 104.84 (21.5)***
CBFV (cm/s) 46.43 (7.9) 46.45 (7.5) 40.79 (14.8) 43.53 (14.8)
PetCO2 (mmHg) 34.23 (2.5) 34.24 (2.2) 34.01 (2.7) 33.8 (2.4)
PS BP (mmHg2) 42.89 (19.1) 15.24 (7.19) 38.36 (26.0) 17.49 (13.8)
PS CBFV ((cm/s)2) 17.28 (9.8) 7.63 (4.2) 18.72 (17.7) 8.24 (5.8)
TFA BP - CBFV++
Number of Subjects 16 18 13 15
Phase (rad) 0.73 (0.29) 0.70 (0.23) 0.81 (0.24) 0.65 (0.21)
Gain (cm/s/mmHg) 0.55 (0.16) 0.60 (0.13) 0.47 (0.17) 0.62 (0.22)
nGain (%cm/ 1.18 (0.29) 1.36 (0.25) 1.25 (0.30) 1.43 (0.31)
s/%mmHg)
Coherence 0.65 (0.12) 0.76 (0.13) 0.68 (0.11) 0.77 (0.10)
Legend: Average of 5 and 4 minutes repeated sit-stand at 0.05 Hz and at 0.1 Hz, respectively.
For CBFV either the average of left and right, or the available signal were included for analysis. 
Values are presented as means, with standard deviation between brackets; BP = blood pressure, 
HR = heart rate, CBFV = cerebral blood flow velocity, PetCO2 = pressure of end-tidal CO2,
PS BP, PS CBFV = spectral power of BP, CBFV. TFA = transfer function analysis.+ Data were only 
included if measurements on all signals were available. ++ Data were only included if coherence of 
the transfer function was > 0.4. * p < 0.01, ** p < 0.05, *** p < 0.1 compared to healthy control in 
the same frequency range.
coherence (that is, ultimately, only 2 patients with (type II) diabetes were included in the 
AD group for this part of the analysis). No differences in transfer function gain and phase 
between BP and CBFV were observed between the controls and AD (Table 3).
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Figure 3 Example of the relation between BP and CBFV, and CBFV and oxygenated 
hemoglobin, during the repeated sit-stand maneuvers at the 0.05Hz
0.05 Hz 0.1 Hz
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Legend: Representative data from one healthy control. The left panel presents the BP and CBFV 
changes (upper panel) and the CBFV and oxygenated hemoglobin ([O2Hb] - bottom panel) 
changes during the 0.05 Hz maneuver. The solid line represents changes in BP (upper panel), 
the long dashed line represents changes in CBFV (upper and bottom panel) and the dotted line 
changes in [O2Hb]. Note that CBFV leads BP, whereas [O2Hb] lags behind CBFV. The data at 0.1 Hz 
are not shown because oscillations in [O2Hb] were not as clear as at 0.05 Hz.
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Figure 4 Transfer function analysis of cerebral blood flow velocity and oxygenated 
hemoglobin in the frontal cortex in healthy controls and Alzheimer patients
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1.0
0.8
0.6
0.4
0.2
0.0
X .
CO AD CO AD
Legend: Values of transfer function analysis between cerebral blood flow velocity and oxygenated 
hemoglobin in healthy controls (CO) and Alzheimer patients (AD) in the very low (0.02 - 0.07 Hz) 
and low (0.07 - 0.13 Hz) frequency range expressed in phase (upper panel), gain (middle panel) 
and coherence (bottom panel). Data of controls are presented left and of Alzheimer patients right. 
The box plots represents group average values with the 95 %  confidence interval.
* p < 0.05 compared to healthy controls.
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Discussion
The present study is the first to assess the dynamic cerebral autoregulation by means of 
the concomitant registration of changes in blood flow velocity in the middle cerebral 
artery and cerebral frontal cortical oxygenation in patients with Alzheimer's disease. 
There are three main findings in this study. First, in view of the fact that the origin of very 
low frequency oscillations in cortical oxygenation remains disputed, our data 
demonstrates that these oscillations are related to changes in global CBF, measured in 
the middle cerebral artery, which in turn were related to changes in systemic blood 
pressure. Second, findings from this study suggest that the dynamic CBF-brain tissue 
oxygenation relation can be assessed using transfer function analysis during repeated 
sit-stand maneuvers associated with a high coherence function (> 0.4) between these 
variables. Third, we have shown that the transmission of changes in CBF into changes in 
brain tissue oxygenation differs essentially in patients with Alzheimer's disease, as 
evidenced by increased transfer function gain and phase between changes in CBF 
velocity and cortical [O2Hb] signal, indicating a compromised function of the cerebral 
microcirculation to maintain brain tissue oxygenation homeostasis in AD.
Oscillations in cerebral cortical oxygenation
The NIRS method directly assesses cerebral cortical oxygenation changes at the cerebral 
cortical tissue level. In accordance with the literature, we detected spontaneous 
oscillations in [O2Hb] and [HHb] in the very low and low frequency range, where also 
spontaneous variability in BP and CBFV can be found.6- 20 In AD patients, their enhanced 
oscillations in BP in the low frequency range (around 0.1 Hz), also led to enhanced 
oscillations in CBFV and [O2Hb].
The repeated sit-stand maneuvers induced large oscillations in [O2Hb] that mirrored 
those in BP and CBFV. Thus far, only one study has succeeded in inducing oscillatory 
[O2Hb] changes, using deep breathing at 0.1 Hz, and these authors observed similar 
oscillations in BP, CBFV and [O2Hb].7 With a repeated sit-stand maneuver, we were able to 
induce oscillatory [O2Hb] changes in the very low frequency of 0.05 Hz, which would not 
have been possible with deep breathing. Our data indicate that oscillatory [O2Hb] 
changes in this frequency range are related to the oscillations in CBFV, which in turn are 
induced by oscillations in systemic BP The larger oscillations in BP and CBFV at 0.05 
compared to 0.1 Hz during repeated sit-stand maneuvers are in agreement with previous 
studies.9' 10 21 Taken together, the relationship between BP, CBFV, and [O2Hb] during 
repeated sit-stand maneuvers lends support to the notion that upstream oscillations in
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CBF induced by changes in BP contribute importantly to the downstream brain tissue 
level oscillations in [O2Hb].
The dynamic CBFV- [O2Hb] relationship
The dynamic relation between oscillations in CBFV and cortical [O2Hb] may reflect a 
cerebral autoregulatory mechanism to maintain brain tissue oxygenation.3, 16 However, 
the investigation of the relationship between spontaneous oscillations in CBFV and 
[O2Hb] using transfer function analysis suffers from the weakness and non-stationarity of 
the [O2Hb] measurement under resting conditions.16 The repeated sit-stand maneuvers 
in this study induced large oscillations in BP, CBFV, and [O2Hb] and enhanced coherence 
between CBFV - [O2Hb] (> 0.4) and therefore improve the reliability of the transfer 
function analysis.5
[O2Hb] oscillations seem to follow those of CBFV (Fig 3). Therefore, the phase difference 
between these variables may reflect a transit time between flow in supplying brain 
arteries and [O2Hb]. In patients with AD, a disease in which it becomes progressively 
clear that the cerebral microvasculature is affected, we identified a larger phase lag and 
higher gain between CBFV and [O2Hb] at the very low frequency of 0.05 Hz - where 
dynamic cerebral autoregulation is active-, but not in the low frequency (0.1 Hz) - where 
autoregulation is not active.22 We speculate that this points towards impairment in 
dynamic autoregulation at the microcirculatory level in AD. Alternatively, the increased 
phase lag in AD could suggest that cerebral microcirculatory oxygen extraction is 
compromised, leading to a longer transit time between CBFV and [O2Hb]. The increases 
in the transfer function gain between CBFV and [O2Hb] provide further insights into the 
cerebral microvascular function in AD. Using positron emission tomography (PET), it has 
been shown that the oxygen extraction fraction, regarded as an indicator of the brain 
tissue metabolic reserve, was increased in AD (a reduction of metabolic reserve).8 
In addition, reduced brain metabolic rate for glucose and oxygen has been observed in 
AD which may reduce the oxygen diffusion gradient from the capillaries to brain tissue. 
Therefore, the increase in CBFV - [O2Hb] gain likely reflects a reduced metabolic reserve 
or a reduced diffusion of oxygen leading to enhanced oscillations in [O2Hb] in response 
to changes in CBF.
The specific mechanisms for vascular abnormalities leading to the altered CBFV - [O2Hb] 
relationship in AD cannot be determined in this study. Amyloid beta, the peptide linked 
to the pathological manifestations in AD, causes cerebrovascular dysfunction2 as well as 
deposits in the small vessels in AD (cerebral amyloid angiopathy). Thus, it is possible that 
these abnormalities may contribute to the altered CBFV- [O2Hb] relation.
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CBFV and dynamic autoregulation
Confirming previous results from a pilot study measuring only CBFV, we observed that 
CBFV was reduced and cerebrovascular resistance was increased in AD.4 We have 
previously shown that this difference could not be explained by differences in individual 
whole brain volume.4 We could however, not reproduce the earlier findings of a lower 
gain between BP - CBFV during either the 0.05 Hz or 0.1 Hz repeated maneuver in AD 
relative to controls. An important difference between these studies is that in the present 
study patients were not treated yet with cholinesterase inhibitors. These drugs potentially 
alter cerebral hemodynamics.23 Moreover, AD patients in the present study were older. 
The CBF response to transient changes in BP, as quantified by transfer function gain and 
phase, reflects dynamic cerebral autoregulation.18 The mechanims underlying dynamic 
autoregulation are not clear. The unaltered gain and phase between BP and CBFV 
observed in this study suggest that dynamic autoregulation - at least at the macrovascular 
level - is preserved in patients with AD. However, several studies have shown that 
cerebral autoregulation was impaired in the mouse models of AD related to beta amyloid 
pathology.2- 3 These discrepancies may highlight the differences in the regulation of 
cerebral hemodynamics between patients with AD and the animal model used. Clearly, 
further work is needed to understand the regulation of CBF and its relation to AD 
pathology.
Study limitations
During screening, controls and patients were matched for blood pressure. Significantly 
more patients however used antihypertensive drugs. However, cerebral autoregulation 
and cerebral blood flow are preserved during treatment with p-blockers, calcium 
channel blockers, angiotensin-converting enzyme inhibitors, AT1-recepter blockers, or 
thiazide diuretics.24-28
In the AD group, 5 subjects suffered from type 2 diabetes. Data regarding the influence 
of diabetes on cerebral autoregulation are mixed, reporting either an impairment or 
preservation of cerebral autoregulation.29-31 For the analysis of the relation between 
CBFV - [O2Hb] at 0.05 Hz - where the current study demonstrated an altered relationship 
in AD - only 2 diabetic AD patients were included. This makes a confounding effect of 
diabetes on our findings very unlikely.
Moreover, hypertension and diabetes mellitus are the most important vascular risk 
factors for AD,32 and exclusion of AD patients with such comorbidities from studies 
would seriously hamper their generalizability .
Both methods to assess cerebral perfusion, TCD and NIRS, have certain limitations that 
have been well described in the literature and that are summarized in the method
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section. We combined these two measurements to provide information on both global 
cerebral perfusion and brain tissue level oxygenation in patients with AD.
Conclusion
Using a unique combination of TCD and NIRS measurements, we have shown that 
oscillations in cerebral blood flow velocity, induced by repeated changes in body 
posture, translated into large oscillations in cerebral cortical oxygenation. Furthermore, 
we demonstrated that Alzheimer patients differed from controls in how these changes 
in flow were transmitted to changes in cerebral cortical oxygenation. This result is 
indicative of a compromised function of the cerebral microcirculation to maintain brain 
tissue oxygenation homeostasis in patients with Alzheimer's disease.
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To the Editor:
The use of cholinesterase inhibitors (ChEI's), commonly prescribed to treat the symptoms 
of Alzheimer's Disease (AD), has been associated with syncope and bradycardia.1 Because 
of their action on cholinergic neurotransmission within the autonomic nervous system, 
these drugs potentially have direct effects on cardiac rhythm and blood pressure (BP).2 
Limited information however is available on the hemodynamic effects of ChEI's in 
patients with AD and the underlying cause of the reported syncopal incidents remains 
unknown.2 Recent technological developments make it possible to perform detailed 
measurements of systemic hemodynamics using non-invasive and non-obtrusive 
methods.3 We tested the hypothesis that ChEI associated syncope in AD patients is 
caused by orthostatic intolerance through altered autonomic control of heart rate and 
peripheral vascular resistance.
Methods
We recruited 21 patients newly diagnosed with mild to moderate (CDR 0.5 - 2.0) probable 
AD according to the NINCDS-ADRDA criteria, from our memory clinic at Radboud 
University Nijmegen Medical Centre, the Netherlands. After baseline measurement, AD 
patients started treatment with the ChEI galantamine (8 mg/day for 4 weeks, followed 
by 16 mg/day).4
Heart rate (HR) (three lead ECG) and BP (Finapres) were continuously measured in AD 
patients and 20 aged matched healthy controls. Recordings were performed during 5 
min of sitting rest and during three repetitions of a single sit-stand maneuver (120 s 
sitting followed by 60 s standing), which is a valid proxy of standing up from supine and 
easier to perform in frail older subjects. In 20 patients, measurements were repeated 
after 10 (SD 4) weeks of treatment.
After alignment with the R peaks of the ECG, beat-to-beat mean, systolic and diastolic 
values were calculated for BP HR was calculated from the RR interval. The maximum 
absolute and percentage changes upon standing compared to sitting were calculated 
for BP and HR.
Data are presented as mean (SD). Normal distribution was tested using Q-Q plots. Group 
comparisons were made using an independent samples T-test and for comparisons 
within AD patients a paired samples T-test was used.
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Results
Baseline characteristics and hemodynamics are presented in table 1. Before treatment, 
HR, and mean and diastolic BP were higher in AD. Galantamine treatment led to a 
reduction in mean and diastolic BP but not in HR.
The sit-stand maneuvers induced a decrease in BP within 20 seconds after standing in all 
subjects (known as initial orthostatic hypotension). One AD patient was excluded, 
because baseline BP variability was so strong that it obscured the hemodynamic effect 
of the sit-stand maneuver. The drop in mean BP (before galantamine) was significantly 
smaller in AD compared to controls (control 16.9 (8.2) mmHg, AD 12.3 (6.2) mmHg, p =
0.024; relative change: control 20.0 (10.1) %, AD 15.2 (8.1) %, p = 0.055). Galantamine did 
not influence this orthostatic BP response (BP drop post- treatment 12.7 (7.0) mmHg, p =
0.72 compared to baseline). The orthostatic HR response was identical in both controls 
and AD (control 10.5 (4.7) bpm, AD pre-treatment 8.9 (7.9) bpm, AD post-treatment 10.7 
(5.2) bpm, p all > 0.2).
Discussion
Unexpectedly we found that orthostatic tolerance was preserved, if not enhanced, in 
AD. This may be explained by enhanced sympathetic tone, given the elevated baseline 
BP and HR at baseline in AD. Galantamine lowered resting BP, but did not affect 
orthostatic tolerance or HR. This suggests that the reported increased incidence of 
syncope in AD patients treated with galantamine,1 is not mediated by negative effects 
on autonomic control of BP and HR.
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Table 1 Baseline characteristics and systemic hemodynamics in healthy controls 
and patients with Alzheimer before and after treatment with galantamine
Healthy Controls Alzheimer Patients
Baseline Characteristics
Age (years) 74.6 (2.7) 72.9 (5.7)
Gender (male : female) 15 : 5 9 : 12
BMI (kg/m2) 25.0 (2.6) 24.5 (3.3)
MMSE 29.2 (1.3) 21.3 (4.6) *
CamCog NA 67.4 (13.4)
Antihypertensive use
Diuretic 3 5
ACE Inhibitor - 4
CA-Channel Blocker - 2
Beta Blocker 2 7
AT II Antagonist - 1
Healthy Controls GAL- GAL+
Hemodynamics * N = 20 N = 21 N = 20
HR (bpm) 60.3 (7.6) 69.5 (11.5)* 67.3 (13.0)
BP mean (mmHg) 77.2 (11.9) 87.9 (18.8)* 79.3 (13.2) f
BP sys (mmHg) 120.1 (18.9) 133.8 (28.6) 124.0 (22.9)
BP dias (mmHg) 56.2 (10.7) 65.6 (16.1)* 58.9 (11.7) f
Legend: Values are presented as mean with standard deviation between brackets.
* p < 0.05 compared to healthy controls, f p < 0.05 compared to GAL-, * assessed from 5 min of 
measurement during sitting rest. Abbreviations: BMI = body mass index, MMSE = mini mental 
state examination (range 0 - 30), CamCog = cognitive and self-contained part of the Cambridge 
Examination for Mental Disorders of the Elderly (range 0 - 104), BP = blood pressure, HR = heart 
rate, GAL- = Alzheimer patients before treatment with Galantamine, GAL+ = Alzheimer patients 
treated with Galantamine. BP sys = systolic blood pressure, BP dias = diastolic blood pressure.
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Abstract
Background and purpose Cerebrovascular function and structure of the cortical 
cerebral microvessels are believed to be profoundly altered in patients with Alzheimer's 
disease (AD). Treatment with cholinesterase inhibitors (ChEI's) may further affect brain 
perfusion through either augmentation or inhibition of cerebral vasodilatation. We 
tested the hypothesis that cerebrovascular regulation is impaired in AD and influenced 
by treatment with the ChEI galantamine.
Methods Blood pressure (BP - Finapres), cerebral blood flow velocity (CBFV) in the 
middle cerebral artery (Transcranial Doppler ultrasonography) and frontal cortical 
oxygenation (Near-Infrared-Spectroscopy) were measured following a hypotensive 
challenge. AD patients were compared to age-matched controls. In AD, measurements 
were repeated after 10 (SD 4) weeks of galantamine.
Results At baseline, cerebrovascular resistance was higher in AD (AD 2.83 (0.87) mmHg/ 
cm/s, control 2.24 (1.3) mmHg/cm/s, p = 0.010). AD patients had a larger postural decline 
in the frontal cortical concentration of total hemoglobin (A [tHb] AD = 1.03 (0.70) pmol/l, 
control = 0.30 (0.90) pmol/l, p = 0.015). Normalized for the orthostatic BP decline, the 
reduction in oxygenated hemoglobin was 57 %  larger in AD (p = 0.085) with a further 
decrease after treatment with galantamine (12 %, p = 0.036), the latter however without 
a concomitant decrease in [tHb].
Conclusion Even for moderate and commonly occurring orthostatic BP changes, 
cerebral cortical perfusion declined more in AD, suggesting increased ischemic 
vulnerability of the brain. Galantamine neither improved nor impaired cerebrovascular 
regulation. The altered oxygenation may be explained by cholinergically enhanced 
frontal cortical metabolism.
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Introduction
For more than 30 years, Alzheimer's Disease (AD) has been classified as a neurodegen­
erative disease. In the last decade however, mounting evidence indicated that cerebro­
vascular impairment acts together with neurodegeneration in the etiology of AD, in 
either a synergistic or additive role.1 Cerebrovascular function and the structure of the 
microvessels are profoundly altered in AD.2 Moreover, cerebral autoregulation, the 
mechanism preserving brain perfusion, is impaired in mouse models of AD and is altered 
in AD patients.3-5
Cholinesterase inhibitors (ChEI's) are drugs commonly prescribed to treat cognitive and 
neuropsychiatric symptoms of AD. This treatment, based on the cholinergic hypothesis, 
enhances cholinergic function by increasing the concentration of acetylcholine in the 
brain, but also acts in a complex manner on the cerebrovascular innervation.6- 7 ChEI's 
may on the one hand augment cerebral perfusion through their stimulant effects on the 
intrinsic cholinergic cerebrovascular innervation,7 whilst on the other hand they may 
promote vasoconstriction through blockade of nicotinic-receptor-mediated autonomic 
vasodilatation.7 ChEI's improved vascular reactivity and neurovascular coupling in AD 
patients,8' 9 suggesting that the - beneficial- vasodilatory effect may be dominant. 
Whether ChEI's also influence cerebral autoregulation - the stabilization of cerebral 
blood flow (CBF) during changes in blood pressure (BP) - remains unknown.
A straightforward technique in old subjects to investigate this issue is a sit-stand 
maneuver, which induces transient hypotension.10 This maneuver provokes a decline in 
cerebral blood flow velocity (CBFV) and cerebral cortical oxygenation, which can be 
measured with transcranial Doppler ultrasonography (TCD) and near-infrared 
spectroscopy, respectively.10,11
We hypothesized that the regulation of CBFV and tissue oxygenation during a transient 
decline in BP, induced by a single sit-stand maneuver, is impaired in AD and may be 
either aggravated or improved following treatment with ChEI's.
Methods
Study type and ethics
This explorative open-label study was approved by our Ethics Committee for Research 
on Human Subjects. All volunteers and the primary caregivers of AD patients gave 
written informed consent, AD patients gave written or verbal consent.
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Participants
We recruited 21 newly diagnosed patients with AD, aged over 65 years, from our memory 
clinic. Patients were diagnosed with probable AD according to the NINCDS-ADRDA 
criteria with mild or moderate Clinical Dementia Rating (CDR 0.5 - 2) and were not yet 
treated with ChEI's. 20 age-matched controls were selected from volunteers who 
responded to a newspaper advertisement. All patients and controls were carefully 
examined by a geriatrician, including physical examination, laboratory evaluation, CT- (n 
= 2) or MRI-scan (n = 39) of the brain, and neuropsychological testing. All controls and 
randomly selected patients (n = 10) underwent a Doppler study of the carotid and 
vertebral arteries to rule out significant stenosis (> 50 %).
Cerebral Blood Flow Measurements
Using TCD, CBFV was measured in the middle cerebral artery. Changes in CBFV represent 
changes in flow, under the assumption that the diameter of the insonated vessel remains 
constant. The diameter of the middle cerebral artery does not significantly change 
during alteration in BP up to 30 mmHg.12-14 Therefore, in this study it can be assumed that 
changes in the diameter of the MCA were minimal and that changes in CBFV represent 
changes in CBF.
Using NIRS, cerebral cortical changes in the concentration of oxygenated and 
deoxygenated haemoglobin can be measured ([oxyHb], [deoxyHb]). The basic principle 
of NIRS is that near-infrared light penetrates the skull and brain and is absorbed by the 
different absorption spectra of the chromophores oxyHb and deoxyHb. Changes in 
concentration of these chromophores can be deduced using the modified Lambert-Beer 
Law. We applied a continuous-wave NIRS device producing 3 light bundles with 
wavelengths of 775 nm, 845 nm, and 904 nm (Oxymon, Artinis Medical Systems™, The 
Netherlands) at a fixed differential path length factor (DPF) of 6.6 (corresponding to age 
50) in all subjects, which accounts for the increased distance travelled by light due to 
scattering. No data are available on the actual variation of the DPF with age above 50 
years, however, because our control and patient group were age-matched this will not 
influence between group comparisons. Active standing induces a measurable decline in 
frontal cortical oxygenation in old subjects,11 which is reproducible at a group-averaged 
level using this specific NIRS device.15
Instrumentation
From three hours before the study, subjects refrained from using caffeinated beverages 
and alcohol. They had a light breakfast at least two hours before the visit. All experiments 
were performed in the morning, in a quiet environmentally controlled laboratory.
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Three ECG leads provided measurement of the R-R interval. The photoplethysmographic 
cuff of the Finapres (Finometer, Finapres Medical Systems™, the Netherlands) was fitted 
to the left index or middle finger to measure beat-to-beat BP. A sling was fitted to 
support the left arm at heart height, eliminating changes in hydrostatic gradient during 
measurements. TCD was used to continuously and bilaterally measure CBFV in the 
cerebral arteries which were insonated by placing a 2-MHz Doppler probe (Multidop, 
DWL medical systems™, Germany) over the temporal window. If only one signal was 
available due to one-sided temporal w indow failure, we included this available signal for 
analysis. The middle cerebral arteries were identified according to their signal depth, 
velocity, and wave characteristics.16 Probes were locked at a constant angle and position 
with a customized headband (Spencer technologies™, Seattle, Wa, USA) The depth, 
sample volume, and power of the TCD measurement were noted for each subject. The 
NIRS transmitters and receivers were placed and tightly fixed over the left and right 
frontal cortex in the same headband that locked the Doppler probes at an interoptode 
distance of 5.0 cm to minimize contamination from the extra-cerebral circulation and to 
maximize signal intensity. Both cables and optodes of the NIRS were tightly fixed to 
prevent motion artefacts.
Arterial saturation (SaO2) was recorded with a pulse oximeter and end- tidal CO2 (EtCO2) 
with a capnograph (N1000, Nellcor, Boulder Co).
Protocol
Baseline recordings were performed during at least 5 min of sitting rest. After baseline 
recordings subjects performed 3 repetitions of a single sit-stand maneuver, consisting of 
120 s sitting followed by 60 s standing. In AD patients, measurements were repeated 
after 10 (SD 4) weeks of treatment with galantamine (8 mg/day for 4 weeks, followed by 
16 mg/day).
Data Processing and Analysis
All data were simultaneously analogue/digital converted and sampled at 125 Hz with 
commercially available data acquisition software (Oxymon, Artinis Medical Systems™, 
The Netherlands). Signals were aligned with the time of the R peaks of the ECG. 
Beat-to-beat mean values were calculated for BP, CBFV, [oxyHb], [deoxyHb], and EtCO2, 
including diastolic and systolic values for BP and CBFV. Baseline heart rate (HR), BP, and 
CBFV-values were calculated from at least 5 min of baseline recording in rest. Cerebro­
vascular resistance index (CVRi) was calculated as the ratio of BP and CBFV. The 3 single 
sit-stand maneuvers of every subject were time-locked and averaged. Changes relative 
to baseline were calculated for BP, CBFV, and [oxyHb] and [deoxyHb]. The total
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hemoglobin concentration ([tHb]) was calculated as the sum of [oxyHb] and [deoxyHb]. 
EtCO2 served as control parameter.
If no TCD signal was recorded because of a left- and right-sided insufficient temporal 
window, BP and NIRS measurements were included for analysis. The level of decrease in 
mean BP necessary to assess the cerebrovascular response to transient hypotension was 
set at an arbitrary 10 mmHg. Below this level it was assumed unrealistic to expect a 
significant response in CBFV, [OxyHb], and [DeoxyHb]. If subjects had a BP decrease < 10 
mmHg, only their BP measurements were included in the group analysis.
Statistical analysis
Data are presented in tables as mean +/- SD. Normal distribution was tested with Q-Q 
plots, and could only be assumed for baseline HR, BP, and CBFV measurements. For 
comparison of group averages either an independent samples T-test or Mann-Whitney 
test was used. The paired samples T-Test and the Wilcoxon signed rank test were applied 
to compare measurements of AD patients before and after treatment with ChEI's. 
Statistical significance was set at p < 0.05. All statistical analyses were performed using 
statistical software (SPSS version 16.0, SPSS Inc, Chicago, Ill).
Results
Subject characteristics and baseline measurements
Table 1 shows demographic data and systemic and cerebral hemodynamics for controls 
and AD patients. Patients and controls were matched for age and blood pressure level at 
screening (Table 1).Specifically, 15 out of 21 AD patients and 13 out of 20 controls were 
hypertensive (BP > 140/90) at screening, however, more AD patients used antihyperten­
sive medication (12 vs 4). Patients had substantially lower cognitive test scores and more 
hippocampal atrophy, as well as somewhat higher age related white matter scores (A 2.4 
on the 30 point scale). Resting Finapres and TCD measurements revealed that AD patients 
had a 26 %  higher CVRi at baseline (p < 0.05).
Systemic hemodynamic response to postural change before and after treatment
Figure 1 presents the mean BP and HR response upon standing. AD patients had a smaller 
decrease in BP (A mean BP controls -16.9 (8.2) mmHg, AD - 12.3 (6.2) mmHg, p = 0.024) 
whereas HR response was similar. The postural change in BP and HR upon standing was not 
affected by galantamine. However, baseline BP in AD was lower while on galantamine 
(mean BP before treatment 87.9 (18.8) mmHg, after treatment 79.3 (13.2) mmHg, p = 0.028).
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Table 1 Baseline characteristics and systemic hemodynamics in patients with 
Alzheimer and controls
Controls Alzheimer Patients
Baseline characteristics N= 20 N=21
Age (years) 74.6 (2.7) 72.9 (5.7)
Gender (male : female) 15 : 5 9 : 12
BMI (kg/m2) 25.0 (2.6) 24.5 (3.3)
Systolic BP (mmHg) 147.6 (20.0) 150.5 (15.8)
Diastolic BP (mmHg) 83.3 (9.2) 80.1 (9.7)
MRI
MTA 0.47 (0.60) 2.00 (0.80)*
ARWMC 2.94 (3.07) 5.25 (3.09)**
MMSE 29.2 (1.3) 21.3 (4.6) *
CamCog NA 67.4 (13.4)
Antihypertensive agents
Diuretic 3 5
ACE Inhibitor - 4
CA-Channel Blocker - 2
Beta Blocker 2 7
AT II Antagonist - 1
Hemodynamics***
HR (bpm) 60.3 (7.6) 69.5 (11.5)*
Mean BP (mmHg) 77.2 (11.9) 87.9 (18.8)*
Systolic BP (mmHg) 120.1 (18.9) 133.8 (28.6)
Diastolic BP (mmHg) 56.2 (10.7) 65.6 (16.1)*
Mean CBFV (cm/s) 39.5 (10.7) 34.4 (13.0)
Systolic CBFV (cm/s) 67.5 (18.5) 61.6 (23.7)
Diastolic CBFV (cm/s) 21.3 (7.0) 16.1 (7.0)*
CVRi (mmHg/cm/s) 2.24 (1.3) 2.83 (0.87)**
Legend: Values are presented as mean with standard deviation between brackets. * p < 0.05 
compared to healthy controls, ** p < 0.01, *** assessed from 5 minutes measurements during 
sitting rest. Abbreviations: MTA score = medial temporal lobe atrophy (Scheltens), range 0-4. 
ARWMC score = agerelated white matter changes (Wahlund), range 0-30, BMI = body mass 
index, MMSE = mini mental state examination, CamCog = cognitive and self-contained part of 
the Cambridge Examination for Mental Disorders of the Elderly, BP = blood pressure, HR = heart 
rate, CBFV = cerebral blood flow velocity, CVRi = cerebrovascular resistance index.
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Figure 1 Systemic hemodynamic response upon standing in healthy controls and 
Alzheimer patients
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Legend: Group averaged mean blood pressure (black) and heart rate (gray) during the sit-stand 
maneuver. Subjects started standing at 0 s point in time. The solid line represents healthy controls, 
the dotted line AD patients before treatment with galantamine, and the dashed line AD patients 
after treatment with galantamine.
Cerebral Hemodynamic Response to Postural Change Before and After Treatment
Table 2 provides an overview of the CBFV, [OxyHb], [deoxyHb], and [tHb] response to 
standing and the number of subjects included for analysis of the sit-stand maneuver. In 
2 controls, 8 AD patients before treatment and 8 AD patients after treatment (of whom 4 
both before and after treatment) the fall in BP upon standing was < 10 mmHg and hence 
these data could not be used to perform a meaningful analysis of orthostatic CBF 
response (see methods). Additionally, 2 controls and 4 patient had an insufficient 
temporal w indow to obtain CBFV data. Of the remaining 13 AD patients, 8 met criteria 
for hypertension (BP >140/90 mmHg) and 7 used antihypertensive medication. Of the 
remaining 17 controls, 12 met hypertension criteria and 4 used medication.
In figure 2, it can be seen that AD patients had a larger decline in frontal cortical tissue 
[oxyHb] and [tHb] upon standing. Treatment with galantamine enhanced this [oxyHb] 
decline but also led to a [deoxyHb] increase, while the decline in [tHb] was not affected. 
Normalized for the reduction in BP we found a 57 %  larger drop in [oxyHb]/BP in AD, which 
was further enlarged (12 % ) after galantamine (control vs AD pre-treatment p = 0.089
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Table 2 Cerebral hemodynamic response to postural changes in Alzheimer 
patients and controls
Controls Alzheimer
Patients
pre-treatment
Alzheimer
Patients
post-treatment
N 17 9 10
A Mean CBFV(cm/s) -4.34 (3.0) -4.27 (4.7) -3.89 (3.2)
N 18 13 12
A [OxyHb] (pmol/l) -0.89 (0.8) -1.19 (0.7) -1.45 (0.8)
A [DeoxyHb] (pmol/l) 0.59 (0.41) 0.17 (0.57)* 0.51 (0.3)
A [tHb] (pmol/l) -0.30 (0.9) -1.03 (0.7)* -0.95 (0.77)*
A[oxyHb]/ABP (pmol/l/ 
mmHg)
0.049 (0.06) 0.077 (0.04) 0.086 (0.05)*#
[AtHb]/ABP (pmol/l/mmHg) 0.018 (0.065) 0.068 (0.05)* 0.055 (0.04)*
Legend: total hemoglobin (DeoxyHb, oxyHb and tHb, respectively) upon standing in healthy 
controls and Alzheimer patients before (pre-treatment) and after 10 weeks of treatment 
with galantamine (post-treatment). * compared to control p < 0.05, * compared to Alzheimer 
patients pre-treatment p < 0.05.
and AD pre- vs post-treatment p = 0.036). The decrease in [tHb] normalized for BP was 
larger in AD both pre- and post-treatment. The postural CBFV response in AD was similar 
pre- and post-treatment. Presence or absence of hypertension or use of antihypertensive 
medication, both in the control group and in AD, did not lead to within-group differences 
in reduction in cortical [oxyHb] and [tHb] nor in CBFV response and did not explain the 
between group (AD vs. control) differences in cortical perfusion (p all > 0.1).
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Figure 2 Cerebral cortical oxygenation in controls and Alzheimer patients during
postural change
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Legend: Group averaged results of near-infrared spectroscopy measurements in the cerebral
frontal cortex during the single sit-stand maneuver. Patients changed posture to standing at
0 s, indicated by the vertical dashed line. The upper panel presents the changes in concentration
oxygenated hemoglobin, the middle panel the changes in concentration deoxygenated
hemoglobin, and the bottom panel the changes in total hemoglobin (=oxygenated +
deoxygenated hemoglobin).The solid line represents healthy controls, the dotted line AD patients
before treatment with galantamine, and the dashed line AD patients after treatment with
galantamine. .
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Discussion
Primary findings
This study provides novel insights in cerebral hemodynamic alterations associated with 
AD in older patients. We have demonstrated a larger postural decline in cerebral cortical 
oxygenation in AD during standing up from sitting. This finding implies that cerebral 
autoregulation fails to preserve cerebral cortical oxygen supply even during commonly 
occurring hypotensive episodes associated with standing up.
Cerebral cortical oxygenation
In this study we combined measurements of frontal cortical oxygenation, using NIRS, 
with global measurements of flow using TCD. This revealed a larger postural decline in 
frontal cortical [oxyHb] and [tHb] in AD, indicating a lower supply of oxygen at brain 
tissue level, which implies an impairment in cerebral autoregulation.11 Earlier observations 
of extensive microvascular involvement in AD may well underlie these findings.17-18 
Alternatively, enhanced functional oxygen demand could explain cortical deoxygenation, 
however, this is highly unlikely since increases in [deoxyHb], reflecting the balance 
between oxygen consumption and delivery, were smaller in AD.
Cerebral blood flow velocity
In accordance with the literature, we found an increased CVRi in AD.3 Despite this 
increased vascular resistance, indicating altered cerebral hemodynamics, the postural 
change in CBFV in AD did not differ from controls. This suggests that the regulation of 
resistance vessels to accommodate changes in BP is preserved in AD during a moderate 
drop in BP.19 We postulate that this suggests a downstream (microvascular) location of 
cerebrovascular impairment to explain the observed reduction in cortical oxygenation.
Effects of galantamine treatment
Galantamine lowered baseline BP while CBFV did not change. This indicates that the 
regulation of CBFV upon gradual changes in BP - static cerebral autoregulation- was 
maintained. In addition, galantamine did not affect the response in CBFV to postural 
change.
At brain tissue level, treatment with galantamine was associated with a larger decline in 
[oxyHb], Since this was not accompanied by a larger decline in [tHb] but by a rise in 
[deoxyHb], these changes do not suggest a further reduction in perfusion but rather an 
increased cortical resting state metabolism, which has indeed been observed in the 
prefrontal cortex after treatment with ChEI's.20
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In summary, these combined findings of TCD and NIRS suggest that the overall effect of 
galantamine on cerebral vasodilatation is neutral.
Possible limitations
Of interest, unexpectedly the sit-stand maneuver induced a smaller decline in mean BP 
in AD compared to controls, which reduced the number of subjects available for analysis 
of the effect of hypotension on CBF. This was not explained by differences in baseline 
blood pressure between AD and controls. AD patients used more anti-hypertensive 
medication, but these are expected to augment rather than reduce orthostatic 
hypotension. Whether this reflects an association between AD and systemic arterial or 
venous hemodynamics cannot be determined from this study. (Van Beek & Claassen, 
research letter accepted for publication, JAGS)
Temporal w indow failure reduced the number of AD patients with repeated 
measurements of CBFV (n = 6), which reduced our power to detect either an improvement 
or deterioration in the regulation of CBFV. However, NIRS signals were available in all 
subjects to compensate for this, suggesting that in this age group, NIRS may be more 
readily applicable than TCD.
Hypertension affects the cerebral circulation and the majority of patients and controls 
were hypertensive or used antihypertensive drugs. We have shown however that 
hypertension per se did not explain the difference in cortical perfusion between AD 
patients and controls. Since hypertension affects more than 60 %  of those over 70 years 
of age and is a risk factor for AD, exclusion of patients and controls with hypertension 
would have seriously hampered the external validity and generalizability of this study. 
Moreover, use of antihypertensive medication per se had no effect on dynamic CA.19' 21
Conclusion
In patients with Alzheimer's disease, the cerebral cortical supply of oxygen was impaired 
during a single sit-stand maneuver, which induces a moderate orthostatic BP response 
as encountered in everyday life. This implies that brain tissue oxygenation is insufficient­
ly protected against hypotensive BP changes in these already vulnerable patients. 
We found no evidence that AD treatment with the ChEI galantamine affected the cere­
brovascular response to hypotension.
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Chapter I 5
Summary and general discussion
CHAPTER  5
This thesis aimed at investigating whether the regulation of cerebral perfusion is 
impaired in patients with Alzheimer's disease (AD), and whether this regulation is altered 
by treatment with cholinesterase inhibitors (ChEI's). This aim has first been translated in 
two literature studies on the clinical and methodological background of this hypothesis, 
and in two studies on methodologies to investigate the regulation of cerebral blood 
flow (CBF) in older persons. Subsequently, we have applied our measurements on the 
regulation of CBF during blood pressure (BP) changes in patients with AD, and we have 
compared the results to those of healthy older subjects. Finally, the effects of ChEI's on 
the systemic circulation and on the regulation of cerebral cortical oxygenation were 
assessed in AD patients.
Before the start of a general discussion of the findings of the presented research, I will 
start with a summary of the results this thesis has produced.
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1. Summary
Chapter 2 - Clinical and methodological background
2.A. ChEI's have widespread use in the treatment of AD, although the average benefits 
of this treatment are very modest and response to treatment is heterogeneous. This 
chapter describes the possible effects of ChEI's on CBF, BP, and cardiac rhythm, which 
could explain the moderate effects and heterogeneous treatment response. Regarding 
their possible influence on the cerebral circulation, ChEI's may augment cerebral 
perfusion through stimulating vasodilatating effects of the intrinsic cholinergic cerebro­
vascular innervation. However, ChEI's may also promote vasoconstriction through 
blockade of nicotine-receptor-mediated autonomic vasodilatation. With regard to the 
effects on the systemic circulation in patients with AD, ChEI's have been associated with 
arrhythmia, syncope, or orthostatic hypotension through a negative effect on BP control 
and cardiac rhythm. Conversely, the ChEI pyridostygmine reduced orthostatic decline 
and postural tachycardia in patients with autonomic failure. Thus, several opposing 
effects may be expected based on the theoretical effects that can be predicted and the 
scarce data that have been collected in this area. At present, there is insufficient 
information available on the systemic and cerebral hemodynamic effects of ChEI's in AD 
to predict the main effects. The quickly increasing application of ChEI's in frail older 
subjects with dementia warrants and urgently asks for more research on their cerebro­
vascular and cardiovascular effects.
2.B. In response to a variation in BP, an adaptation in cerebrovascular resistance will 
cause CBF to return to its baseline. This hemodynamic process is known as cerebral au­
toregulation (CA). The regulation of CBF in response to fast BP changes, dynamic CA, has 
to be distinguished from static CA, which describes the adaptation to slower and more 
gradual BP changes. Technological developments such as transcranial Doppler ultraso­
nography (TCD) and servo controlled finger photoplethysmography (Finapres) to 
continuously measure CBF and BP, respectively, have offered the possibilities to 
thoroughly investigate the dynamic process of CA. These measurements are less time 
consuming then the assessment of static CA. Moreover, they are entirely non-invasive. 
This chapter includes a thorough search of the literature, which yielded eight studies 
that have measured dynamic CA in healthy old subjects, aged up to 75 years. It was 
concluded from these studies that dynamic CA was preserved in this population. It was 
also concluded that there is a lack of standardization in both measurements and quanti­
fications in the assessment of dynamic CA. This chapter therefore provides an overview 
of the methods and a clarification of the mathematical methods applied to quantify
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dynamic CA. To determine dynamic CA during orthostatic stress, a single sit-stand 
maneuver provides a feasible CA-test method in old healthy subjects and (frail) patients. 
Another easy to perform method in the assessment of dynamic CA is the analysis of 
spontaneous fluctuations in BP and CBF. Those oscillations however, are weak in 
magnitude and seriously hamper the analysis and interpretation dynamic CA.
Chapter 3 - Methods to investigate the regulation of cerebral perfusion
3.A. This chapter introduced a new method to investigate dynamic CA. To augment 
oscillations in BP and CBF, simple and non-obtrusive repeated sit-stand maneuvers were 
developed. These maneuvers were compared to the analysis of spontaneous BP and CBF 
oscillations in the assessment of dynamic CA. Also, feasibility and reproducibility were 
tested. In 27 healthy old subjects, aged 76 (SD 4) years, measurements of BP (Finapres) 
and CBF (TCD) were performed during sitting rest and during repeated sit-stand 
maneuvers at two different frequencies, at 0.05 Hz (10 s sit - 10 s stand) and at 0.1 Hz (5 
s sit - 5 s stand). In 11 subjects, the measurements were repeated after 3 months. 
Compared to the measurements during sitting rest, repeated sit-stand maneuvers 
successfully augmented BP and CBF oscillations at the intended frequencies of 0.05 Hz 
and 0.1 Hz. Moreover, the maneuvers were very well tolerated and served as a method 
to assess dynamic CA. The repeated sit-stand maneuvers however, did not improve the 
reproducibility of the assessment of dynamic CA at all frequencies. For the measurements 
during sitting rest and during the repeated sit-stand maneuvers, reproducibility of the 
estimates of dynamic CA were only acceptable around the 0.1 Hz oscillations (coefficient 
of variation < 23 %, and intraclass correlation coefficient > 0.72).
3.B. Cerebrovascular reactivity (CR) refers to the unique response of cerebral blood 
vessels to changes in arterial carbon dioxide (CO2). This chapter investigated the breath 
hold method, which has frequently been used to assess CR. This method only requires 
the volunteer to hold their breath and it does not requires additionally measurements of 
BP and end-tidal CO2. The reliability and reproducibility of this method has only been 
described in subjects aged up to 70 years, whereas diseases which might impair CR 
primarily affect subjects aged 70 and over. In this chapter, the breath hold method was 
compared to a reference method (hyperventilation and inhalation of CO2) in 25 subjects 
aged over 70 years, during continuously measurements of CBF (TCD), with additional 
measurements of BP (Finapres) and end-tidal CO2 (capnography). In 11 subjects 
measurements were repeated after 3 months. After careful instruction, every volunteer 
was instructed to perform 2 consecutive breath holds.
Despite apparent compliance with the instructions during performance of the breath
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hold, only 58% attempts had been accurately executed. Breath holds mostly had to be 
excluded because of the performance of a Valsalva maneuver or secret exhalation. 
Furthermore, two volunteers were not able to hold their breath. The performance of the 
Valsalva maneuver or secret exhalation led to an underestimation of CR, and could only 
be identified from the additional BP and end-tidal CO2 measurements. Further, there 
was only a weak correlation between CR estimates from breath hold indices and the 
reference method. The reproducibility for valid breath holds was comparable to the 
reference method (coefficient of variation 18.4 %  and 14 %, respectively).
Chapter 4 - Application in patients with Alzheimer's disease
4.A. Measurements of CBF with TCD do not provide information on cerebral tissue 
oxygenation. In AD however, especially the structure of the cerebral cortical microvessels 
is comprised. Therefore, in this chapter, measurements with near-infrared spectroscopy 
(NIRS) were added to the CA measurements with Finapres and TCD. NIRS continuously 
measures changes in cerebral cortical oxygenation, resulting in values of changes in 
cerebral cortical concentrations of oxygenated and deoxygenated hemoglobin ([oxyHb] 
and [deoxyH b], respectively). In 21 patients with mild to moderate AD and 20 age-matched 
healthy controls, it was investigated how oscillations in CBF and [oxyHb] are associated 
with oscillations in BP during powerful hemodynamic oscillations induced through 
repeated sit-stand maneuvers at 0.05 Hz and at 0.1 Hz. During these maneuvers, BP 
oscillations clearly resulted in CBF oscillations, which in turn led to oscillations in frontal 
cortical [oxyHb]. Whereas in chapter 3.B. it has been shown that repeated sit-stand 
maneuvers can be used to assess the dynamic CA between BP and CBF, in the current 
chapter it was shown that the maneuvers also can be used to assess the dynamic relation 
between CBF and cortical [oxyHb] changes. In the application of this new finding to AD 
patients, it was demonstrated that the translation of CBF to [oxyHb] essentially differed 
from healthy old controls.
4.B. The use of ChEI's in AD patients has been associated with syncope and bradycardia. 
In this chapter the hypothesis was tested that ChEI associated syncope in AD patients is 
caused by orthostatic intolerance through altered autonomic control of heart rate and 
peripheral vascular resistance. Heart rate (three lead ECG) and BP (Finapres) were 
measured during a single sit-stand maneuver in 21 AD patients before and after treatment 
of 10 weeks with galantamine, and in 20 age-matched healthy controls. In AD patients, 
baseline BP and HR were elevated, and orthostatic tolerance was preserved. Unexpectedly, 
galantamine did not affect orthostatic tolerance.
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4.C. Ultimately, in this chapter the influence of galantamine on the regulation of cerebral 
perfusion was assessed. During a single sit-stand maneuver, BP (Finapres), CBF (TCD), and 
frontal cortical changes in [oxyHb] and [deoxyHb] (NIRS), were measured in 21 AD 
patients before and after 10 weeks treatment with galantamine, and in 20 healthy 
aged-matched controls. The changes in concentration total hemoglobin ([tHb]) were 
estimated by adding up [oxyHb] and [deoxyHb]. The declines in [tHb] and [oxyHb] were 
larger in AD patients compared to controls. However, difference in CBF regulation upon 
standing were not observed in patients compared to controls. Galantamine augmented 
the decline in [oxyHb], but not in [tHb].
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2. General discussion
This thesis provides important novel insights in the regulation of cerebral perfusion in 
patients with AD and in the effects of ChEI's on the systemic and cerebral circulation in 
these patients. The advanced methodology used in this thesis and the application of 
this method in a patient group extensively growing in number, make the findings 
relevant for both researchers and clinicians:
Messages for the researcher: Repeated sit-stand maneuvers provide a simple method to 
augment fluctuations in blood pressure, cerebral blood flow, and cerebral cortical oxygenation. 
Using transfer function analysis, the maneuvers provide a method to quantify the relation 
between both blood pressure and cerebral blood flow on the one hand, and cerebral blood 
flow and cerebral cortical oxygenation on the other hand.
Messages for the clinician: the function of the cerebral microcirculation to maintain tissue 
oxygenation during fast blood pressure and cerebral blood flow changes is impaired in 
patients with Alzheimer's disease. Treatment with cholinesterase inhibitors does not provoke 
(initial) orthostatic hypotension, neither does it impair the regulation of cerebral cortical 
oxygenation. Therefore, in Alzheimer patients the use of cholinesterase inhibitors is unlikely to 
be the sole cause for the increased risk of bradycardia, falls, and syncope noted in this group.
In the following section I will provide a discussion of these results for the following items: 
the applied methodology, the group of AD patients, the regulation of CBF in this patient 
group, and the effects of ChEI's on the systemic and cerebral circulation.
2.1 Methodological consideration
Figure 1. demonstrates the experimental set up used for the research presented in this 
thesis. It shows all the instruments and the headgear which were necessary to perform 
the measurements. Controls and patients were equipped with:
1. a headgear containing:
a. two transcranial Doppler probes
b. 4 near-infrared spectroscopy optodes (2 x transmitter, 2 x receiver)
2. a photoplethysmography cuff on the finger
3. three electrocardiogram leads
4. a nasal cannula
These devices were connected to a data acquisition system, which synchronically 
sampled the data at 125 Hz. After a measurement, all the obtained signals were aligned 
with the ECG signal, and beat-to-beat values (either mean, systolic, or diastolic) were 
extracted. Then, these highly sampled, beat-to-beat data were used for further analysis.
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Figure 1 The experimental set-up, connected to a healthy volunteer
Legend: The photo demonstrates all the equipment and gear used in the experiments presented 
in this thesis. NIRS = near infrared spectroscopy, TCD = transcranial Doppler ultrasonography,
ECG = electrocardiogram.
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Dynamic cerebral autoregulation measurements
For the assessment of dynamic CA, continuous measurements on BP and CBF are 
essential. As described in detail in chapter 3.B., servo controlled finger photoplethysmo­
graphy (Finapres) and transcranial Doppler provide in easy applicable methods to 
measure both BP and CBF.1 In this chapter, the advantages and disadvantages of TCD 
measurements have been discussed in detail. In short, the most common mentioned 
disadvantage of TCD is that it actually measures CBF-velocity, determined by flow and 
vessel diameter, instead of CBF. However, during moderate changes in BP, the diameter 
of the insonated vessels, mostly the middle cerebral artery, does not change.2-4 Therefore, 
it is permitted to assume that changes in CBF-velocity represent changes in CBF. Two 
important disadvantages of TCD however, remain: it provides information on global CBF 
and not on cerebral tissue perfusion. And second, TCD requires a temporal window, a 
small area of the skull penetrable by ultrasound. Unfortunately, advancing age and 
female gender are associated with a higher risk of 'temporal w indow failure', i.e. the 
w indow is not penetrable by ultrasound.
Therefore, in this thesis, NIRS measurements were added. These measurements provide 
additional information on changes in cerebral cortical [oxyHb] and [deoxyHb], and it 
does not depend on the 'suitability' of the skull. At our department, it was previously 
shown that NIRS can reliably be used in the assessment of perfusion regulation during 
BP changes. It provides reliable information on both cerebral cortical oxygenation 
changes during single sit-stand maneuvers and on cerebral blood volume, in older 
subjects.5-7 A disadvantage of both TCD and NIRS is that they do not provide measures 
on steady-state CBF. With TCD, the absolute CBF-velocity cannot be used as an indicator 
of CBF due to the inter-individual differences in the diameter of the middle cerebral 
artery.8 With NIRS, it is impossible to know the exact size of the tissue that is examined, 
which makes it subsequently impossible to obtain absolute values of cortical hemoglobin. 
This thesis however aimed at investigating the regulation of cerebral perfusion and not 
at measuring absolute cerebral perfusion. Measurements of TCD and NIRS, together with 
Finapres, have provided reliable information on changes in beat-to-beat BP, CBF in the 
middle cerebral artery, and frontal cerebral cortical [oxyHb] and [deoxyHb].
Less obvious then the necessity of the measurement on BP and CBF in the assessment of 
dynamic CA, is the requirement of monitoring the arterial pressure of CO2. The 
measurement of end-tidal CO2 with a capnograph, also included in our experimental 
set-up, serves as a reliable surrogate of the arterial CO2 pressure.9 CO2 is both a very 
potent vasodilator and vasoconstrictor and further causes sympathetic activation. 
During CA measurements stable end-tidal CO2 must be warranted. In chapter 3.B. of this 
thesis, it was further discussed that the interplay between BP, end-tidal CO2, and CBF
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needs to be considered in the assessment of cerebrovascular reactivity.10-11 This holds 
also true for the assessment of CA, which makes it more complex and more prone to 
measurement error. However, the combined application of continuous measurements of 
BP (Finapres), CBF (TCD), cerebral cortical oxygenation (NIRS), and end-tidal CO2 
(capnography), makes it possible to compensate for the limitations of the single 
measurements. Moreover, we showed that this unique and sophisticated combination 
of devices can be used in frail older patients, even when they show cognitive decline. 
This non-invasive set up is therefore highly valuable for future research, for example for 
proof of principle studies on new drugs or drugs already applied but not tested in 
geriatric patients.
Intra-individual changes in autoregulation
A fast change in BP is indispensable in the assessment of dynamic CA. A single sit-stand 
maneuver has been confirmed to be a suitable and reliable method to provoke a drop in 
BP.12 Further, it has a low within-subject variability in the assessment of dynamic CA.12 
Recently, this technique has served to measure both the CBF and cortical oxygenation 
response during a BP change in healthy old subjects.13 Subsequently, we have applied 
this technique in patients with AD. In this patient group however, the decline in BP upon 
standing was much less than expected and the single sit-stand maneuver was not 
challenging enough. Previously, it was shown that single squat-stand maneuvers are 
effective in inducing a considerable drop in BP in AD patients.14 However, this maneuver 
is far more strenuous. Before application a thorough consideration of the pros and cons 
of the single sit-stand and single squat-stand maneuver has to be made.
On the contrary, the repeated sit-stand maneuvers applied in chapter 3.A. and 4.A. 
produced considerable fluctuations in BP and CBF in both healthy controls and AD 
patients. They served as a more reliable method then the analysis of spontaneous 
fluctuations (chapter 3.A.) and the CBF oscillations were followed by oscillations in 
cerebral cortical oxygenation (chapter 4.A.). For the BP - CBF relation, the maneuvers did 
however not improve the reproducibility of the measurements. In the lowest frequency 
range where autoregulation is considered to be the most active,15 group average data 
were reproducible, but intra-individual reproducibility was low for both the analysis of 
spontaneous oscillations and the repeated sit-stand maneuver (the 0.05 Hz maneuver). A 
possible explanation for these results is a high biological variability of CA in older 
subjects. Further studies are needed, as well as further improvement of the current 
measurement devices to test this hypothesis.
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The current role of the assessment of dynamic cerebral autoregulation
In 1989 the term dynamic CA was introduced by Aaslid et al.16 Since then, a lot of studies 
have measured dynamic CA in both young subjects, older subjects, and different patient 
groups.1 Currently however, no uniform method exists to obtain information on the 
dynamic BP - CBF relation, which makes it not applicable in clinical practice. Moreover, 
to my knowledge, there are no data on cut-off values between normal and abnormal 
values of dynamic CA, and only one study obtained good reproducibility in the 
assessment of dynamic CA.17 Yet, the method used in this study, high vacuum lower 
body negative pressure, is not useful in clinical practice. In intervention studies, repeated 
assessments of dynamic CA can be performed at group average level, but intra-individu­
al changes can only be assessed reliably in the low frequency range. Currently, this thesis 
provides the second study which quantifies the dynamic relation between CBF and 
cortical oxygenation using transfer function analysis.18 Additionally, the study presented 
in chapter 4.A., is the first to assess this relation in the very low frequency range, i.e. 
during the 0.05 Hz repeated sit-stand maneuver. The NIRS measurements have proven to 
be of additional value to the standard measurements of BP and CBF. However, more 
studies in different age groups and on within subject reproducibility are necessary. For 
both the assessment of dynamic CA and the addition of NIRS measurement, consensus 
and agreement on both method and quantification of the mentioned relations are the 
first requirements to make these measurements applicable in clinical practice and in 
monitoring intra-individual changes. For further spread in both research and clinical 
practice the interface between raw data and clinically recognizable results needs to be 
improved and simplified as well. There is a need for signal analysis software programs 
that describe and analyze the large number of data from these time series with 'sense 
and simplicity', but still in a reliable and valid manner.
2.2 Application in patients with Alzheimer's disease
Alzheimer's disease
For the research presented in this thesis, 21 newly diagnosed patients with AD were 
recruited. They were aged over 64 years, had probable AD according to the NINCDS-ADRDA 
criteria,19 and were not treated yet with ChEI's (drug naive patients). Although patients 
shared a common profile regarding cognition and medial temporal lobe atrophy, the group 
of patients still was heterogeneous. For example, whereas patients and controls were 
matched for blood pressure at screening, patients used more antihypertensive medication, 
and some patients used medication for type II diabetes. Patients further demonstrated a 
somewhat higher score for age related white matter lesions. For the research presented in 
this thesis, it was carefully considered to include patients with probable AD and to tolerate
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the inclusion of patients who were suffering from vascular risk factors as hypertension and 
diabetes. In old age, AD is both a neurodegenerative disease and cerebrovascular disease 
and exclusion of these patients would make the process of inclusion looking for a needle in 
a haystack. In practice, this would seriously jeopardize inclusion of patients. More important 
however, it would hamper the generalizability (external validity) of the presented studies. 
It is well known that, on the contrary to familial AD, sporadic AD is heterogeneous, caused 
by ageing together with a complex interaction of both genetic and environmental risk 
factors.20 Additionally, the relationship between the clinical manifestations of dementia and 
underlying neuropathological findings varies with age within the population.21 In a large 
community-based study on neuropathology, it was found that Alzheimer pathology and 
vascular pathology were both major correlates of cognitive decline, but there were no clear 
thresholds of these features that predicted the dementia status.22 Mono-causal thinking is 
therefore not appropriate in respect of research in older AD patients.23 For a long time, 
research has focused on the amyloid hypothesis20 and has been trapped in mono-causal 
thinking. For familial AD, an autosomal dominant disorder, this approach seems legitimized. 
In old AD patients however, this is a simplification and the pathologic basis of AD in this age 
group should be considered as an interaction between pathological changes, caused by 
genetic and environmental factors, compensatory mechanisms, and underlying synaptic 
dysfunction. Vascular factors probably play a very important role in the causation and the 
spread of this cumulative brain damage in old age. The important and challenging aim is to 
determine the relative weight in the contribution to AD, but also to other dementia types, 
in the population. We aimed at adding reliable and valid tools for measuring important 
cerebrovascular variables.
The regulation of cerebral blood flow in patients with Alzheimer's disease
In mouse models of AD, the regulation of CBF is severely impaired. The relation between 
BP - CBF in AD patients however, is only subtly changed compared to healthy old 
(chapter 4.A.).24 The difference found between AD patients and mouse models of AD, lies 
not only in the cause of the disease, multi causality in old AD patients vs. mono causality 
in mouse models, but also in the measurements on CBF and in the model. In mice 
studies, CBF is measured in the cerebral cortex, whereas during measurements with TCD, 
CBF is assessed in the middle cerebral artery.
The assessment of the relation between CBF - cortical oxygenation in our human studies 
revealed important differences between AD patients and non-AD older subjects during 
the 0.05 Hz repeated sit-stand maneuvers, i.e. performed in the autoregulatory range,15 
and during a single hypotensive challenge. So, these results confirm the results of mouse
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studies in AD patients. These results more or less confirm the findings of Alzheimer, 
more than 100 years ago, of the pathological findings on cerebrovascular vessels and 
nicely fit within the more recent literature which has focused on the cerebrovascular 
pathological changes in AD.25 The structural changes in cerebral cortical microvessels in 
AD patients observed in studies on pathology,25 already lead to a dysfunction of the 
regulation of cerebral cortical oxygenation in patients with mild - moderate AD. Whether 
this is a cause or consequence of AD pathology cannot be determined from the studies 
presented in this thesis. Causality can only be assessed from studies with an observational 
prospective design, allowing the assessment of time relationships (or in intervention 
studies). If the regulation of cerebral perfusion is one of the causes for AD in old age, this 
could be a target for treatment. Most likely, aggressive treatment of vascular risk factors 
(e.g. early life hypertension) can protect the brain from cerebrovascular disease, which is 
likely to impair the dynamic CA and thus further harms the brain.
Treatment with cholinesterase inhibitors in patients with Alzheimer's disease
More than 10 years ago, the licensing of ChEI's brought hope in the treatment of AD. 
Whereas in large studies statistically significant benefits were obtained on cognitive 
assessment scales and on scales for behavioral problems and activities of daily living,26 
the clinical relevance of the treatment remains questionable and response to treatment 
is heterogeneous. In chapter 2.A., this thesis has provided an overview of evidence which 
suggests a complex mode of action of ChEI's which may be the cause for these conflicting 
results. This chapter elaborated on the cholinergic-vascular hypothesis, which was 
introduced at our department.27 Together with the former development at our 
department of the measurements with Finapres, NIRS, and later TCD in older subjects 
(thesis' Mehagnoul-Schipper and Claassen), it was now possible to study the systemic 
and cerebral hemodynamic effects of the ChEI's in patients with AD.
Besides the well known side-effects of ChEI's like gastrointestinal upset and diarrhea, 
and the more rare hypersalivation and muscle cramps, ChEI's have also been associated 
with syncope and bradycardia,28 and with a more than doubling of the risk of hospitali­
zation for bradycardia.29 The research presented in this thesis however, does not support 
the conclusion that ChEI's provoke bradycardia or syncope. After 10 weeks of treatment 
with galantamine, a common described ChEI, heart rate was not changed. And, although 
diastolic BP was lowered after treatment with galantamine, the orthostatic BP response 
and static CA were not influenced by treatment (chapter 4.B. and 4.C.). Further, the 
cortical oxygenation response pointed more towards an increased resting state cortical 
metabolism and not to a further decline in oxygenation of the frontal cortex (chapter
4.C.). An explanation for the discrepancy between the findings in this study and the
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reported association with bradycardia and syncope, may be found in the patients 
studied. Although AD patients included in this thesis displayed vascular risk factors, 
major co-morbidity was ruled out. The patients included in the reports on bradycardia 
and syncope, displayed many serious medical conditions, and received more drug 
therapy.28- 29 Obviously, in AD patients with multiple treatments and co-morbidity, the 
use of ChEI's need to be carefully considered and followed-up. For the use of ChEI's in 
patients with dementia, research should focus on defining clinical characteristics of true 
responders, which could help to select patients who will really benefit from ChEI's.30 
Research should further focus on the interaction of ChEI's with other medication, 
especially since polypharmacy is common in older people.31
At present, there is no other medical drug treatment registered for AD. However, many 
compounds currently are studied in phase 0 - phase 3 studies.32 The vascular risk factors 
may represent an interesting target for either prevention or slowing down progression 
of AD. However, a recent trial investigating the effect of multi-component vascular care, 
was not effective in slowing down the decline in AD patients with cerebrovascular 
lesions.33 To date, only one trial has shown that BP lowering therapy protects against 
dementia in older patients with systolic hypertension.34 The development and design of 
new proof of principle and proof of concept studies focusing on the vascular mechanisms 
underlying dementia in old age needs urgent attention, as one of the most important 
questions in dementia research is the role of age related cumulative damage and its 
relation with vascular factors and the risk of dementia.35 Polypills, addressing more risk 
factors by a combination of several active compounds in low doses may be a reasonable 
and promising way of addressing the multiple causality, which is highly likely in old age 
dementia. Future studies on drugs addressing vascular (risk) factors are perhaps the 
most promising tool, either in prevention or in delaying the onset of dementia and AD. 
As we showed in this thesis, such new drugs or combination of drugs should also be 
tested for their effects on blood pressure and cerebral autoregulation to monitor side 
effects, while improvement of the regulation of cerebral perfusion may be a new 
biomarker for positive effects.
3. Conclusions and directions for future research
To briefly sum up the main findings presented in this thesis:
1. Repeated sit-stand maneuvers:
a. Provide an adequate method to assess the dynamic relation between BP - CBF 
and between CBF - cerebral cortical oxygenation.
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b. Can be used to obtain information on dynamic CA at a group level.
2. In patients with Alzheimer's disease:
a. The regulation of cerebral perfusion during fast blood pressure changes, dynamic 
CA, is not affected at the level of the major supplying artery of the brain, the 
middle cerebral artery.
b. The function of the cerebral microcirculation to maintain brain tissue oxygenation 
during fast blood pressure changes, is comprised.
3. Treatment with cholinesterase inhibitors in patients with Alzheimer's disease:
a. Does not provoke initial orthostatic hypotension and does not impair static CA.
b. Seems to stimulate cerebral metabolism and oxygen use.
These results may encourage both the basic and clinical researcher to further investigate 
the role of dynamic CA and the regulation of cerebral cortical oxygenation in a variety of 
domains. First off all, the methodology used in this study can be improved regarding 
intra-individual reproducibility. To improve the reproducibility of the dynamic CA 
assessments, the sit-stand maneuvers should extensively be tested using repeated 
measurements, consecutively during one experiment and at different times. For example, 
the baseline or end measurement of a clinical trial can comprise two assessments of the 
dynamic CA, and the average of these two assessments can significantly reduce the 
variance of estimates of treatment effects. The methodology in this study can further be 
extended, using more comprehensive modeling of the signals. Ultimately, this should 
lead to the development of a conclusive method and model for the assessment of 
dynamic CA and the regulation of cerebral cortical oxygenation. This should subsequently 
lead to a simple, but valid and reliable analysis technique, that makes the measurements 
more applicable in large clinical studies and eventually in clinical practice.
In the old, the most important vascular risk factor for AD, hypertension, suffers from the 
widespread concern that lowering of BP to targets proposed by recent guidelines may 
cause cerebral hypoperfusion, resulting in ischemia and cognitive decline. The 
experimental set-up presented in this study, is highly suitable to assess the effects of 
antihypertensive treatments in the old on the regulation of cerebral perfusion. Currently 
at our lab, a large study is executed to proof that a reduction in systolic blood pressure 
in hypertensive old subjects does not impair the regulation of cerebral perfusion. This 
study also investigates the cognitive effects of antihypertensive treatment and will 
further shed light on the relation between blood pressure, dynamic CA, and cognition in 
the old. For the role of hypertension in the pathology of AD, either additive or synergistic, 
our department further started collaboration with the department of anatomy. Research
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is underway to investigate the regulation of cerebral perfusion after hypertension and 
after treatment with antihypertensive medication, in on the one hand "pure" AD 
pathology in mouse models of AD, and on the other hand in aging atherosclerotic mice. 
This study is linked to the studies presented in this thesis in human AD patient and to the 
above mentioned study in human hypertensive patients. It adds to disentangle the role 
of the multiple causes of AD.
Short-term treatment (approximately 10 weeks) with galantamine in the study presented 
in this thesis did not impair the regulation of cerebral cortical oxygenation, but rather 
stimulated cerebral cortical metabolism. An important question that this result raises, is 
whether improvement of the regulation of cerebral perfusion translates in a clinical 
relevant benefit for patients. Improvement of dynamic CA could prevent progression of 
cerebrovascular lesions in AD patients and this could translate in slowing down disease 
progression and thus will have clinical benefit. The role of cerebrovascular lesions and 
the progressions of these lesions correlated to the regulation of cerebral perfusion, 
should be investigated in relation to clinical outcome measures in the treatment of 
ChEI's and other drugs in AD patients. To answer these question, large trials with a long 
follow-up period are necessary. These trials can also serve to identify the characteristics 
of patients who benefit from treatment with ChEI's and novel anti-dementia drugs.
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De regulatie van de hersendoorbloeding 
bij patiënten m et de ziekte van Alzheim er
Nederlandse samenvatting
Veroudering is de belangrijkste risicofactor voor dementie. Door de vergrijzing neemt 
het aantal mensen met dementie toe. In 2001 hadden wereldwijd 24.3 miljoen mensen 
dementie, in 2040 zullen dit naar verwachting 81.1 miljoen patiënten zijn. Zestig tot 
zeventig procent van de mensen met dementie heeft dit in de vorm van de ziekte van 
Alzheimer. De ziekte van Alzheimer is een hersenziekte, maar uit onderzoek blijkt dat bij 
het ontstaan van de ziekte ook risicofactoren voor hart - en vaatziekten, zoals 
bijvoorbeeld een hoge bloeddruk, cholesterol en roken, een belangrijke rol spelen. 
Het doel van dit proefschrift was om de regulatie van de hersendoorbloeding te 
onderzoeken bij patiënten met de ziekte van Alzheimer. De verwachting was dat deze 
regulatie slechter is bij Alzheimer patiënten in vergelijking met gezonde personen van 
dezelfde leeftijd, en dat een veelgebruikt medicijn bij de behandeling van Alzheimer 
dementie, de zogenaamde acetylcholinesterase remmers, deze regulatie beïnvloedt. 
Voordat een samenvatting zal worden geven van de belangrijkste resultaten die dit 
proefschrift heeft opgeleverd, zal ik hieronder de begrippen die veel gebruikt worden in 
de samenvatting toelichten. Zowel de uitleg van begrippen als de samenvatting zijn op 
de eerste plaats bedoeld voor niet-medisch geschoolde personen. Medisch en/of 
biologisch geschoolde lezers verwijs ik graag naar de Engelse samenvatting of de 
abstracts bij de start van de hoofdstukken.
Begrippenlijst
Dem entie: een verzamelnaam voor een aantal stoornissen die met name op hogere 
leeftijd voorkomen en die met elkaar gemeen hebben dat het geestelijk functioneren 
achteruitgaat, terwijl het bewustzijn helder blijft. Dementie gaat gewoonlijk gepaard 
met een verminderde emotionele controle en slechter sociaal functioneren. Bovendien 
wordt de dagelijkse zelfredzaamheid duidelijk beperkt. Dementie wordt meestal steeds 
erger en voor de meeste vormen bestaan geen behandelingsmogelijkheden.
Z iek te  van Alzheimer: de meest voorkomende vorm van dementie, die meestal begint 
na het 70e levensjaar. De ziekte is genoemd naar de Duitse neuropatholoog en psychiater 
Aloïs Alzheimer die als eerste een patiënt met deze aandoening beschreef.
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Acetylcholine: een neurotransmitter die in veel delen van de hersenen en de rest van 
het lichaam actief is. Een neurotransm itter is een chemisch stofje dat wordt gebruikt 
voor signaaloverdracht tussen zenuwcellen in het zenuwstelsel.
Acetyo lcho linesterase  rem m ers zijn medicijnen die de afbraak van acetylcholine 
remmen, waardoor de concentratie acetylcholine toeneemt.
Meetopstelling
Op bladzijde 162 staat een overzicht van de meetopstelling die is gebruikt bij de 
onderzoeken in dit proefschrift, hieronder volgt een omschrijving van de apparatuur: 
Capnograaf: een meetinstrument dat de concentratie koolzuurgas (CO2) meet in de 
uitademinglucht van een persoon. De concentratie CO2 in de uitademinglucht is een 
afspiegeling van de concentratie CO2 in het bloed.
Electrocard iogram  (ECG): wordt in de volksmond 'hartfilmpje' genoemd en registreert 
de elektrische activiteit van de hartspier.
Finapres: staat voor FINger Arterial PRESsure. Meet continu de bloeddruk met een kleine 
bloeddrukmanchet om de vinger.
Transcraniele D oppler u ltrasonography (TCD): met behulp van echografie wordt de 
stroomsnelheid van het bloed in een vat binnen de schedel, in dit geval de middelste 
hersenslagader (de arteria cerebri media), gemeten om een indruk te krijgen van de 
bloedvoorziening van de hersenen.
Near-Infrared Spectroscopy (NIRS): dit apparaat maakt een 'hersenfilmpje' door 
gebruik te maken van licht dat buiten het zichtbare spectrum valt, bijna infrarood licht. 
NIRS registreert de concentratie veranderingen van aan zuurstof gebonden hemoglobine 
en niet aan zuurstof gebonden hemoglobine in de buitenste laag van de hersenen, de 
hersenschors of ook wel de cerebrale cortex genoemd. Hemoglobine is een eiwit dat in 
het bloed van mensen voorkomt en verantwoordelijk is voor het transport van zuurstof 
en CO2. De concentratie veranderingen van aan zuurstof gebonden hemoglobine in de 
hersenschors/cortex is een maat voor de veranderingen in cerebra le  corticale 
oxygenatie.
Cerebrale autoregulatie: de hersenen zijn uiterst gevoelig voor veranderingen in de 
bloedtoevoer. Bij wisselende aanvoer moeten de hersenen dan ook zorgen voor een 
stabiele, continue doorbloeding. Onderscheid wordt gemaakt tussen statische en 
dynamische cerebrale autoregulatie. Statische cerebra le  au to regu la tie  omschrijft het 
vermogen van de hersenvaten om hun doorbloeding constant te houden tijdens 
langzame (in het verloop van uren optredende) bloeddruk veranderingen, dynam ische 
cerebra le  autoregu la tie  is van belang tijdens snelle (binnen enkele seconden)
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bloeddruk veranderingen. Cerebrale autoregulatie moet onderscheiden worden van 
cerebrovasculaire reactiviteit, dat wil zeggen de reactie van de hersenvaten na een 
verandering in concentratie CO2 in het bloed. Bij een toename in CO2 neemt de 
bloedtoevoer toe, terwijl bij een afname de toevoer af neemt.
Syncope: in de volksmond 'flauwvallen'. Dit begrip beschrijft een kortdurende bewuste­
loosheid veroorzaakt door een verminderde bloedtoevoer naar de hersenen. 
Orthostatische hypotensie: een plotselinge bloeddruk daling die optreedt binnen 
drie minuten na opstaan.
Samenvatting
In hoofdstuk 1 is een algemene inleiding gegeven en zijn de doelstellingen van het 
onderzoek uiteengezet. Dit proefschrift bevat vervolgens drie onderdelen: een 
verkennende literatuurstudie, methodologische studies en de toepassing bij Alzheimer 
patiënten. In hoofdstuk 2 zijn de twee literatuurstudies opgenomen, in hoofdstuk 3 
worden de methodologische stukken besproken en in hoofdstuk 4 worden de drie 
studies gepresenteerd die bij Alzheimer patiënten zijn verricht. Hoofdstuk 5 bevat een 
algemene Engelstalige samenvatting en discussie. Hieronder volgt een Nederlandse 
samenvatting van de hoofdstukken 2 , 3 en 4.
Hoofdstuk 2 - Klinische en methodologische achtergrond
Acetylcholinesterase remmers (ChEI's) worden veel gebruikt bij de behandeling van de 
ziekte van Alzheimer. De klinische effecten zijn echter gering en verschillen sterk van 
patiënt tot patiënt.
Hoofdstuk 2.A. beschrijft de mogelijke invloed van dit medicijn op de hersendoorbloe- 
ding, de bloeddruk en het hartritme. Deze invloed zou de oorzaak kunnen zijn van de 
sterk verschillende klinische effecten van deze geneesmiddelen. ChEI's kunnen door 
verschillende mechanismen de hersendoorbloeding zowel doen toenemen als afnemen. 
De invloed van ChEI's op de bloeddruk en het hartritme bij Alzheimer patiënten zijn 
meestal remmend: ChEI's zijn geassocieerd met ritmestoornissen, syncope en orthosta­
tische hypotensie. Momenteel is weinig bekend over de effecten van ChEI's op de 
dynamiek en regulatie van het hartritme, de bloeddruk en de hersendoorbloeding.
De term cerebrale autoregulatie werd in 1959 geïntroduceerd door de onderzoeker 
Lassen. Hij vatte meer dan 200 studies samen die de hersendoorbloeding onderzochten 
bij gezonde personen en verschillende patiëntgroepen. Lassen beschrijft in zijn artikel
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de statische cerebrale autoregulatie. Door recente technologische ontwikkelingen is het 
ook mogelijk dynamische cerebrale autoregulatie (dCA) te meten. In Hoofdstuk 2.B. 
worden de apparatuur en methoden besproken die zijn gebruikt om dCA te meten. Ook 
wordt een overzicht gegeven van de (wiskundige) maten die worden gebruikt om dCA 
te kwantificeren. Daarnaast is literatuuronderzoek gedaan naar studies die dCA hebben 
onderzocht bij gezonde ouderen. Dit leverde 8 studies op die dCA hebben onderzocht 
bij ouderen tot 75 jaar, waarbij verschillende methoden zijn gebruikt om dCA te meten 
en te kwantificeren. Op basis van deze literatuur kan worden geconcludeerd dat de 
regulatie van de hersendoorbloeding niet is verstoord. Boven de leeftijd van 75 jaar is 
geen onderzoek verricht. Bovendien bleken veel van de methoden niet geschikt om 
dCA te meten bij oudere (kwetsbare) patiënten.
Hoofdstuk 3 - Methoden om de regulatie van de hersendoorbloeding te onderzoeken
Hoofdstuk3.A. introduceert een nieuwe methode om dCA te onderzoeken. Door middel van 
herhaaldelijke zit/staan bewegingen werden schommelingen in zowel de bloeddruk als de 
hersendoorbloeding opgewekt. Deze bewegingen konden goed uitgevoerd worden door 
gezonde ouderen. De schommelingen in bloeddruk en hersendoorbloeding waren goed en 
betrouwbaar om dCA te kwantificeren. In een subgroep werden de metingen herhaald na 
drie maanden. De resultaten van de metingen waren goed reproduceerbaar op groepsniveau, 
terwijl op individueel niveau de uitkomsten relatief veel verschilden.
In hoofdstuk3.B. is onderzoek gedaan naar een veelgebruikte methode om de cerebro- 
vasculaire reactiviteit te meten, namelijk het inhouden van de adem, dat een stijging van 
CO2 in het bloed veroorzaakt. Voor deze meting is in principe alleen het meten van de 
hersendoorbloeding voldoende. In hoofdstuk 3.B. is de betrouwbaarheid van deze 
meting onderzocht bij gezonde ouderen. Naast de hersendoorbloeding is ook de 
concentratie uitgeademde CO2 en de bloeddruk geregistreerd. Terwijl tijdens de meting 
alle vrijwilligers goed de adem leken in te houden, bleek bij zorgvuldige analyse van de 
ademlucht en de bloeddruk registratie dat slechts 58 %  van de pogingen goed was 
uitgevoerd. Uit de bloeddruk metingen bleek dat een aantal vrijwilligers overmatig 
persten tijdens het adem inhouden (dit wordt ook wel een Valsalva maneuver genoemd). 
Verder bleek uit de CO2 metingen dat een aantal vrijwilligers toch uitademden tijdens de 
poging om hun adem in te houden.
Hoofdstuk 4 - Toepassing bij patiënten met de ziekte van Alzheimer
Het meten van de hersendoorbloeding met TCD geeft alleen informatie over de 
bloedtoevoer naar de hersenen, met andere woorden, de bloedstroom in een
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aanvoerend bloedvat van de hersenen wordt gemeten. Bij patiënten met de ziekte van 
Alzheimer zijn echter vooral de zeer kleine vaten (de zogenaamde haarvaten) in de 
hersenschors aangetast. Om de zuurstof voorziening van de haarvaten in de hersenschors, 
de cerebrale oxygenatie, te meten, is daarom NIRS toegevoegd aan het onderzoek met 
Finapres en TCD.
In hoofdstuk4.A. wordt aangetoond dat de herhaalde zit/staan bewegingen - zoals ge- 
introduceerd in hoofdstuk 3.A. - ook leiden tot schommelingen in de cerebrale corticale 
oxygenatie, zowel bij gezonde ouderen als patiënten met de ziekte van Alzheimer. dCA 
gemeten met Finapres en TCD was gelijk bij gezonde ouderen en Alzheimer patiënten. 
Echter, de relatie tussen de bloed aanvoer en corticale oxygenatie was essentieel anders 
in de groep Alzheimer patiënten. De resultaten duidden aan dat de regulatie van 
cerebrale oxygenatie is verslechterd in deze patiëntgroep.
Hoofdstuk 4.B. Het gebruik van ChEI's bij patiënten met de ziekte van Alzheimer wordt 
geassocieerd met syncope en verlaging van de hartfrequentie. In dit hoofdstuk is 
onderzocht of dit wordt veroorzaakt doordat ChEI's de controle van het hartfrequentie 
en de vaatweerstand verslechteren. Hartslag en bloeddruk werden gemeten met res­
pectievelijk ECG en Finapres bij zowel gezonde ouderen als Alzheimer patiënten. Dit 
werd gedaan tijdens zitten en een enkele zit/staan beweging. In de Alzheimergroep 
werden de metingen herhaald na 10 weken behandeling met de ChEI Galantamine. De 
Alzheimer patiënten hadden een verhoogde hartfrequentie en bloeddruk vergeleken 
met gezonde ouderen. De bloeddruk werd verlaagd door het gebruik van Galantamine, 
het hartritme bleef onveranderd. De daling in de bloeddruk bij het gaan staan na het 
zitten, was niet verschillend tussen controles en patiënten en werd ook niet veranderd 
door Galantamine bij de Alzheimer patiënten.
Tot slot wordt in hoofdstuk4.C. het effect van ChEI's op de regulatie van de hersendoor- 
bloeding onderzocht bij Alzheimer patiënten. Tijdens een enkele zit/staan beweging 
zijn de bloeddruk, hersendoorbloeding en corticale oxygenatie gemeten bij Alzheimer 
patiënten, voor en na 10 weken behandeling met Galantamine, en bij gezonde ouderen. 
Bij Alzheimer patiënten nam het aan zuurstof gebonden hemoglobine en het totaalhe- 
moglobine meer af bij het gaan staan in vergelijking met de groep gezonde ouderen. 
Galantamine vergrootte de afname van aan zuurstof gebonden hemoglobine, maar 
beïnvloedde de afname van het totaal hemoglobine niet.
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Conclusie
De resultaten van dit onderzoek hebben zowel wetenschappelijke als maatschappelijke
betekenis die kan worden samengevat in de volgende punten:
• We hebben een methode ontwikkeld om bij gezonde ouderen en (kwetsbare) 
patiënten op een weinig belastende manier te meten hoe de hersendoorbloeding 
wordt gereguleerd tijdens snelle veranderingen in bloeddruk.
• Deze methode is van groot belang voor onderzoek naar bijvoorbeeld de behandeling 
van hoge bloeddruk en de eventuele effecten op de hersendoorbloeding bij ouderen
• We zijn de eerste onderzoeksgroep die deze methode toegepast heeft om de regulatie 
van de hersendoorbloeding te meten bij patiënten met de ziekte van Alzheimer.
• Een belangrijke bevinding van ons onderzoek is dat patiënten met de ziekte van 
Alzheimer een grotere kans lopen op zuurstoftekort in de hersenschors, doordat de 
doorbloeding daar slechter gereguleerd wordt.
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“D ankbaarheid zoekt achter de gave de gever"
(Dietrich Bonhoeffer)
Woorden van Dank
Beste Marcel en Jurgen, mijn promotor en co-promotor, ieder met je eigen expertise 
waren jullie onmisbaar voor het tot stand komen van dit proefschrift. Jurgen, je heldere 
kijk op data en uiteraard de daarbij behorende interpretatie gaven richting aan de 
resultaten- en discussiesecties van de artikelen in dit proefschrift. Rustig een middagje 
staren, data op je laten inwerken en nadenken over wat dit alles nu betekent. En ondanks, 
of wellicht dankzij, je soms chaotische manier van werken, was je op de nodige 
momenten daar met flexibiliteit, tijd en aandacht. Het was een voorrecht om onder je 
dagelijkse begeleiding te werken. Marcel, dank voor je sturende rol, je overzicht en je 
leiding. Je  zorgde dat op de juiste momenten beslissingen werden genomen. Marcel en 
Jurgen, dank voor alle mogelijkheden die jullie me gaven in de opleiding tot onderzoeker; 
cursussen, meet apparatuur, ondersteuning door studenten, congressen, symposia, het 
heeft me aan niets ontbroken.
Alle gezonde vrijwilligers, Alzheimer patiënten en mantelzorgers: jullie spelen de 
hoofdrol in dit proefschrift. Jullie waren niet alleen deelnemers aan deze studie, maar 
jullie zijn een deel van de studie. Het was me een groot genoegen met jullie samen te 
werken. Jullie gaven en geven veel, niet alleen aan de medische wetenschap, maar ook 
aan mij als promovendus.
Lieve Mirry en Marieke: er waren eens een student biomedische wetenschappen, een 
huisarts en een student-assistent die begonnen aan een promotieonderzoek. En we 
volgden gedrieën de weg naar wonderland, met alle ups en downs. Het waren soms 
moeilijke tijden, vaak heerlijke tijden, al dan niet onder het genot van een lekker biertje. 
Ik had me geen betere maatjes kunnen wensen om de afgelopen jaren mee te delen. 
Mirry, geweldig dat je nu m'n paranimf bent. Het staat symbool voor de afgelopen jaren, 
voor je aanwezigheid, je trouw, je liefde. Dank je wel!
Alle onderzoekers van de afdeling geriatrie, in de afgelopen jaren een grote, gezellige en 
warme groep van zowel promovendi als postdocs geworden. Els, Petra en Diane, het 
was me een waar genoegen met jullie te werken op de grote onderzoekerskamer. Verder 
Rene, Olga, Sarah, Janneke, Bianca, Wilma, Miriam, Saskia, Mirjam. Dank jullie voor je
187
C H A P T E R  5
steun en de benodigde gezelligheid! Jaap: je was een goede stagiair, daarna een nog 
betere collega. Ik draag het stokje in volle vertrouwen aan je over. Anouk, je was een 
zelfstandige en hardwerkende stagiair. Dank je wel voor het uitbreiden van de metingen. 
Roy, dank voor je betrokkenheid en de prettige samenwerking.
Francien, dank dat je aan het begin van mijn onderzoek weer op de geriatrie wilde 
komen werken. Jouw  praktisch en stimulerend werk, samen met veel mensenkennis, zijn 
voor mij een grote steun en geweldig voorbeeld geweest voor het uitvoeren van de 
metingen. Anja en William, dank jullie wel voor het helpen bij het includeren van 
patiënten en uiteraard voor de gezellige en bemoedigende babbeltjes. Joep, leuk dat je 
mee wilde werken aan een van de artikelen in dit proefschrift. Onze korte samenwerking 
is me meer dan goed bevallen.
Lieve en zeker ook zeer toffe vrienden, Rhona & Erik, Heleen, Amy, Marloes, Bianka en 
Mirjam. Op je eigen manier zijn jullie van onschatbare waarde, zowel bij het schrijven 
van dit proefschrift als ook in mijn leven. Dank dat ik jullie mag kennen, mijn vreugde en 
verdriet met jullie kan delen. Trouwe vrienden zijn onbetaalbaar, jullie maken mij rijk!
Lieve zussen, broer, zwager en schoonzus: je familie heb je niet voor het uitkiezen. 
Gelukkig maar, want ik had me geen betere naaste familie kunnen wensen dan jullie. 
Pieter, fijn dat je nu mijn paranimf wilt zijn.
Pim, Bas, Sander, Ariënne, Thijs, Koen: Dank voor jullie ontwapenende afleiding. Jullie zijn 
geweldige kinderen en ik ben trots dat ik jullie tante Arrie mag zijn.
Lee & Inge, Marleen en verdere schoonfamilie, dank jullie wel voor jullie belangstelling 
en interesse in mijn promotie-onderzoek.
Lieve mama, een dankwoord schiet te kort om u te bedanken. Ik doe toch een poging. 
Dank u voor uw zorg en vertrouwen in mij. Dank u voor uw onvoorwaardelijke liefde. 
Dank u voor de stevige basis die u en papa me gaven. Dank u voor het oprechte geloof 
dat u voorleeft. Dank dat u de herinnering aan papa levend houdt, niet door de leegte 
te vullen, maar door in dankbaarheid te blijven herinneren.
Opgedragen aan mijn geliefde vader: papa leerde mij over de wondere wereld van de 
wetenschap. Hij leerde mij echter ook over de schaduwkanten, het spanningsveld tussen 
geloof en wetenschap. Wat betreft dit spanningsveld gaf hij mij geen kant en klare 
oplossing. Daarentegen leefde hij voor vanuit zijn vertrouwen en de daarbij behorende 
positieve levensinstelling. En nu mag ik samen met hem opschrijven: de genade van de
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Eeuwige is mij genoeg. Lof is aan onze God, de God van Israel, Abraham, Isaak èn Jakob, 
aan Zijn nooit genoeg volprezen Naam.
Lieve en stoere Leander, deze beide eigenschappen en gaven van jou, waarin je rijkelijk 
deelt en geeft, maken je tot een pracht mens. Dank voor al de tijd die je me gaf om naar 
hartenlust te 'hobbyen'. Dank voor je liefdevolle opvang als hobbyen overging in 
gekkenwerk. Dank voor het voorrecht dat ik mijn leven met jou mag delen. Met de juiste 
en gepaste aandacht en overgave worden die vier kleine woorden nooit teveel gezegd: 
ik hou van je. Elke dag een beetje meer.
Arenda Dado - Van Beek
"But now  faith, hope, and love rem ain— these three. The greatest o f  these is love."
(1 Corinthians 13: 13)
5
189

C U R R IC U L U M  V ITA E
Curriculum vitae
Arenda van Beek werd in Sprang-Capelle geboren op 4 mei 1983. Zij behaalde in juni 
2001 cum laude haar VWO diploma aan scholengemeenschap 'Het Noordik' te Almelo, 
waarna ze startte met de opleiding geneeskunde aan de Radboud Universiteit Nijmegen. 
Nog voor zij haar doctoraal examen afrondde, ging zij werken als student-assistent op de 
afdeling Geriatrie van het UCM St Radboud, bij prof. dr. Marcel Olde Rikkert en dr. René 
Jansen. Daar werd zij zo gefascineerd door wetenschappelijk onderzoek en de toepassing 
daarvan bij ouderen, dat zij haar wetenschappelijke stage verrichtte op dezelfde afdeling. 
Daarmee rondde zij haar doctoraal examen geneeskunde af, en startte zij vervolgens in 
2006 onder begeleiding van prof. dr. Marcel Olde Rikkert en dr. Jurgen Claassen aan het 
promotie onderzoek beschreven in dit proefschrift. In december 2008 ontving zij 
hiervoor een Frye stipendium waarmee zij haar wetenschappelijke kennis uitbreidde 
door verschillende onderzoekscentra in de Verenigde Staten te bezoeken. In februari 
2010 vervolgde ze haar studie geneeskunde met de co-schappen.
Arenda is getrouwd met Leander Dado.
Arenda van Beek was born in Sprang-Capelle on May 4th 1983. In June 2001 she 
graduated cum laude from secondary school, 'Het Noordik' Almelo. Thereafter, she 
studied medicine at the Radboud University Nijmegen. Before she graduated, she 
started working as a student-assistant at the Department of Geriatric Medicine of the 
Radboud University Nijmegen Medical Centre under supervision of prof. dr. Marcel Olde 
Rikkert en dr. Rene Jansen. There, she was fascinated by scientific research and the 
application of this research to older patients, and she finished Master's examination with 
a research project at the same department. In 2006 - 2009 she performed the studies 
presented in this thesis under supervision of professor Marcel Olde Rikkert and dr. Jurgen 
Claassen. In December 2008 she received a Frye stipend to extend her research 
knowledge by visits to research groups in the United States.
Arenda is married to Leander Dado.
191

P U B L IC A T IO N S
Publications
• Arenda HEA van Beek, Jurgen AHR Claassen, Marcel GM Olde Rikkert, Rene WMM 
Jansen. Cerebral Autoregulation: an overview of current concepts and methodology 
with special focus on the elderly. J Cereb Blood Flow Metab. 2008 Jun;28(6):1071-85. 
Epub 2008 Mar 19. Review.
• Jurgen AHR Claassen, Arenda HEA van Beek, Marcel GM Olde Rikkert. Short review: 
acetylcholinesterase-inhibitors in Alzheimer's disease have opposing effects on 
blood pressure and cerebral perfusion. J Nutr Health Aging. 2009 Mar;13(3):231-3.
• Arenda HEA van Beek, Marcel GM Olde Rikkert, Jaco W  Pasman, Maria T Hopman, 
Jurgen AHR Claassen. Dynamic cerebral autoregulation in the old using a repeated 
sit-stand maneuver. Ultrasound Med Biol. 2010 Feb;36(2):192-201
• Arenda HEA van Beek, Jaap C Sijbesma, Marcel GM Olde Rikkert, Jurgen AHR Claassen. 
Research Letter: Galantamine-associated syncope in Alzheimer patients is not caused 
by aggravated orthostatic hypotension. J Am Geriatr Soc. 2010 Feb; 58(2):409-410
• Arenda HEA van Beek, Jurgen AHR Claassen. Invited Review. The cerebrovascular role 
of the cholinergic neural system in Alzheimer's disease. Behav Brain Res. 2010. In press
5
193

Chapter I 5
Series Donders Institute for Brain, 
Cognition and Behaviour
5

s e r ie s  d o n d e r s  i n s t i t u t e  f o r  b r a i n , c o g n i t i o n  a n d  b e h a v i o u r
Series Donders Institute for Brain, Cognition and Behaviour
1. van Aalderen-Smeets, S.I. (2007). Neural dynamics o f  visual selection. Maastricht 
University, Maastricht, The Netherlands.
2. Schoffelen, J.M. (2007). Neuronal com m unication through coherence in the hum an  
m oto r system. Radboud University Nijmegen, Nijmegen, The Netherlands.
3. de Lange, F.P. (2008). Neural mechanisms o f  m otor imagery. Radboud University 
Nijmegen, Nijmegen, The Netherlands.
4. Grol, M.J. (2008). Parieto-frontal circu itry in v isuom otor control. University Utrecht, 
Utrecht, The Netherlands.
5. Bauer, M. (2008). Functional roles o f  rhythm ic neuronal ac tiv ity  in the hum an visual and  
somatosensory system. Radboud University Nijmegen, Nijmegen, The Netherlands.
6. Mazaheri, A. (2008). The influence o f  O ngoing Oscillatory Brain A ctiv ity  on Evoked 
Responses and Behaviour. Radboud University Nijmegen, Nijmegen, The Netherlands.
7. Hooijmans, C.R. (2008). im pac t o f  n u tritiona l lipids and vascular factors in Alzheimer's 
Disease. Radboud University Nijmegen, Nijmegen, The Netherlands.
8. Gaszner, B. (2008). Plastic responses to stress by the rodent urocortinergic Edinger-West- 
pha l nucleus. Radboud University Nijmegen, Nijmegen, The Netherlands.
9. Willems, R.M. (2009). Neural reflections o f  m eaning in gesture, language and action. 
Radboud University Nijmegen, Nijmegen, The Netherlands.
10. Van Pelt, S. (2009). Dynam ic neural representations o f  hum an visuom otor space. 
Radboud University Nijmegen, Nijmegen, The Netherlands.
11. Lommertzen, J. (2009). Visuomotor coupling a t d ifferent levels o f  complexity. Radboud 
University Nijmegen, Nijmegen, The Netherlands.
12. Poljac, E. (2009). Dynamics o f  cognitive contro l in task sw itching: Looking beyond the 
switch cost. Radboud University Nijmegen, Nijmegen, The Netherlands.
13. Poser, B.A. (2009) Techniques for BOLD and b lood volume weighted fMRi. Radboud 
University Nijmegen, Nijmegen, The Netherlands.
14. Baggio, G. (2009). Semantics and the electrophysiology o f  meaning. Tense, aspect, event 
structure. Radboud University Nijmegen, Nijmegen, The Netherlands.
15. van Wingen, G.A. (2009). Biological determ inants o f  am ygdala function ing. Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands.
16. Bakker, M. (2009). Supraspinal contro l o f  walking: lessons from  m otor imagery. Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands.
17. Aarts, E. (2009). Resisting tem ptation: the role o f  the anterior cingulate cortex in adjusting  
cognitive control. Radboud University Nijmegen, Nijmegen, The Netherlands.
197
s e r ie s  d o n d e r s  i n s t i t u t e  f o r  b r a i n , c o g n i t i o n  a n d  b e h a v i o u r
18. Prinz, S. (2009). Waterbath stunning o f  chickens -  Effects o f  electrical parameters on the 
electroencephalogram and physical reflexes o f  broilers. Radboud University Nijmegen, 
Nijmegen, The Netherlands.
19. Knippenberg, J.M.J. (2009). The N150 o f  the Aud ito ry Evoked Potential from  the rat 
am ygdala: in search for its functiona l significance. Radboud University Nijmegen, 
Nijmegen, The Netherlands.
20. Dumont, G.J.H. (2009). Cognitive and physiological effects o f  3,4-methylenedioxy­
m etham phetam ine (MDMA or 'ecstasy') in com bination w ith  a lcohol o r cannabis in 
humans Radboud University Nijmegen, Nijmegen, The Netherlands.
21. Pijnacker, J. (2010). Defeasible inference in autism: a behavioral and electrophysiogical 
approach. Radboud Universiteit Nijmegen, The Netherlands.
22. de Vrijer, M. (2010). Multisensory in tegration in spatia l orientation. Radboud University 
Nijmegen, Nijmegen, The Netherlands.
23. Vergeer, M. (2010). Perceptual visib ility and appearance: Effects o f  color and form. 
Radboud University Nijmegen, Nijmegen, The Netherlands.
24. Levy, J. (2010). in Cerebro Unveiling Unconscious Mechanisms during Reading. Radboud 
University Nijmegen, Nijmegen, The Netherlands.
25. Treder, M. S. (2010). Symmetry in (inter)action. Radboud University Nijmegen, 
Nijmegen, The Netherlands.
26. Horlings C.G.C. (2010). A Weak balance; balance and  falls in patients w ith neuromuscular 
disorders. Radboud University Nijmegen, Nijmegen, The Netherlands
27. Snaphaan, L.J.A.E.. (2010). Epidem iology o f  post-stroke behavioural consequences. 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
28. Dado - Van Beek, H.E.A. (2010). The regulation o f  cerebral perfusion in patients with  
Alzheimer's disease. Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands.
198
s e r ie s  d o n d e r s  i n s t i t u t e  f o r  b r a i n , c o g n i t i o n  a n d  b e h a v i o u r
5
199

